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The overarching thesis under investigation is that the endogenous opioid system plays a key 
role in depression subsequent to traumatic childhood social experiences.  This is suggested by 
the fact that animal work indicates that mu-opioids robustly mediate separation-distress, and 
that early social stressors lead to long term dysregulation in key related circuitries and 
neuroanatomical structures.  Moreover, although depression remains poorly characterized, it 
is clear that early social adversity may act as a risk factor for this disorder.  The search for 
effective pharmacological treatments for depression is ongoing, and preliminary clinical 
evidence suggests that the synthetic opioid buprenorphine may be effective in treating certain 
cases of refractory depression.  As a first step in a program aimed at investigating the role of 
opioids in depression, the current study examined the impact of an opioid manipulation on 
subjective experience of affect, social cognition, and neural activation in two groups of 
medically and psychiatrically healthy normal young adults (N = 32).  The groups differed on 
one key variable – exposure to early social trauma.  In this exploratory study, a double-blind, 
placebo controlled crossover design was employed.  It demonstrated that these groups 
showed a different pattern of response to a low dose of buprenorphine across all domains 
measured.  In terms of baseline characteristics, the trauma-exposed and control groups 
differed on a primary-process, appetitive emotion system, with the trauma group showing 
reduced SEEKING.  Buprenorphine reduced the experience of both positive and negative 
emotion in the trauma (but not control) group.  In terms of social cognition, it enhanced a 
positivity bias in the control (but not the trauma) group.  In terms of neural activation, region 
of interest analysis indicated that the trauma group was more sensitive to the effects of 
buprenorphine in reducing response to negative social signals in the anterior insula.  Region 
of interest analysis also indicated that the trauma group was more responsive to negative than 
positive social signals on placebo, and that buprenorphine was able to attenuate this effect.  
Although preliminary, these findings support the idea that long term opioid dysregulation 
follows early social traumatic experiences, and that the role of opioids in the etiology and 







Psychosocial adversity in childhood plays a critical role in at least some cases of 
depression (Flinn, Muehlenbein & Ponzi, 2009; Heim & Nemeroff, 1999; Heim et al., 
2009).  Although there are likely to be complex interacting neurochemical mechanisms 
underpinning this association, the overarching thesis under investigation here is that the 
endogenous opioid system plays a key role in depression subsequent to traumatic 
childhood social bonding experiences.   
In brief, the key points which give rise to this broad thesis are the following: 
Major depressive disorder is a heterogenous phenomenon.  Its etiology is unresolved, and 
its treatment remains problematic.  Around 30% of all cases do not respond to current 
treatment options (Mayberg, 2004; Warden, Rush, Trivedi, Fava & Wisniewski, 2007).  
Many researchers in this field seem to be increasingly convinced that single factor 
accounts cannot explain the disorder, and that a broader consideration of interacting 
neurochemistries and variable presentations is required (Drevets, Price & Furey, 2008; 
Nemeroff, 2007).  There is a body of evidence to suggest that early separation 
experiences predispose to depression, and that depressive episodes are frequently 
triggered by experiences of social loss (Bowlby, 1969, 1980; Flinn et al., 2009; Heim & 
Nemeroff, 1999; Heim, Shugart, Craighead & Nemeroff, 2010; Slavich, O'Donovan, Epel 
& Kemeny, 2010).  Preliminary clinical evidence indicates that mu-opioid therapy is 
effective in certain cases of refractory depression (Bodkin, Zornberg, Lukas & Cole, 
1995; Emrich, Vogt & Herz, 1982).  Animal research clearly indicates a strong role for 
the mu-opioid system in mediating social reward and attenuating social loss in several 
mammalian and avian species (Herman & Panksepp, 1978, 1981; Nelson & Panksepp, 
1998; Panksepp, 1980, 2005a).  Neuroimaging research is beginning to confirm that the 
same is true in humans (Eisenberger, Lieberman & Williams, 2003; Kennedy, Koeppe, 
Young & Zubieta, 2006; Liberzon et al., 2007; Zubieta et al., 2003).  Furthermore, it is 
clear from the animal literature that early social losses, which provoke strong separation-
distress responses, impact permanently on stress-related neurochemistries (Anisman & 
Matheson, 2005; Braun, Lange, Metzger & Poeggel, 2000; de Kloet, Joels & Holsboer, 
2005; Meaney, 2001; Meaney et al., 1996; Poeggel et al., 1999; Ziabreva, Schnabel, 
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Poeggel & Braun, 2003).  There is thus good reason to infer that the opioid system, which 
is closely involved in mediating stress and emotional responses, may also be dysregulated 
subsequent to early social traumatic experiences.   
Systematic investigation of this overarching thesis is thus warranted.  Such an 
investigation requires research at multiple levels (for example, neurophysiological, 
neurochemical, epigenetic, and behavioral indicators as well as subjective affect need to 
be explored in both healthy and depressed individuals), which clearly constitutes an 
enormous and long-term task.  The current project represents a first step in this direction, 
asking whether exposure to early social trauma can lead to identifiable changes in affect, 
social cognition and neural reactivity, and whether mu-opioid manipulation can alter 
these effects.  If early social trauma leads to long-term mu-opioid dysregulation, there 
may well be detectable changes in these domains in adults who have experienced such 
trauma in childhood.  Most critically, a different pattern of response to mu-opioid 
manipulation should be present in these individuals when compared to appropriate 
controls who have not experienced early social trauma. 
Because this is such a complex arena of investigation, with so many potential 
variables of influence, the present investigation was initiated in a relatively homogenous 
set of participants.  Although the overaching question ultimately concerns depression, 
due to the heterogeneity present within this disorder it seemed prudent to begin the 
examination of mu-opioid system function subsequent to early social trauma in a more 
easily defined group.  Medically and psychiatrically healthy young adults were recruited 
who differed primarily on one key feature – exposure to early social trauma.  This 
exposure was assessed using the Childhood Trauma Questionnaire - Short Form, and 
stringent inclusion criteria were employed to constitute the trauma and control groups.  A 
double blind, placebo-controlled crossover design, using a low-dose mu-opioid 
manipulation, was employed.  Baseline characteristics including key personality traits 
and general experience of affect were assessed.  In response to the opioid manipulation, 
current experience of affect, implicit or preconscious evaluation of social stimuli, and 
neural activation in response to social-emotional stimuli were examined.     
The research described in this dissertation is exploratory, and consequently has 
several notable limitations.  These limitations have to be judged in the context of the 
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larger research program within which the current research is nested, however.  The 
ultimate aim of this program is to clarify whether a particular type of depression exists – 
one that follows experience of early social trauma, and that is mediated at a neural level, 
at least in part, by mu-opioid dysregulation.  It is thus important to bear in mind that the 
work reported here is preliminary, seeking to establish whether one small, but important, 
set of associations exists.  Given the significant challenges present in the field of 
depression research, both in terms of establishing etiology and in terms of successful 
intervention, the value of the overarching investigative program is evident.  Successful 
research programs must, however, proceed in small successive steps, and that is where 




In order to contextualize this research, the review that follows provides an overview of: 
1) Panksepp‟s model of social attachment and emotion; 2) the neurochemistry of the 
opioid system; and 3) the empirical neuroscience literature on depression.  Each of these 
topics is associated with a substantial body of knowledge.  Of necessity, the overviews 
provided here are extremely limited, and focus only on the information that seems most 
relevant to the topic at hand.  My aim is to embed this investigation within a theoretical 
framework that will allow us to understand not only whether, but also how and why mu-
opioid medication may ameliorate certain cases of depression.   
 
Conceptual Foundations for this Research 
This dissertation is grounded in the model of basic emotion systems developed by 
Jaak Panksepp (1998).  Multiple competing models and taxonomies of human emotion 
currently exist, with little immediate prospect of resolution on the basis of the available 
evidence.  An adequate critical analysis of the strengths and weaknesses of the competing 
models would require a thesis in itself.  For this reason I will not be reviewing any of the 
other established models of emotion (such as those developed by, for instance, Cosmides 
& Tooby, 2000; Darwin, 1872/1965; Davidson, 1995; Ekman, 1992; Heller, 1993; Izard, 
1977; Tracy & Robins, 2004).   
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Panksepp‟s general theoretical articulation of the core emotion systems of the 
mammalian brain is a work in progress.  Its chief strengths lie in the fact that it seeks to 
build a comprehensive synthesis in multiple ways.  Specifically, it looks to evolutionary 
principles to account for the development and function of emotion, looking back in 
phylogenetic terms to find the origins of emotion in more primitive, less cerebrally 
developed (mainly mammalian) species.  Furthermore, it seeks to disentangle core 
emotion systems in neural and neurochemical detail.  This approach makes it unique, and 
incommensurate with other human-centered, more cognitively focused sets of ideas on 
emotion.  Importantly this model, although based mainly on animal research, takes into 
account the affective feeling states that accompany behavioral and neurochemical 
changes in animals and humans – an approach that is of great relevance to psychiatric 
research.  Panksepp (2004) argues that psychiatry requires a theory of emotion that is 
grounded in evolutionarily conserved neural circuitry and neurochemistry, and which 
incorporates understanding of the resultant subjective experiences, for the core 
mechanisms of psychiatric disorders to begin to come into focus.  
It is thus well worth investigating whether some of the ideas generated from this 
work can shed light on the neural and neurochemical puzzles of depression.  Within this 
theoretical approach, the argument is that in order to understand depression, one must 
understand social pain.  The following section on Panksepp‟s core emotion systems will 
attempt to illustrate how animal research, and subsequent work in humans, has indicated 
that mu-opioids are involved in the positive feeling states/rewards associated with social 
contact, and that physical and social pain are closely related, with both being robustly 
mediated by this neuropeptide. 
Specifically, the section that follows will: 1) contextualize the core emotion 
systems of interest by detailing Panksepp‟s broad conceptualization of emotion; 2) 
provide some detail on the two core emotion systems of greatest relevance here; and 3) 
present some pertinent research involving humans which confirms some of the ideas 





Conceptual  Foundations: Panksepp’s Core Emotion Systems 
Panksepp‟s research has focused on ancient subcortical emotion systems, 
conserved across mammalian species.  Based on this work, he has constructed a general 
theoretical conceptualization of core emotions and their role in social affects and 
functioning (Panksepp, 1998; Panksepp, 2005a).   
 
Defining emotion.  Panksepp (1998) conceptualizes core emotions as command 
systems that developed through the course of evolution – they are “evolutionarily 
prepared and epigenetically refined states of the brain” (p. 122).  These core emotions 
serve to organize mental, physiological, and behavioral responses to events of universal 
biological significance.  The characteristic affective feeling states associated with the 
various basic emotions serve to encode value: Emotions are thus seen as intrinsic value 
systems, generating lived experience of the „goodness‟ or „badness‟ of situations, events, 
other animals, and conspecifics.  Emotion systems, although unconditioned in 
themselves, are regarded as being modifiable by experience; indeed one of their main 
functions is to facilitate associative learning, and thus promote adaptive and successful 
behavior.  There is thus a distinction between primary process affects, which are 
genetically coded and located sub-neortically, and which generate characteristic 
unconditioned behavioral patterns, and secondary and tertiary processes.  Secondary 
processes include emotional learning via varieties of conditioning, whereas tertiary 
affects include higher cortical elaborations of emotion, including reflective awareness 
(Panksepp, 2010).  Panksepp‟s work centers on what have been variously termed basic, 
core or, most recently, primary process emotion systems.  
In sum, core emotions are conceptualized as innate subjective value systems that 
are generated at the neural level, and which impact in major ways on both simple 
instinctive, and complex, more cognitively controlled behavior.  Panksepp‟s perspective 
is that affective consciousness – that is, the experience of these basic emotion states – 
preceded the evolution of higher forms of cognitively resolved consciousness.     
 
Brain substrates of emotion.  The core emotions are instantiated largely 
subcortically, but also involve areas of archicortex.  The core emotion command systems 
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possess a remarkable degree of cross-mammalian similarity at the neural level (Panksepp, 
1998; 2005a).  Both the so-called reptilian brain (including the basal ganglia) and the 
limbic regions of the brain are similar in proportional size across mammalian species.  
The basal ganglia encode basic motor plans including those related to fear, anger and 
sexual behavior.  The limbic regions encode more social emotions including maternal 
care, social bonding, rough-and-tumble play and separation-distress.  A key point in this 
model is that neocortex, although it is influenced by and in turn influences emotion in the 
brain, is not necessary for the generation, experience, or enactment of core emotions. 
 
Core emotion systems.  These include four emotions that are evident soon after 
birth, viz. SEEKING, FEAR, ANGER, and SEPARATION-DISTRESS.
1
  Other 
important emotion systems including PLAY and CARE become evident later in 
development.  These terms are capitalized in order to prevent confusion with colloquial 
usages of the same terms, and the multiple associations attached to everyday emotional 
terminology.  The capitals indicate specific reference to the core emotion systems that 
have been distinguished at a neural level (Panksepp, 2010).  Ongoing neural activity in 
these emotion systems results in the generation of moods, and in the long term, in the 
development of personality characteristics, such as tendencies to be cheerful, aggressive, 
fearful or depressed (Panksepp, 1998, 2004).  
 
Clearly, adopting Panksepp‟s theoretical framework indicates an acceptance of 
the relevance of animal work to human research.  This standpoint is by no means 
uncontroversial (see, e.g., Blumberg & Sokoloff, 2001), but many arguments in support 
of such an approach have been made.  For instance, Darwin (1872/1965), in his 
celebrated work on emotion, argued that differences between animals are likely to be 
differences in degree, rather than differences in kind.  Many current researchers regard 
animal work as relevant, due to clear phylogenetic continuities in mammalian brain 
anatomy and behavior; with structural and proportional size similarities in key brain 
regions in all mammals, and a great deal of shared genetic material (Adolphs, 2003; 
                                                 
1
 I choose to use the term SEPARATION-DISTRESS as it relates most clearly to the ideas under 
investigation here.  Panksepp uses this term as well as PANIC/GRIEF or SADNESS at different times to 
refer to the same system. 
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Damasio, 1994; Damasio et al., 2000).  In light of these cross-mammalian continuities, 
the idea that animal and human emotion exists on a continuum is acceptable.  From this 
standpoint, a particularly compelling argument is that understanding neural emotion 
systems may be easier in animal models, where causal relationships can be studied 
directly, and where more complex, later developing emotions, characteristic perhaps only 
of humans, are not present (Panksepp, 2003, 2005b). 
Hence, the research described here proceeds from the perspective that core 
emotion systems evolved to guide human behavior in adaptive ways, and that these 
evolutionarily ancient, bottom-up processes impact in major ways on the nature of 
subjective lived experience.  In depression, this adaptive function seems to go awry, but 
the emotions continue to exert a disproportionate and negative impact on the individual.  
To date a single coherent account of the role and dysfunction of emotion in depression is 
lacking: Low mood, sadness, and anxiety all feature, alongside anhedonia, lack of 
motivation and psychomotor retardation, and a variety of other symptom clusters, with no 
satisfactory explanation of why all these features, and so many varied clinical 
manifestations, may occur.  The importance of a focus on emotion in depression research 
is evident. 
I propose that two of the core emotion systems identified by Panksepp are worth 
considering in this regard: SEEKING and SEPARATION-DISTRESS.  In fact, the 
newest articulations of what is now termed the separation-distress hypothesis of 
depression allocate a role to both systems in the genesis of depression
2
 (Alcaro & 
Panksepp, in press; Panksepp & Watt, 2011; Zellner, Watt, Solms & Panksepp, in press).  
SEEKING is mediated by dopamine, and SEPARATION-DISTRESS by the mu-opioid 
system; two chemistries that are closely interactive.  Social loss and social pain are often 
key features of depression, and are the defining characteristics of SEPARATION-
DISTRESS.  Anhedonia, the loss of interest or pleasure in a variety of activities, is 
commonly seen in depression, and can be argued to reflect downregulation of the 
SEEKING system.  I provide a brief overview of these two core emotion systems below.   
                                                 
2
 Because these new articulations of the separation-distress hypothesis were published after the current 
research had been designed and executed, and therefore did not shape the focus of this study, it seems more 
appropriate to present detail on them in the Discussion section. 
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The SEEKING system.  The SEEKING system is one of two positive emotion 
systems that have been the focus of much research across mammalian species – viz., this 
dopamine modulated SEEKING system, and the opioid modulated system of social and 
consummatory pleasure (Alcaro, Huber & Panksepp, 2007).  Both systems are involved 
in „rewarding‟ affective states, although the precise details of their roles remain 
controversial.  The systems interact closely, with opioid and dopamine levels in key 
circuits influencing each other in various ways.  It is thus difficult to examine the effects 
of opioids without considering interactions with this system.   
The SEEKING system is conceptualized as an expectancy system, energizing all 
appetitive behavior: it is not specific to any particular drive or need.  It stimulates animals 
to engage with the world in order to meet a multiplicity of needs.  Through experience 
and learning, it also generates expectancy states that enable animals to anticipate reward.  
The associated affective experiential state is clearly positive, and has been described as “a 
generalized incentive „emotional‟ reward state, that does not reflect the pleasure of 
sensation, but rather the euphoria of appetitive eagerness” (Alcaro & Panksepp, in press; 
this paper provides a comprehensive recent review of this system).  
 
Brain substrates of the SEEKING system.  The neural circuits of the SEEKING 
SYSTEM run in the extended lateral hypothalamic corridor, from area A10 in the ventral 
tegmental area to the ventral striatum or nucleus accumbens, which projects to the 
prefrontal cortex and other structures.  Direct electrical stimulation along this pathway 
results in the “most energized exploratory and search behaviors an animal is capable of 
exhibiting” (Panksepp, 1998, p. 155).  The ascending mesolimbic dopamine pathways 
delineate this system fairly well, but other components also exist, most importantly 





Brain substrates of the SEEKING system. 
Abbreviations: PFC = Prefrontal cortex; NA = Nucleus accumbens;  
LH = Lateral hypothalamus; VTA = Ventral tegmental area.  
 
 
A brief aside is necessary regarding the arguments around this dopamine system 
and reward, as it clarifies some of the relevant dopamine-opioid interactions.  
Researchers following the behaviorist tradition conceived of this mesolimbic dopamine 
system as a reward system, largely due to the fact that research animals will self-
stimulate here to the point of collapse: they clearly find such stimulation rewarding, and 
will ignore more basic reinforcers.  Those following an affective neuroethological 
tradition take issue with the reward system designation, as the system seems more 
responsive to the possibility than to the presence of reward.  In fact, dopamine activity is 
reduced in consummatory behavior, and another system, modulated by opioids, is 
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activated (Alcaro & Panksepp, in press; Panksepp, 1998).  There seems to be, however, a 
complex interaction between appetitive SEEKING and consummatory behavior.  The 
chemistries interact in several ways, with for example, ventral tegmental area opioids 
stimulating dopamine activity, while opioids in the striatum inhibit dopamine.  It should 
also be noted that mild opioid stimulation arouses the SEEKING system, while high 
stimulation reduces the desire for all rewards (Panksepp, 1998).  Broadening the 
conceptualization of this system from a pure learning systems to an affective 
neuroethological  perspective  allows a fuller understanding of its key features, for 
example, the fact that stimulation of the system generates an unconditioned and coherent 
emotional response pattern (foraging or SEEKING), which consists of energized, goal-
directed activity (Alcaro et al., 2007).  Most critically, the learning system 
conceptualizations are silent on the affect associated with the activation of this system, 
and thus cannot contribute to an understanding of its key psychological and psychiatric 
aspects.  Understanding the full emotional picture is integral to understanding what 
„reward‟ or „reinforcement‟ actually mean (Panksepp, 2005a).   
 
It is perhaps interesting to note that throughout history, drugs of abuse for humans 
have consistently been psychostimulants, which act on the ascending mesolimbic 
dopamine SEEKING pathway, and opiates, which act on the opioid receptors present at 
the consummatory end of this pathway (Panksepp, 1998).  The interaction of dopamine 
and opioids in SEEKING and reward is fairly clear, and is something that must be borne 
in mind when investigating opioid involvement in depression.  Opioids are also strongly 
implicated in positive social contact, and in mediating the pain of social loss. 
 
Social bonding and the SEPARATION-DISTRESS system.  The brain 
chemicals involved in social bonding – those that are activated by positive social 
engagement such as physical contact, grooming, play and sex – include oxytocin, 
prolactin and the endogenous opioids. Evolution has provided mammals with a neural 
system characterized by motivation to form affective social bonds, the first exemplar of 
which is the attachment of the infant to its mother.  Evidence for this attachment is 
apparent across mammalian species: Infants form bonds and demonstrate affiliative 
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behavior toward their primary caregiver (usually the mother).  These bonds are 
characterized by infants displaying very selective approach and interaction behaviors 
towards these caregivers, alongside manifest distress if they are separated from the 
caregiver (Ainsworth, 1967; Bowlby, 1969, 1973, 1980; Harlow, Dodsworth & Harlow, 
1965).  This system continues to play a critical role in social bonding across the lifespan 
(Nelson & Panksepp, 1998; Panksepp, 1998).   
This system is regarded as responsible for monitoring both social presence and 
social absence.  It has dichotomous associated affective states: positive states associated 
with social reward, such as contact comfort, and negative states associated with 
separation-distress or social loss.  The neural and neurochemical systems that modulate 
both affective states developed from more primitive, already extant systems.  The system 
for mediating the positive affects of social contact and bonding may have developed as an 
extension of existing mechanisms that serve to regulate energy balance, thermoregulation 
and place preferences, while the system that mediates separation-distress and social loss 
is an extension of that for physical pain (Panksepp, Nelson & Bekkedal, 1997). 
Various chemistries, as mentioned above, appear to play a role in positive 
affective states associated with social contact, and they may need to act in concert to 
exert their full impact.  It is known that opioids are not invariably involved in social 
reward, but in many cases they are strongly implicated (Panksepp et al., 1997).  
The fact that opioids are involved in certain positive affective experiences related 
to social bonding has been clearly established.  Mu-opioids are experienced as rewarding, 
as illustrated by the fact that they successfully condition odor- and place-preferences 
(Nelson & Panksepp, 1998).  It is known that physical contact stimulates opioid 
activation (Nelson & Panksepp, 1998), and this perhaps accounts for the ability of touch 
to lower heart rate and reduce distress vocalizations (Bermant, 1963; Panksepp, Herman, 
Vilberg, Bishop & DeEskinazi, 1980b).  Social interaction stimulates opioid release – this 
is particularly true of prosocial activities such as play or grooming (Keverne, Martensz & 
Tuite, 1989; Panksepp & Bishop, 1981).  In animals, proximity of friendly, caring others 
or positive social interaction can in fact lead to relief of physical pain via opioid release 
(D'Amato & Pavone, 1993; McMillan, 2000).  Gentle touch has been shown to reduce 
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both physical and emotional pain (Panksepp, Burgdorf, Beinfeld, Kroes & Moskal, 2004; 
Uvnas-Moberg, 1998). 
It is also critical to note that altered levels of opioids can alter social behavior.  A 
key study indicated that mu-opioid receptor knockout mice displayed markedly altered 
attachment behavior toward their mothers, seeming apparently blind to maternal rewards 
(Moles, Kieffer & D'Amato, 2004).  Other animal research provides important evidence 
regarding the effects of opioids on social behavior.  Work using receptor blockades, 
antagonists, and agonists indicates that reduced levels of mu-opioids result in increased 
seeking of social contact, while high levels appear to reduce motivation to seek out such 
contact (Fabre-Nys, Meller & Keverne, 1982; Herman & Panksepp, 1978; Kalin, Shelton 
& Lynn, 1995; Keverne et al., 1989; Martel, Nevison, Simpson & Keverne, 1995; 
Panksepp, Najam & Soares, 1979).  These findings are in line with the hypothesis that 
any agent which activates social reward processes in the brain should reduce pro-social 
behavior, and vice-versa (Panksepp et al., 1997).  
Although the systems and chemistries involved in social reward are not 
comprehensively delineated, it is clear that opioids play an important role in social 
bonding and in social reward.  The system that mediates social distress or emotional pain 
is closely related, and seems to have emerged from the existing system for modulating 
physical pain.  This system is more clearly delineated, in part because distress is easier to 
observe and measure, but also because social distress is more immediately compelling in 
terms of its clinical implications (Panksepp et al., 1997).   
Researchers who have explored the hypothesized relationship between physical 
and social pain have pointed out that we use words for physical pain to describe social 
pain (for example hurt feelings, or a broken heart), and their research indicates that these 
constructions may well reflect more than the use of metaphor (Eisenberger et al., 2003).  
Social bonds carry great adaptive value for mammals, so it seems plausible to reason that 
evolution might have „wired in‟ a warning mechanism – similar to pain sensation – to 
elicit responses that attempt to re-establish vital social contact.  Pain is extremely 
aversive, and thus promotes rapid responses aimed at its alleviation.  It may be that the 
experience of social pain, and the associated underlying neural circuitry are uniquely 
found in mammals (Eisenberger & Lieberman, 2004).  
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Evidence that the SEPARATION-DISTRESS system is closely related to the pain 
system is strong.  This evidence is highly relevant to the current study for the following 
reason: We know that mu-opioids are among the most effective painkillers.  If social and 
physical pain are shown to be related, this connection not only supports the contention 
that opioid intervention should be effective in reducing social pain, it helps to explain 
why this should be so. 
All mammals „cry‟ when separated from their mothers.  This distress is not trivial.   
It has been shown that many young animals, if isolated, seem to experience such intense 
pain due to this social loss that other life regulatory systems are impacted – the animals 
evidence anaclytic depression and often die (Yates, Panksepp, Ikemoto, Nelson & 
Conner, 1991).  Panksepp thus hypothesized that intense social distress could be 
monitored using distress vocalizations as objective indicators of its presence.  Panksepp 
and colleagues (Herman & Panksepp, 1978, 1981; Nelson & Panksepp, 1998; Panksepp, 
Herman, Conner, Bishop & Scott, 1978) demonstrated that opioids, which had already 
been established as powerful analgesics, are remarkably effective at substantially 
reducing or even eliminating separation-related distress vocalizations, and that these 
effects are mediated by the mu-opioid system.  This was shown to be true for a number of 
animal species, including guinea-pigs, dogs, and primates (Herman & Panksepp, 1978; 
Kalin & Shelton, 1989; Panksepp et al., 1978).  In fact, it became evident that opioids are 
even more successful at mediating social distress than physical pain (Panksepp, 1998; 
Panksepp, Bean, Bishop, Vilberg & Sahley, 1980a; Panksepp, Meeker & Bean, 1980c). 
These findings have been independently confirmed by other laboratories (e.g. Kalin, 
Shelton & Barksdale, 1988; Kehoe & Blass, 1986).  
Although other neurochemicals also modulate SEPARATION-DISTRESS (e.g. 
oxytocin and prolactin; notably also chemistries that are involved in social reward), 
opioids achieve this marked effect at extremely small doses.  It is hypothesized that their 
effectiveness is due to the fact that they cause feelings associated with positive social 
bonding and social reward (Panksepp et al., 1980a; Panksepp et al., 1980b).   
In Panksepp‟s conceptualization, opioids are particularly important in social 
bonding and SEPARATION-DISTRESS for the following key reasons: 1) Although the 
chemistries of reward in general, and of social reward in particular, are not 
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comprehensively understood (Panksepp et al., 1997), opioids clearly play a critical role in 
mediating social behavior and social affiliation;  2) opioids have been shown to exert a 
very strong influence on social distress, even at very low doses, suggesting that they are 
powerful mediators of social pain;  3) the opioid system is perhaps unique in that its 
anatomy and function both indicate a clear association between social and physical pain 
(Panksepp, 2005b).  The connection between physical and social pain is central to 
Panksepp‟s theoretical construction, where the regulatory mechanisms for social pain are 
thought to have evolved as an extension of those already in place for regulating physical 
pain.  This link is also central to the model of depression proposed in this dissertation. 
 
Brain substrates of the SEPARATION-DISTRESS system.  The system arises in 
the periaquaductal gray of the midbrain, close to sites where physical pain can be elicited.  
(Note that the periaquaductal gray is the area at which emotional distress is most easily 
evoked in both humans and animals).  The pathway progresses through the dorsomedial 
thalamus, to the ventral septal area, the preoptic area and the bed nucleus of the stria 
terminalis.  In higher animals it also continues to the anterior cingulate cortex and some 
amygdala sites.  This path is very similar to the corticotrophin releasing factor (CRF) and 
opioid systems.  Notably, CRF seems to increase distress vocalizations, while opioids 





Brain substrates of the SEPARATION-DISTRESS system. 
Abbreviations: ACC, = Anterior cingulate cortex; VS = Ventral septal area;  
DMT = Dorsomedial nucleus of the thalamus; BNST = Bed nucleus of the stria terminalis;  
PAG = Periaqueductal grey.  
 
 
It is of the greatest importance to note that when separation-distress is not 
followed by a successful reunion, the conditions for depression are realized.  This has 
been suggested by both animal research and studies of human children (Bowlby, 1969; 
Harlow et al., 1965; Panksepp, 1998), where the initial distress vocalization phase (the 
„protest‟ phase) gives way to a depressed, inert state (the „despair‟ phase).  Alterations in 
neurochemistries account for this transition: the initial distress phase involves raised 
corticotrophin releasing factor (CRF) and increased activity in the hypothalamic–
pituitary-adrenal (HPA) stress axis.  These processes rapidly result in depletion of 
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norepinephrine, serotonin, and some dopamine reserves in the brain.  Depressive 
behaviors can in fact be artificially induced by creating these exact physiological 
changes.  It is hypothesized that this inert state has benefits in evolutionary terms: the 
isolated youngster conserves energy, does not wander any further from „home‟ seeking 
the mother, and is less likely to alert predators to its presence and vulnerable state.  The 
depressed state may thus increase the chances of the mother eventually finding the 
youngster alive (Panksepp, 1998).  However, the potential negative psychiatric 
implications for humans in whom this mechanism has been over-sensitized, putatively 
following traumatic early social loss, are evident. 
There are indeed indications from the animal literature that early social distress 
can lead to long-term alterations in key structures and circuits.  Studies have 
demonstrated that 24 hours of neonatal maternal separation disinhibits the infant‟s HPA 
system, and that this alteration in glucocorticoid feedback mechanisms persists into 
adulthood (Anisman, Zaharia, Meaney & Merali, 1998; Biagini, Pich, Carani, Marrama 
& Agnati, 1998; Meaney et al., 1996; Vazquez, Lopez, Van Hoers, Watson & Levine, 
2000).   
HPA axis changes are not the only sequelae.  Notably, in a recent paper on the 
SEEKING system, Alcaro and Panksepp (in press) reviewed a body of work that 
demonstrates that chronic stress protocols resulting in behavioral depression, also result 
in a simultaneous dysregulation of mesolimbic dopamine transmission and receptor 
function. 
Furthermore, an important series of studies on rats (Braun et al., 2000; Poeggel et 
al., 1999; Ziabreva et al., 2003) indicates that repeated maternal separation and social 
isolation result in alterations in neuronal development, most notably in the medial 
prefrontal cortex, including the anterior cingulate cortex and the nucleus accumbens core.  
The authors call these changes „functional scars‟ in emotional brain circuits.  Importantly, 
these authors illustrated that having access to some social contact (viz., the mother‟s 
voice) during separation protected against this effect.  They also demonstrated that early 
maternal separation resulted in a reduced number of neurons implicated in inhibitory 
GABA-ergic function, notably in the anterior cingulate cortex and nucleus accumbens 
core.  They suggest this neuronal reduction may lead to increased excitatory output from 
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the anterior cingulate cortex, which could in turn result in significantly altered limbic 
function. 
Although the studies reviewed above do not refer specifically to opioid substrates, 
they do indicate long-term dysregulation in relevant chemistries, as well as structural 
changes in regions with dense concentrations of mu-opioid receptors.  The hypothesis 
under examination here is that early exposure to significant social trauma results in long-
term dysregulation not only of stress-related chemistries, but also of the mu-opioid 
system which has a significant role in mediating these effects.    
 
To summarize, the animal literature I have reviewed so far indicates that:   
 The mu-opioid system is involved in positive affect associated with social 
contact, and has a role in mediating social behavior.   
 A close relationship exists between physical and social pain, with common 
neural structures involved, and with interchangeable effects in their 
mediation; what were traditionally thought of as physical pain mediators 
(mu-opioids) robustly resolve social distress, while social contact seems 
able to alleviate physical pain.  
 Early social stress leads to long-term dysregulation in stress and emotion 
systems, including the mesolimbic dopamine system (which interacts with 
the mu-opioid system), and to altered development in regions with high 
concentrations of mu-opioid receptors.  The effect of early social stress 
has not been investigated directly for the opioid system but it seems 
reasonable to propose that this system may be dysregulated in the long-
term following early social trauma. 
 
Critical Evidence from Human Neuroimaging 
Evidence from human neuroimaging research supports the contention derived 
from the animal literature that physical and social pain are closely related.  This link is 
important to establish because showing that physical and social pain share neural 
substrates accounts for why mu-opioids should attenuate social pain and should thus be 
effective in treating depression.  The work reviewed below provides evidence that 
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regions high in opioid receptors are key in both the affective components of physical pain 
and in the pain of social loss or rejection.  It also gives some insight into the way in 
which social contact might mediate both physical and social pain, through its mediation 
of stress responses, which according to the literature reviewed above, is likely to involve 
opioids. 
 
Shared neural substrates for physical and social pain:  A number of human 
neuroimaging studies suggest there may be shared neural substrates for social and 
physical pain.  Functional magnetic resonance imaging (fMRI) studies attempting to elicit 
feelings of grief have noted activation in pain circuitry; notably in the dorsal anterior 
cingulate and periaqueductal gray and insula (Gundel, O'Connor, Littrell, Fort & Lane, 
2003; O'Connor et al., 2008).  Damasio and colleagues (2000) demonstrated, using 
positron emission tomography (PET), that the experience of sustained sadness correlates 
with activation in regions known to be implicated in physical pain, including the insula 
bilaterally, and the anterior cingulate and dorsal pons.   
In 2003, Eisenberger and colleagues published the first in a series of studies 
aimed at directly testing the hypothesis that social and physical pain share common 
neural substrates in humans.  Concurring with Panksepp (1998), they proposed that social 
pain represents a similar affective experience to physical pain, with the cause being actual 
or potential separation from significant others or the social group, rather than physical 
damage.   
In this study, Eisenberger et al. (2003) used an fMRI protocol, where participants 
were initially included in, and then later excluded from, a computer-based social game 
(tossing a ball between three people).  During the game, it appeared that the other two 
players simply stopped including the participant and only threw to each other.  
Participants were asked to indicate how distressed they felt during this exclusion.  The 
areas found to be strongly associated with the pain of social rejection were the dorsal 
anterior cingulate cortex, and a region in the right ventral prefrontal cortex. 
The anterior cingulate is known to be involved in the affective component of 
physical pain (Peyron, Laurent & Garcia-Larrea, 2000; Rainville, Duncan, Price, Carrier 
& Bushnell, 1997; Tolle et al., 1999).  There is also evidence regarding the importance of 
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the anterior cingulate cortex in social bonding and separation-distress.  Research has 
indicated that the cingulate gyrus must be intact for the generation of distress 
vocalizations (Lorberbaum et al., 2002): Stimulation of the anterior cingulate cortex 
results in the production of distress vocalizations, whereas ablation can eliminate distress 
vocalizations entirely (Kirzinger & Jurgens, 1982; MacLean & Newman, 1988; 
Robinson, 1967; Smith, 1945).  Ablation of the anterior cingulate cortex in primate young 
has also been shown to lead to reduced affiliative behavior (Hadland, Rushworth, Gaffan 
& Passingham, 2003; Ward, 1948).  The authors thus argued that the anterior cingulate 
region was implicated in generating the feelings of social pain, and that the right ventral 
prefrontal region was involved in regulating that distress response.   
Eisenberger et al. (2003) thus provided critical evidence of a shared neural 
substrate for social and physical pain in humans.  Ongoing work has confirmed activation 
of the anterior cingulate region in distress related to social rejection.  Additionally, 
anterior insula regions – also implicated in affective aspects of physical pain – have been 
shown to be involved in this response (DeWall et al., 2010; Masten et al., 2009; Masten, 
Telzer, Fuligni, Lieberman & Eisenberger, in press).   
DeWall et al. (2010) provide additional evidence of the overlap between physical 
and social pain systems.  They illustrated that a physical pain reliever reduced both social 
pain and neural activity in regions involved in physical and social pain.  Acetaminophen, 
a common physical pain reliever, whose mechanism of action is unclear, was contrasted 
with placebo over a 3-week administration period.  Administration of acetaminophen led 
to reduced self-reports of daily social pain, and in an fMRI task, those who had taken the 
drug for 3 weeks showed reduced activity in regions known to respond to affective 
components of physical pain – the dorsal anterior cingulate and anterior insula. 
Across all studies reviewed thus far, during the affective experience of social loss 
or social pain, areas known to be implicated in physical pain, notably the periaqueductal 
gray, and very consistently, the anterior cingulate cortex and anterior insula, are 
activated. 
Subsequent work has provided further evidence supporting the link between 
physical and social pain, by demonstrating shared sensitivity to both.  Because of the 
strong neural link between physical and social pain, Eisenberger et al. (2006) 
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hypothesized that there should be a relationship between sensitivity to both types of pain.  
There was pre-existing evidence in support of this idea: Young children who are in 
physical pain tend to exhibit increased sensitivity to social pain (Bowlby, 1969), and 
individuals who suffer from chronic pain tend to have anxious attachment styles, 
indicating fear of social loss (Ciechanowski, Sullivan, Jensen, Romano & Summers, 
2003).  Furthermore, those who are extremely sensitive to social rejection report greater 
distress at seeing others in physical pain (Macdonald & Shaw, 2005).  Social support is 
also known to mediate both physical and social pain (Brown, Sheffield, Leary & 
Robinson, 2003; Hoogendoorn, van Poppel, Bongers, Koes & Bouter, 2000; Kennell, 
Klaus, McGrath, Robertson & Hinkley, 1991; King, Reis, Porter & Norsen, 1993; Leary 
& Springer, 2000; Macdonald & Leary, 2005; Zaza & Baine, 2002), and this review has 
already covered evidence indicating that mu-opioid medication seems to attenuate both 
types of pain, at least in non-human animals. 
Eisenberger and colleagues (2006) conducted a study following up on some of 
these ideas.  They tested two hypotheses: 1) That baseline sensitivity to physical pain 
should predict sensitivity to social rejection, and 2) that experiences that lead to increased 
social distress should increase pain sensitivity.  Both hypotheses were supported: 
Participants who scored higher on baseline sensitivity to pain manifested greater levels of 
social distress when excluded from social activity, while participants who experienced 
social rejection in the study rated pain stimuli administered towards the end of the 
assessment as more aversive.  These relationships remained significant after neuroticism 
was controlled for; the results thus cannot be ascribed simply to high anxiety across 
conditions (Eisenberger et al., 2006).  This work provides further evidence for a strong 
association between physical and social pain in humans.   
Subsequent work has investigated mechanisms linking social support to reduced 
physiological reactivity to stressors, and suggests that opioids may be implicated.  The 
effects of social support are not trivial: Lack of social support is known to be associated 
with a markedly increased risk for morbidity and mortality, even compared to well-
known risk factors such as smoking, obesity and hypertension.  The authors found that, 
over a period of 10 days, participants who had regular supportive interactions had lower 
cortisol reactivity to a social stressor (Eisenberger, Taylor, Gable, Hilmert & Lieberman, 
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2007).  Critically, both greater social support and reduced cortisol reactivity were 
associated with reduced acitivity in regions previously shown to be associated with social 
disress (dorsal anterior cingulate and right ventral prefrontal regions).  The authors point 
to two possible ways in which social support could reduce physiological reactivity to 
stressors.  The first possibility is that social support changes perception of stressors; these 
are simply not perceived as threatening and thus the physiological stress response is not 
elicited.  If this were true, they argue you would expect to see reduced activity in neural 
structures usually involved in response to threats.  The second possibility is that social 
stressors might exert their effect after threat perception but before the full physiological 
response takes effect – this would mean that those with social support are better able to 
regulate their responses to stress. If this is the case, one would expect to see increased 
activation in prefrontal regions known to be associated with regulation. 
Eisenberger et al. found, confirming results from previous studies, that increased 
dorsal anterior cingulate activity correlated with greater self-reports of distress.  During 
social exclusion, greater right-sided activation in the ventral prefrontal region was 
associated with less self-reported distress.  This region is known to be involved in 
inhibition and affect regulation (Aron, Robbins & Poldrack, 2004; Lieberman et al., 
2007; Ochsner et al., 2004).  They concluded that this evidence lends support to the 
second of the two possibilities listed above; that is, that social support exerts its effect in 
aiding individuals to better regulate their responses to stressors.  Furthermore, they 
suggested that social support acts on the anterior cingulate as follows:  The anterior 
cingulate has one of the highest densities of opioid receptors (Schlaepfer et al., 1998; 
Vogt, Wiley & Jensen, 1995); Eisenberger and her colleagues (2007) suggested that, over 
time, consistent social support leads to regular release of opioids, which in turn 
desensitizes the anterior cingulate and results in an attenuated response to stress. 
Recent work provides further support for the idea that social support may 
desensitize individuals to social stressors (Masten et al., in press).  In a prospective study, 
high school students recorded daily time spent in interaction with friends and 2 years later 
took part in an fMRI study featuring social exclusion.  The authors found that greater 
time spent with friends 2 years previously related to reduced current activity in areas 
associated with social pain (dorsal anterior cingulate and anterior insula).  They 
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suggested that these findings indicate that social support can lead to reduced social 
sensitivity, and thus reduced reactivity to social stressors.  Of course these findings also 
suggest the opposite possibility – that social loss or lack of supportive social interaction 
may promote sensitivity to social pain, with increased activation in areas associated with 
the experience of these negative feelings. 
 
To summarize, the human neuroimaging work reviewed here indicates that: 
 Physical and social pain share common neural substrates, notably in the 
anterior cingulate cortex and anterior insula.  (The fact that some deeper 
subcortical regions implicated in animal work have not been identified in 
human fMRI studies is unsurprising, and by no means excludes the 
possibility that they form part of the SEPARATION-DISTRESS system in 
humans.  fMRI remains better suited to examining cortical than 
subcortical activations, with very particular imaging sequences being 
required to access deeper regions with any degree of accuracy.  Moreover, 
although fMRI‟s spatial resolution is considered good (in contrast to EEG, 
for example) commonly used preprocessing techniques like spatial 
smoothing limit its ability to accurately identify BOLD responses in small 
regions).    
 Further supportive evidence of the link between physical and social pain is 
demonstrated by shared sensitivities to both types of pain. 
 Social support is associated with desensitization to social stressors, and 
with reduced activity in regions known to be associated with response to 
physical and social pain (anterior cingulate and anterior insula).  It is 
entirely possible that this effect is opioid-mediated; however, this cannot 
be concluded from the reviewed research.  These findings also raise the 
possibility that adverse social circumstances and lack of social support 
could have the opposite impact on sensitivity and neural activity in the 
face of social stressors. 
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In the following section of the literature review I present a brief overview of the 
opioid system, and present some human neuroimaging findings that confirm the role of 
mu-opioids in dysregulated stress and affective responses. 
 
Conceptual  Foundations: The Endogenous Opioid System 
 
Current knowledge of the opioid system.  Despite a long history of both use and 
abuse of plant-derived opiates, the existence of endogenous opioid neuropeptides was 
only established in the 1970‟s (Stefano et al., 2000).  The question of why opiate 
sensitive receptors existed in the brain at all led to the search for naturally occurring 
chemistries that interacted with these receptors, and hence to the ongoing investigation 
and elucidation of the endogenous opioid system.  Delineating the full complexity and 
function of this system remains an active area of investigation. 
Three types of G protein-coupled opioid receptors have been identified – mu, 
delta, and kappa receptors (Gillan & Kosterlitz, 1982; James & Goldstein, 1984; Martin, 
Eades, Thompson, Huppler & Gilbert, 1976).  Although various other potential receptors 
and receptor subtypes have been considered, the general consensus seems to be that there 
is insufficient evidence to accept any of these as opioid receptors proper.  It should, 
however, be noted that Opioid-Receptor-Like 1 (ORL-1) is often included in lists of 
opioid receptors, and that splice variants of mu-opioid receptors have also been identified 
(Evans, 2004; Henriksen & Willoch, 2008; Pasternak, 2004). 
Three families of endogenous ligands were identified by the end of the 1970‟s – 
enkephalins, dynorphins, and endorphins.  Each derives from a specific precursor protein 
and has high binding affinity with particular receptor types.  The enkephalins methionine 
and leucine derive from proenkephalin and show high affinity for delta receptors.  The 
dynorphins A, B and neo-endorphin derive from prodynorphin, and bind with high 
affinity to kappa receptors.  The endorphin, beta-endorphin derives from pro-
opimelanacortin, and has high affinity for both mu and delta receptors (Drolet et al., 
2001; Henriksen & Willoch, 2008; Stefano et al., 2000).  Mu-opioid receptors were soon 
shown to be critically implicated in analgesia and in other key opioid functions (Evans, 
2004).  Some early researchers thus wondered why no mu-selective ligand had been 
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found: beta-endorphin displays equal affinity for both mu and delta receptors.  This 
question led to the discovery in the 1990s of two new peptides that demonstrate a very 
high and selective affinity for mu-opioid receptors – the endomorphins, EM1 and EM2 
(Zadina et al., 1999). 
 
Opioid receptor distribution.  The opioid system is represented, with varying 
densities and profiles of receptors, throughout the mammalian nervous system.  It is 
found not only in the central nervous system, but also in the peripheral and autonomic 
systems.  Moreover, it is implicated in a wide spectrum of functions, from regulating 
autonomic system function, to modulating physical pain, to involvement in processing 
reward and social emotions.  Clearly, both the complexity of its components and the 
multiple processes in which it is involved indicate that the opioid system cannot be 
considered a single functional unit (Drolet et al., 2001; Henriksen & Willoch, 2008).  A 
full understanding of the biological advantages conferred by the multiple opioid peptides 
has yet to be achieved (Evans, 2004). 
The broad research program within which my study is nested centers on affective 
processes mediated by mu-opioid receptors and mu-agonists, hence this brief overview 
will focus on this component of this complex system.  There is a substantial body of 
animal research, and a growing body of human research, indicating that the mu-opioid 
system is distributed in, and serves to modulate the function of, brain regions known to 
be critically involved in affective processing (Galynker et al., 1996; Liberzon et al., 2007; 
Sanders, Kieffer & Fanselow, 2005; Zubieta et al., 2003). 
Although much animal work has been done to map opioid receptors in general, 
with some focused on mapping mu-opioid receptors, I have been unable to find a single 
source that sets out specifically to map the distribution of mu-opioid receptors in the 
human brain.  It is not possible to extrapolate without some caution from animal to 
human systems, as inter-species variability has been demonstrated (Henriksen & Willoch, 
2008).  However, given the lack of human mapping work, it is worth looking to animal 
studies for some guidelines on the distribution patterns of receptors.  
Animal research has indicated that opioid receptors are represented throughout the 
brainstem, limbic system, and cortex, although the density of receptor subtypes varies (Le 
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Merrer, Becker, Befort & Kieffer, 2009).  Most sources focus on mapping mu-opioid 
receptors in deep and limbic brain regions, and give very little detail on their distribution 
in cortex.  In rats, mu-opioid receptors are synthesized in greatest numbers in the 
thalamus, striatum, locus coeruleus, and the nucleus of the solitary tract (Mansour, Fox, 
Akil & Watson, 1995).  In non-human primates, very high densities of mu-opioid 
receptors are found in the periaqueductal gray, medial hypothalamic and limbic regions 
of the brain, including the amygdala and hippocampus (Snyder, 2004).  Subcortically, 
mu-opioid receptors are found in the nucleus accumbens, caudate-putamen, diagonal 
band of Broca, globus pallidus, ventral pallidum, bed nucleus of the stria terminalis, and 
nucleus of the solitary tract.  They are also found in the ventral rostral medulla (raphe 
nucleus and nucleus coeruleus), septum, parabrachial complex, and medial preoptic area 
(Drolet et al., 2001; Panksepp, 1998; Sanders et al., 2005; Stefano et al., 2000).  Taking a 
broad overview, it seems that animal research indicates that mu-opioid receptors are 
highly represented in brain regions involved in pain, reward, and affective processing.   
Most human research has focused on particular questions or specific regions, 
rather than on mapping per se.  Human post-mortem studies have indicated a high 
concentration of mu-opioid receptors in the prefrontal cortex, cingulate, temporal cortex, 
basal ganglia, ventral tegmental area, cerebellum, thalamus, and hypothalamus (Kennedy 
et al., 2006; Maurer, Cortes, Probst & Palacios, 1983; Pfeiffer, Pasi, Mehraein & Herz, 
1982).  Functional imaging work using SPECT and PET has indicated that administration 
of mu-agonists leads to increased cerebral blood flow in prefrontal cortex, anterior 
cingulate cortex, bilateral amygdala, and thalamus (Adler et al., 1997; Jones et al., 1991; 
Schlaepfer et al., 1998), while a mu-opioid antagonist resulted in reduced blood flow in 
the anterior cingulate (van Dyck et al., 1994).  High densities of mu-opioid receptors are 
found in brain regions known to participate in emotion, stress, and reward responses –
including the thalamus, striatopallidal circuitry, extended amygdala, insula, anterior 
cingulate and prefrontal cortex.  Mu-opioids are thought to regulate the function of these 
regions and the neurochemistries associated with them (Greenwald et al., 2007; Zubieta 
et al., 2003).   
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A brief note on opioid function.  Opioids are implicated in human affective 
responses (Liberzon et al., 2007; Schlaepfer et al., 1998).  In general, it seems that 
agonists for mu and delta receptors produce effects that are analgesic and rewarding, 
whereas those that act on kappa receptors produce aversive affects such as dysphoria and 
psychotomimesis.  It may be that mu and delta agonists have these positive effects, at 
least in part, because both increase dopamine release in the nucleus accumbens, whereas 
kappa agonists decrease dopamine release in this region (Henriksen & Willoch, 2008; 
Mansour et al., 1995). 
Mu-opioids have been shown to be critically implicated in key opioid effects, 
including analgesia, euphoria, and reward (Evans, 2004; Mansour et al., 1995).  This role 
has been verified by studies using mu-opioid receptor knockout mice, where morphine-
induced analgesia and place-preference conditioning do not occur (Gaveriaux-Ruff & 
Kieffer, 2002).  The role of mu-opioids in human affective function will be discussed in 
some detail below. 
 
Opioid interactions with other neurochemistries.  Although it is important to 
attempt to tease out the role played by any single neurochemical, it is misleading to think 
of these chemistries as acting independently of each other.  Opioids are no exception, and 
their interactions with other neurotransmitters and neuropeptides are multiple and 
complex.  Given the focus of this study, the interacting chemistries relevant to stress and 
depression are highlighted below. 
Focusing again on mu-opioid effects, this peptide is known to impact on 
monoamines: it inhibits norepinephrine, and stimulates release of dopamine and serotonin 
(Mansour et al., 1995).  Norepinephrine inhibition occurs via mu-opioid activity in the 
locus coeruleus, which inhibits neuronal firing in this region and hence norepinephrine 
release in the cortex.  Stimulation of dopamine release occurs via mu-opioid activity in 
the nigrostriatal and mesolimbic dopamine systems, through inhibition of inhibitory 
GABA interneurons, which results in increased release of dopamine.  (Note that delta 
agonists also increase striatal dopamine, while kappa agonists have the opposite effect.) 
Mu-opioid stimulation of serotonin release occurs in the raphe nucleus.  Thus, it is 
evident that mu-opioids can exert a significant effect on neurochemistries already 
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implicated in depression (more detail on the role of monoamines is provided in the 
section on depression).  Of particular interest here, however, is their interaction with 
stress-related chemistries. 
Of importance with regard to depression is the impact mu-opioids have on 
corticosteroid release in relation to stress responses.  Mu- and delta-opioids impact upon 
neuroendocrine and autonomic responses to stress stimuli; specifically, they act to reduce 
or halt the stress response (Drolet et al., 2001).  They thus play a critical role in ongoing 
adaptation to chronic stress.  Unsuccessful regulation of stress responses, in which mu-
opioids may well be implicated, is thought to result in both physical and affective 
disorders (see, e.g., Heim & Nemeroff, 1999; Heim et al., 2000; Heim et al., 2002; Heim 
et al., 2009; Lupien, McEwen, Gunnar & Heim, 2009; McEwen, 2007; McEwen & 
Stellar, 1993).     
A vital consideration is the possibility of permanent dysregulation in the stress 
and mesolimbic dopamine systems following early trauma.  Chronic stress results in 
changes in both the mu- and delta-opioid systems (Drolet et al., 2001).  Critically 
important recent research illustrates that long-term mu-opioid mediated changes in 
mesolimbic dopamine pathways may well occur following social stress.  Nikulina, 
Miczek and Hammer (2005) initially showed that ventral tegmental area mu-opioid 
receptor stimulation in stressed rats led to increased mesolimbic dopamine levels, which 
in turn led to increased Fos protein expression in the ventral striatum/nucleus accumbens.  
Moreover, acute social stress led to rapid upregulation of mu-opioid receptors in the 
ventral tegmental area and periaqueductal gray.  A follow-up study showed that these 
effects are long-lasting (Nikulina, Arrillaga-Romany, Miczek & Hammer, 2008).  
Following repeated social stress, mu-opioid receptor messenger RNA in the ventral 
tegmental area doubled, and remained high for 21 days.  Fos changes occurred in the 
nucleus accumbens, striatum and amygdala, and similarly persisted for 21 days.  
Furthermore, they unequivocally demonstrated the role of ventral tegmental area mu-
opioid receptors in this process by stimulating these cells with a mu-opioid receptor 
agonist several days after the stress manipulation; this stimulation resulted in increased 
Fos changes in the nucleus accumbens.  They also showed that the induction of these 
protein changes in the nucleus accumbens is eliminated by administration of a mu-opioid 
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receptor antagonist.  Repeated social stress thus led to long lasting mu-opioid-mediated 
changes in mesolimbic dopamine function.  It seems clear that the mu-opioid system may 
have a critical role in mediating long-term effects of social stress. 
 
In summary, this brief review focused on mu-opioids has indicated that: 
 Mu-opioid  receptors are found in high concentrations in brain regions 
involved in pain and affective processing 
 Mu-opioids interact with neurochemistries already known to be implicated 
in depression; viz. the monoamines. 
 Mu-opioids play a role in regulating (attenuating) stress responses; and it 
is known that unsuccessful regulation of stress responses is implicated in 
the development of physical and affective disorders. 
 There is evidence from animal research that early trauma results in 
permanent dysregulation of the stress and mesolimbic dopamine systems; 
and specifically that social stress leads to lasting mu-opioid mediated 
changes in mesolimbic dopamine function. 
 
Critical Evidence from Human Neuroimaging 
 
Mu-opioid involvement in affective dysregulation.  A series of studies by 
Zubieta and colleagues has made a valuable contribution to knowledge of mu-opioid 
function in relation to affective processing in humans.  Using PET imaging, with the mu-
opioid selective radiotracer carfentanil, they have illustrated that mu-opioid activity is 
associated with the regulation of both affective components of physical pain, and of 
social pain.   
This work has shown that mu-opioid activation mediates the experience of pain, 
and that this may differ across men and women.  Activity in the dorsal anterior cingulate, 
anterior thalamus and ventral basal ganglia plays a key role in suppressing aversive 
affective perception of pain (Zubieta et al., 2001).  Females are known to show higher 
pain reactivity, and a study by this group demonstrated that hyperalgesia in females was 
associated with mu-opioid deactivation in the nucleus accumbens (Zubieta et al., 2002).  
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Given the increased incidence of depression in women, sex differences of this nature may 
be implicated in this disorder. 
Moreover, in the first study to show dynamic changes in a human 
neurotransmitter system during a sustained emotional state, this research group examined 
patterns of activity exhibited during sustained sadness versus a sustained neutral state 
(Zubieta et al., 2003).  In the sadness condition, the authors noted a significant 
deactivation of mu-opioid transmission in key limbic and striatal regions – the rostral 
anterior cingulate, ventral pallidum, amygdala, and inferior temporal cortex.  
Deactivation in the ventral pallidum and amygdala was found to correlate with self-
reports of increased negative and reduced positive feeling states. 
Subsequently, this research group went on to show that mu-opioid emotion 
regulation circuitry in women with major depression appears to function abnormally 
(Kennedy et al., 2006).  They again used carfentanil in a PET study, and contrasted mu-
opioid receptor binding potential in sustained sadness state (vs. neutral) in women with 
major depression compared to matched controls.  They found that, in the normal controls, 
sustained sadness was associated with deactivation in the rostral anterior cingulate, 
amygdala, inferior temporal cortex, ventral striatum/nucleus accumbens, and 
hypothalamus.  The rostral anterior cingulate deactivation furthermore correlated with 
increased reported negative affect.  This constituted a replication of their previous 
findings in normals, and is consistent with the idea that mu-opioids function to regulate 
and dampen negative affective responses.   
Kennedy et al. (2006) also found that, in contrast to psychiatrically healthy 
women, in women with major depression, sustained sadness was associated with 
increased activation in the anterior cingulate, amygdala, inferior temporal cortex, nucleus 
accumbens and hypothalamus.  They also observed a correlation between anterior 
cingulate activation and plasma cortisol levels in the major depression group, and – the 
argued that this was another indicator that the mu-opioid system is involved in regulating 
stress responses.  Kennedy et al. further examined this response in those who later did 
and did not respond to a follow-up SSRI intervention.  They found that rostral anterior 
cingulate activation in these groups was different as follows: Those who later responded 
to the SSRI evidenced reduced rostral anterior cingulate activation patterns, similar to 
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those seen in the normal controls, whereas those who did not respond to SSRIs showed 
increased rostral anterior cingulate activation.  Thus we see an abnormal mu-opioid 
response in key limbic and subcortical regions in the depressed subjects.  Furthermore, 
this abnormal response is associated with raised plasma cortisol levels, and with non-
response to a SSRI trial. 
Given the role of mu-opioids in mediating stress responses, this research group 
went on to investigate mu-opioid function after trauma, comparing healthy normals to 
participants exposed to war (Liberzon et al., 2007).  The latter comprised two groups – 
those with and those without post-traumatic stress disorder (PTSD).  In this protocol, 
PET imaging was done at rest, so the findings indicate differences in baseline mu-opioid 
function, rather than a response to any challenge or cognitive task.  They found distinct 
between-group differences, with both trauma groups showing reduced binding potential 
in the extended amygdala, insula, nucleus accumbens, and dorsal prefrontal cortex.  The 
PTSD group had lower binding potential than both non-PTSD groups in the anterior 
cingulate, while the trauma non-PTSD group had lower binding potential than both other 
groups in the amygdala and higher binding potential in the orbitofrontal cortex.   
The authors interpreted these alterations in baseline mu-opioid function as 
indicating adaptation: they argued that trauma exposure leads to opioid release, with 
subsequent downregulation of mu-opioid receptors; hence the reduced binding potential 
in important and highly interconnected areas (extended amygdala, thalamus and dorsal 
prefrontal cortex) in both trauma groups.  In contrast, the orbitofrontal cortex‟s primary 
function appears to be inhibitory: It modulates responsiveness in lower limbic regions, 
with the anterior cingulate perhaps contributing to this modulation.  The non-PTSD 
trauma group demonstrated greater upregulation in the orbitofrontal cortex, and the 
authors suggest this indicates that failure to fully upregulate mu-opioid activity in this 
region may be an important characteristic of PTSD.  This failure to upregulate is 
suggested to have permissive effects on mu-opioid activity in lower regions, which in 
their previous work was shown to be associated with sustained negative mood in women 
with depression.   
An important suggestion has been made by Liberzon et al. (2007): If exposure to 
trauma in adults results in changes in baseline mu-opioid function, it is entirely possible 
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that early trauma may lead to changes in the development of the opioid system.  This 
contention is also made by Panksepp based on his animal work.  This possibility is a key 
factor that the current research program seeks to examine. 
 
In summary, the PET imaging work reviewed above has shown that: 
 Mu-opioids regulate physical and social pain in humans.  There may be a 
sex difference in this function, which would be of obvious relevance to 
depression.  
 In healthy normal subjects, reduced mu-opioid activity in limbic and 
striatal areas is associated with increased experience of sadness. 
 This pattern is inverted in women with major depressive disorder, 
suggesting that mu-opioid function is dysregulated in this disorder. 
 Changes in baseline mu-opioid function are evident subsequent to 
exposure to trauma in adult life. 
 Seeing altered patterns of mu-opioid activity in these two disorders 
(depression and PTSD) supports the contention that this neuropeptide is 
critical in problematic regulation of stress responses and affective 
modulation.  
 
I now turn to the literature on depression.  It is far beyond the scope of this 
dissertation to provide a comprehensive review of the enormous body of research done in 
the field of depression over the past five or six decades.  Hence, in the section that 
follows, I will only address the issues that seem most pertinent to the current research 
question, with some focus on work around the neurobiology of depression. 
 
Conceptual  Foundations: Major Depression 
 
Classification and diagnosis.  Depression is defined as a disorder of mood, and 
is most often diagnosed according to criteria laid out in the Diagnostic and Statistical 
Manual of the American Psychiatric Association, the current edition of which is the 
DSM-IV-TR (APA, 2000).  The DSM-IV-TR recognizes two forms of unipolar 
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depression – major depressive disorder and dysthymia.  Major depressive disorder is 
diagnosed when the following criteria are met: Sad mood and/or anhedonia present for at 
least 2 weeks, in addition to four of the following symptoms: changes in sleep, weight or 
appetite; psychomotor changes; difficulties with decision making; feelings of 
worthlessness, excessive guilt, or suicidal ideation.  Thus, despite being regarded as a 
disorder of mood, depression impacts on multiple domains of function.  Although single 
episodes of major depression do occasionally occur, it is generally regarded as a chronic, 
remitting and relapsing disorder (Mayberg, 2004).  Dysthymia is a related mood disorder, 
characterized by longer chronicity alongside a less severe symptom profile.  Dysthymia is 
diagnosed when sad mood and at least two symptoms of major depression (excluding 
psychomotor agitation and suicidal agitation) are present for at least 2 years.  This review 
will focus on major depressive disorder.  
The DSM-IV-TR delineates a number of subtypes of major depressive disorder, 
which are termed specifiers of the disorder.  The first subtype, melancholic, has the 
longest history, actually predating the term „depression‟ itself.  In the modern 
classification system, melancholic depression‟s presentation profile features marked 
anhedonia and endogenous low mood (Rush, 2007).  This subtype contrasts with atypical 
depression, where mood is defined as reactive to external events.  In addition, marked 
sensitivity to rejection, and an inverse pattern of vegetative symptoms (i.e., hypersomnia, 
increased appetite, and weight gain) are said to characterize atypical depression (APA, 
2000).   
Four other subypes are recognized by the DSM-IV-TR – two very severe forms 
(major depressive disorder with psychotic features and catatonic major depression), and 
two subtypes that have specific onsets (postpartum depression and seasonal affective 
disorder).  A further subtype, anxious depression, is often mentioned in the literature but 
is not part of DSM nosology.  In this classification system, a diagnosis of major 
depressive disorder is often noted as being accompanied by marked anxiety, or a 
comorbid anxiety disorder is diagnosed (Drevets et al., 2008). 
 
Epidemiology and impact estimates.  Major depressive disorder is one of the 
most common serious psychiatric disorders, causing great cost to affected individuals, 
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health services and national productivity (Nemeroff, 2007).  By 2020, it is projected to be 
the second leading cause of disability in the developed world (Giacobbe, Mayberg & 
Lozano, 2009; Kaplan & Harvey, 2009).  The National Comorbidity Study conducted in 
the United States indicated a 12-month prevalence of 5.3%, and a lifetime prevalence of 
13.3%, for major depression.  Rates are at least twice as high in women than in men 
(Kessing, 2007; Mayberg, 2004).  Rates in South Africa appear to be slightly lower, with 
a 12-month prevalence of 4.9%, and lifetime prevalence of 9.7% (Tomlinson, Grimsrud, 
Stein, Williams & Myer, 2009).   
Major depression has been estimated to result in moderate role impairment in 
28% of cases, and in severe role impairment in 59% of cases.  This impairment leads to 
an inability to work or to carry out normal daily activities for an average of 35 days per 
annum for each affected individual (Wang et al., 2003).  In the South African 
epidemiology study, 90% of those with depression reported global role impairment 
(Tomlinson et al., 2009).  Major depressive disorder is associated with increased risk of 
medical disease, including heart disease, stroke, and diabetes, along with increased risk of 
suicide (Golden et al., 2004; van Melle et al., 2004; Williams, 2005).  Because of its high 
prevalence rates and marked impact on function, major depression ranks as number two 
in the developed world when calculating disability-adjusted life years (WHO, 2001).   
 
Heterogeneity of major depression.  Depression is thus clearly a major health 
problem.  Yet despite decades of research, and ongoing attempts to provide nosological 
clarity, it seems that the single point of agreement among researchers and clinicians in 
this field is that the disorder is poorly characterized, and that, as a result, pharmacological 
treatment options remain unsatisfactory.   
To date, major depressive disorder remains a clinical syndrome; this means that it 
does not meet criteria to be defined as a disease.  The latter requires that diagnosis can be 
made upon determining the presence of a specific etiology and pathophysiology, and that 
a specific clinical course for the disease is known.  Major depressive disorder, in contrast, 
is marked by heterogeneity of “presentation, genetics, neurobiology, clinical course and 
treatment responsiveness” (Rush, 2007, p.4).  In the face of this heterogeneity, attempting 
to define subtypes that have unique etiological, symptomatic, and medication sensitivity 
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profiles seems a sensible route to take, but the current nosological subtypes appear to 
have, at best, questionable validity. 
At the most basic level, the distinction between major depressive disorder and 
dysthymia is problematic.  Long-term studies indicate that in most individuals, depressive 
symptoms fluctuate over time, meeting criteria for different diagnoses at different times, 
and ranging from subclinical states to dysthymia to major depressive disorder.  It seems 
clear that there is no categorical distinction between these nosological entities – they 
simply represent different points on a continuum of symptom severity (Kessing, 2007; 
Rush, 2007). 
Definitive differentiation of subtypes is similarly lacking.  Researchers are not 
convinced that there is empirical support for the two most commonly diagnosed DSM-
IV-TR subtypes (melancholic and atypical depression).  Some reviewers argue that 
various studies have found no reliable differences in clinical presentation or outcome for 
these subtypes (Kessing, 2007; Nandi, Beard & Galea, 2009).  In contrast, other 
reviewers argue strongly for the existence of the melancholic subtype, based on evidence 
of a specific symptom profile, and the presence of certain biological markers, notably 
increased cortisol levels (Rush, 2007).   
Despite being the most commonly identified subtype, atypical depression is a 
problematic category.  The presence of one of its key characteristics, reactive mood, has 
not been supported empirically (Kaplan & Harvey, 2009; Nandi et al., 2009).  It seems 
the reverse vegetative symptoms constitute a more reliable differentiator (Matza, Revicki, 
Davidson & Stewart, 2003; Seemuller et al., 2008; Thase, 2007).  The attempt to define 
subtypes based on symptom profiles has thus not been particularly successful.   
Another problem with the current nosological system is that it views anxiety as 
belonging to a separate set of disorders.  However, around half of all depression cases 
feature marked anxiety, and this feature is associated with greater severity and increased 
suicidal ideation (Rush, 2007).  The current nosology thus excludes an important 
symptom of the disorder. 
Several reviewers concur that it may be incorrect to conceptualize major 
depression as a homogenous disorder with a single underlying pathophysiology (Nandi et 
al., 2009; Nemeroff, 2007; Wijeratne & Sachdev, 2008).  Most authors highlight the need 
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to determine the etiology of depression.  Such a step would enable a far more reliable 
diagnostic system that would include subtyping based on distinct pathophysiological 
mechanisms (Drevets et al., 2008; Kessing, 2007).  However, currently there is little 
consensus in the literature as to what these mechanisms may be. 
 
Indeterminate etiology of major depression.  There is as yet no clarity on the 
biophysiological mechanisms of depression.  The once-promising monoamine hypothesis 
(Shildkraut, 1965) cannot fully account for the spectrum of the disorder, and some regard 
it as having impeded progress in the attempt to elucidate the biological underpinnings of 
depression (Norman, 2006). 
The monoamine hypothesis originated in the 1950s, when it became evident that 
medications that provided relief from depressive symptoms acted on the monoamine 
neurotransmitter systems, particularly the serotonin or norepinephrine systems, by 
increasing their synaptic availability.  Investigation of these neurotransmitters has 
remained at the forefront of psychopharmacological research for five decades, with the 
successful development of selective serotonin reuptake inhibitors (SSRIs) only serving to 
strengthen this focus (Lee, Jeong, Kwak & Park, 2010; Lopez-Munoz & Alamo, 2009; 
Mayberg, 2004).  Relatively recently, profound problems with this model have become 
increasingly evident.  The idea that dysregulation in these specific systems is of 
fundamental significance is not tenable for the following reasons: 1) years of research 
have failed to demonstrate that depression results from any specific monoamine 
dysfunction or that monoamine depletion can produce depression in normal people, and 
2) certain drugs that provide relief from depression do not act in accordance with the 
hypothesis, acting either to reduce monoamine availability, or acting on other chemistries 
entirely (Mayberg, 2004; Watt & Panksepp, 2009).   
Research into the biological basis of depression has continued to investigate the 
monoamine neurochemistries, but has also expanded to include investigation of many 
other chemistries and peptides, as well as the examination of genetics and intracellular 
mechanisms, and structural and functional correlates of depression. To date, no definite 
pathogenesis has been defined, and preclinical markers have yet to be established 
(Drevets et al., 2008; Giacobbe et al., 2009; Lee et al., 2010).  In the sections to follow I 
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will give a very brief indication of the current breadth of investigation in these 
enormously complex arenas. 
 
Structural and functional neuroanatomical markers.  In unipolar depression, no 
reliable gross structural abnormalities have been established.  Postmortem studies have 
indicated that glial loss occurs in depression, but that this loss appears to take place in 
various distributed areas; no critical region has been defined (Bowley, Drevets, Ongur & 
Price, 2002; Drevets et al., 2008; Mayberg, 2009; Ongur, Drevets & Price, 1998).  
Structural neuroimaging studies have indicated the presence of volumetric changes in 
various frontal, limbic, paralimbic and cortico-striatal structures.  Various regions of the 
cingulate gyrus (most often, but not always, anterior) have been implicated.  Temporal 
areas including the superior temporal gyrus, temporal poles, hippocampus, 
parahippocampal gyrus and amygdala have been listed.  Key subcortical regions include 
the ventromedial striatum and thalamic nuclei.  Reviewers agree that a great deal of 
variability is present in this literature, both in terms of the types of changes seen, and in 
the precise regions implicated (Drevets et al., 2008; Mayberg, 2009; Pizzagalli et al., 
2004; Sheline, 2003).   
Functional changes (in blood flow and glucose metabolism) have also been noted 
in many of these, and other, areas (Baxter et al., 1985; Drevets et al., 2008; Drevets et al., 
1992; Fitzgerald, Laird, Maller & Daskalakis, 2008; Mayberg, 2003).  Several 
researchers argue that depression is characterized by reduced frontal activity alongside 
increased limbic and subcortical activity, indicating a failure of emotion regulation 
(Dannlowski et al., 2009; Drevets et al., 2008; Giacobbe et al., 2009; Johnstone, van 
Reekum, Urry, Kalin & Davidson, 2007; Mayberg, 2004).  Difficulties with this model, 
however, stem from the fact that the literature is not consistent: although hypoactive 
frontal regions along with hyperactive limbic and subcortical regions are often shown, 
many studies provide contradictory evidence – for example, of normal, or hyperactive 
states in frontal cortex, and reduced activity in the limbic or subcortical regions.  The 
possible reasons for this variability in the literature are multiple and include: 1) functional 
imaging data is impacted by structural volume loss, but most studies do not correct for 
this (Drevets et al., 2008); and 2) despite the general consensus that great heterogeneity is 
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present in depression, much work in the field includes cases with major depression as 
though they constitute a homogenous group; thus participants are likely to have very 
different clinical symptom profiles, which may reflect differing underlying mechanisms.  
This heterogeneity may thus also serve to confuse matters (Mayberg, 2009).  As yet, 
there is no consensus regarding the reliability of these observed structural and functional 
changes, and thus deriving an account of what they may mean is problematic. 
A more robust set of observations indicates that resting state activity is abnormal 
in depression (Greicius et al., 2007; Grimm et al., 2009; Sheline et al., 2009).  These 
observations have led to the generation of a complex model of depression as a systems-
level disorder, which impacts at multiple anatomical and functional levels (Northoff, 
Wiebking, Feinberg & Panksepp, in press).  The abnormal patterns of resting-state 
activation in depression feature hyperactivity in medial, limbic regions and hypoactivity 
in lateral cortical regions.  This model emphasizes the fact that medial regions are 
implicated in core emotions and in self-representation, whereas lateral cortical regions 
deal primarily with processing and reacting to external stimuli.  The resting-state 
imbalance is thought to allow the medial, primitive emotion systems to derail higher 
cortical emotional and cognitive functions.  This model is very promising in that it 
presents details of nested functional neuroanatomical hierarchies that account for how the 
systems interact, and how multiple domains of function may be impacted. 
 
Neurochemistries implicated in depression.  Changes in multiple 
neurochemistries have been documented in depression, including the monoamine 
systems, and the cholinergic, glutamatergic, GABA-ergic, and glucocorticoid chemistries 
(Drevets et al., 2008; Mayberg, 2004; Mineur & Picciotto, 2010).  Many neuropeptides 
and hormones are currently being investigated, including, for example, galanin, substance 
p, neuropeptides s and y, argnine vasopressin, melatonin, oxytocin and the opioid system 
(Alldredge, 2010; Bourin & Prica, 2009; Machado-Vieira, Salvadore, Ibrahim, Diaz-
Granados & Zarate, 2009; Parker et al., 2010).  The possible role of opioids will be 
discussed in more detail in a later section.  Here I will focus briefly on the more widely 
investigated substances – the monoamines and stress-related chemistries. 
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Classic monoaminergic models of depression centered on norepinephrine or 
serotonin.  Although there is a well-established correlation between changes in the 
norepinephrine system and depression, it has not been possible to show a direct causal 
role for norepinephrine in depression (see, e.g., Charney, 1998; Delgado & Moreno, 
2000).  Similarly, although decreased serotonin function is often present in depression, 
this is not invariable (for a recent review, see Jans, Riedell, Markus & Blokland, 2007).  
More recent monoaminergic theories of depression propose that all three monoamines are 
involved, and that dysfunction is present in brain regions modulated by these chemistries 
(for example, frontal cortex, hippocampus, amygdala, and basal ganglia).  In such 
models, decreased motivation is thought to result from dysregulation in the 
norepinephrine and dopamine systems, while increased anxiety and irritability may be 
due to dysregulation in the norepinephrine and serotonin systems (Mayberg, 2004).  
Although these amines clearly are implicated in depression, precisely what their role is 
remains unclear (see Watt & Panksepp, 2009, for a detailed review of this literature). 
A key problem with regarding norepinephrine or serotonin as primary causative 
factors in depression is the delay in response to treatment targeting these chemistries: on 
average a delay of 3-6 weeks is present before therapeutic effects are seen.  This delay 
strongly suggests that these drugs exert indirect effects: that is, antidepressive effects are 
not due to direct manipulation of the monoamines themselves (Lopez-Munoz & Alamo, 
2009).  This line of thinking has led to investigations of downstream molecular events, 
such as impact on second-messenger systems and gene expression, to account for the 
observed antidepressant effects.  Some of this research will be discussed below in the 
section on genetics.   
Recently, investigations focused on the dopamine system have increased.  The 
link between this system and anhedonia seems intuitively obvious, and altered 
dopaminergic function in the ventral tegmental area and nucleus accumbens has been 
found in depression (Nestler & Carlezon, 2006).  Furthermore, medications that target 
this system have been found to relieve some symptoms of depression.  For example, 
methylphenidate (Ritalin) has been shown to improve mood and drive (Mayberg, 2004), 
while the dopamine reuptake inhibitor Bupropion has been found to be effective in 
treating some cases (Watt & Panksepp, 2009).  Reduced dopamine activity is now widely 
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considered to be a key feature of the amotivational and anhedonic state that is a major 
characteristic of depression (Lee et al., 2010; Malhi & Berk, 2007; Zellner et al., in 
press). 
One currently influential line of thinking sees depression as a stress-related 
illness.  Not only does a stressful life event often act as the trigger for (at least) the first 
episode of depression, it seems that changes in corticotrophin releasing factor and 
glucocorticoid signaling may be a key factor in depression (de Kloet et al., 2005; 
Holsboer, 2000).  Corticotrophin releasing factor (CRF) modulates hypothalamic- 
pituitary-adrenal axis (HPA) stress responses.  Dysregulated CRF function, chronically 
elevated cortisol levels and altered glucocorticoid signaling are often evident in 
depression (Burke, Davis, Ottec & Mohra, 2005; Maier & Watkins, 2005; Rush et al., 
1996).  Immune responses may also be implicated here: some evidence indicates that 
cytokines impact on glucocorticoid receptors, resulting in ineffective signalling  (Pace & 
Miller, 2009).   
The role of chronic stress and the resultant complex physiological responses is 
clearly important in major depression.  For the current investigation, the impact of early 
social separation-distress or social trauma is of primary concern.  As reviewed above, 
early social trauma in the form of separation-distress strongly arouses the HPA axis, and 
can cause long-term alterations in the functioning of this system, with permanent 
dysregulation of CRF.  These events may result in a lifelong vulnerability to depressive 
episodes (Heim & Nemeroff, 1999; Levine, 2001, 2005; Rosenfeld, Suchecki & Levin, 
1992; this literature will be discussed in more detail below). 
 
Genetic factors in depression.  Research into the role of genetics appears to be 
yielding similarly complex results.  Studies of heritability indicate a strong genetic 
component in vulnerability to unipolar depression (see Sullivan, Neale & Kendler, 2000, 
for a review of this literature).  Work attempting to identify which particular gene may be 
implicated has not been successful, however.  The initial optimism around a pivotal role 
for the serotonin transporter (5-HTT) has not been maintained.  Early research indicated 
that the short variant of this gene was strongly associated with neuroticism and with 
greater susceptibility to depression (Caspi et al., 2003; Kaufman et al., 2004; Ogilvie et 
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al., 1996).  However, later findings have been mixed, with meta-analyses failing to 
substantiate the association of this gene variant with depression, possibly due to small 
effect sizes (Canli & Lesch, 2007; Gillespie, Whitfield, Williams, Heath & Martin, 2005; 
Risch et al., 2009).  It seems that although genetic factors are clearly implicated in the 
risk for developing major depression, the search for a single candidate gene has been 
unsuccessful (Lee et al., 2010; Shyn & Hamilton, 2010).  It appears that multiple genes 
may be involved, each having only a small effect; neurotrophic, glutamatergic, 
cholinergic, serotonergic, and intracellular signaling pathways all appear to be implicated 
(Drevets et al., 2008). 
Some genetic research supports a neurogenesis hypothesis. CRF dysregulation 
and chronically elevated cortisol levels are thought to lead to neuronal atrophy, 
particularly in the hippocampus (Bremner et al., 2000; Dranovsky & Hen, 2006).  The 
neurogenesis hypothesis states that antidepressant treatments, including monoaminergic 
drugs and electroconvulsive therapy, achieve their effects by promoting cell growth.  
Monoaminergic therapy may achieve its effects by causing multiple changes in 
intracellular messengers (for instance G proteins and cyclic AMP), leading to modified 
gene expression, which in turn leads to synthesis of certain critical substances, like 
proenkephalin and brain-derived neurotrophic factor (BDNF; Lopez-Munoz & Alamo, 
2009; Martinowich & Lu, 2008).  Thus antidepressant therapy, through indirect effects, 
promotes neurogenesis and the synthesis of neurotrophins (Jacobs, Praag & Gage, 2000; 
Lee et al., 2010; Norman, 2006; Savitz, Lucki & Drevets, 2009; Valdez, 2009).   
Precisely how neurogenesis leads to improvement in depressive symptoms has yet 
to be established, however.  For example, although upregulation of BDNF clearly 
accompanies improvement, BDNF itself does not directly modulate mood (Groves, 2007; 
Martinowich, Manji & Lu, 2007).  The impact of opioid synthesis has yet to be 
elucidated.   
 
Inefficacy of current pharmacological treatment for major depression.  A 
wide variety of antidepressant medications, most targeting the monoamine systems, are 
currently the first choice in treating depression (Norman, 2006).  As will be discussed 
below, the efficacy of these medications remains unsatisfactory. 
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In the 1950s, tricyclic antidepressants and monoamine oxydase inhibitors were 
developed, and remained standard treatment for depression until the 1980s.  Tricyclic 
antidepressants act to inhibit the uptake of serotonin or norepinephrine, but also have 
anticholinergic and antihistamine effects.  They thus have a poor side-effect profile, poor 
tolerability, and notable safety concerns (Roose, 2003).  They are no longer considered 
the first choice for initial treatment, but are broadly considered to be useful for treatment 
of severe melancholic or treatment resistant depression.
3
  Early monoamine oxydase 
inhibitors also have problematic tolerance and safety concerns, and are now used mainly 
for treating atypical or treatment resistant depression.  Newer reversible monoamine 
oxydase inhibitors appear to have a better safety profile.  Selective serotonin reuptake 
inhibitors (SSRIs) are currently the first choice in treating depression.  They are widely 
regarded as effective, and have far better tolerability and safety profiles than the early 
medications (Nemeroff, 2007). 
However, many researchers and clinicians remain unsatisfied with the efficacy of 
available treatment, as it is known that a substantial proportion of cases do not respond to 
standard interventions.  The Sequenced Treatment Alternatives to Relieve Depression 
(STAR*D) study was conducted to assess the efficacy of first-choice and standard 
alternatives in treating major depression.  This constituted a 7-year prospective 
randomized controlled clinical trial, conducted at multiple sites in the United States, 
including primary health care and psychiatric facilities, with a total of 3671 outpatients 
enrolled (Warden et al., 2007).  The results of this study confirmed that current medical 
treatment options are not particularly effective. 
The STAR*D study found no indication that any particular antidepressant 
medication was better than any other in treating major depression (Norman, 2006; Rush 
et al., 2006b).  Moreover, contrary to what was commonly believed, the newer SSRIs 
were not shown to have greater efficacy than older medications (Wijeratne & Sachdev, 
2008).  It was also found that when initial treatment trials were not successful, 
conventional alternatives – for example augmenting antidepressant medication, using 
older generation antidepressants, or using ECT – simply were not as effective as had been 
                                                 
3
 Treatment resistant depression is usually defined when a case does not respond to a minimum of two trials 
of different antidepressant medications (Nemeroff, 2007).  
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thought.  The standard strategy of sequential trials of medication was shown to yield 
diminishing results (Giacobbe et al., 2009; Wijeratne & Sachdev, 2008). 
Only 28% of the STAR*D sample achieved remission of symptoms following a 
single trial of SSRIs. Sixty percent of cases required all four sequenced levels of 
treatment to achieve remission, and cases requiring multiple treatment trials were shown 
to have higher relapse rates: of those who required the 4
th
 level of treatment, 50% 
relapsed within 4 months (Little, 2009; Rush et al., 2006a; Warden et al., 2007).  
Researchers in the field were alarmed by these findings: “The results of STAR*D 
are as sobering as they are unequivocal.  The results highlight that currently available 
antidepressant medications and the dominant paradigm of the pathophysiology of 
depression as a deficiency of monoaminergic transmission, have major limitations” 
(Giacobbe et al., 2009, p. 45).  In sum, standard first choice treatments do not work for 
most cases, and relapse occurs at alarmingly high rates. 
Treatment resistant depression is thus clearly not uncommon.  However, 
attempting to identify which cases are likely to be refractory is also not simple, as 
treatment resistance is not synonymous with severity, nor is it associated with any 
particular subtype in the current nosology (Nemeroff, 2007; Wijeratne & Sachdev, 2008).   
Invasive techniques may be used in the attempt to obtain relief for patients with 
treatment resistant depression.  Electroconvulsive therapy (ECT), despite its known side-
effects, is often used when depression is refractory.  Cognitive deficits such as memory 
loss and reduced attention occur subsequent to ECT, although these are often argued to 
be temporary.  It seems, however, that an inverse relationship exists between treatment 
efficacy and the severity of the cognitive deficits (Little, 2009).  Furthermore, ECT‟s 
efficacy is not long-lasting, with relapse appearing to be the rule.  A double-blind placebo 
controlled trial showed that almost all (N = 84) patients relapsed within 6 months of 
ceasing ECT (Nemeroff, 2007). 
Newer invasive treatments have been developed, but their long-term efficacies 
have yet to be established.  For instance, Vagal Nerve Stimulation is approved for use in 
severe or refractory cases.  It involves electrical stimulation of the vagus nerve, requiring 
surgery and permanent placement of a stimulator, usually under the skin of the chest. 
Repetitive Transcranial Magnetic Stimulation (rTMS) involves repetitive intense 
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magnetic stimulation of 1 Tesla being applied to areas of cortex (Little, 2009; Nemeroff, 
2007; Wijeratne & Sachdev, 2008).  Deep brain stimulation, especially targeting 
particular regions beneath the anterior cingulate shows promise (Giacobbe et al., 2009; 
Mayberg, 2009).  Obviously, improved medication treatment options would be preferable 
to these invasive methods, and a great deal of very recent work has focused on 
investigating alternative neurochemical and hormonal targets.  Opioids, however, have 
not received much attention. 
 
In conclusion, although the move to look beyond the monoamine hypothesis of 
depression must be regarded as progression, the field is not yet any closer to a definitive 
understanding of the disorder.  It is now confronted with fragmented neurobiological 
correlates, and the task of attempting to determine whether unipolar depression comprises 
a set of relatively distinct disorders, or whether it is a systems level disease that impacts 
variably at multiple levels (Lee et al., 2010; Northoff et al., in press).  It is clear that 
neurochemistries involved in responses to stress play a key role in this complex picture.  
The contention of the broad research program within which this current study is nested is 
that opioids are also critically implicated in these responses.  Hence the investigation of 
the effects of buprenorphine, a partial mu-opioid agonist, is required.   
 
Opioids and Depression 
The use of opiates in treating mental disorders has a long history, starting with the 
ancient civilizations of Sumeria, Persia, and Egypt (Stefano et al., 2000).  Throughout the 
nineteenth century, opiates were the first choice in treating melancholia, recommended 
by well-regarded physicians such as Emil Kraepelin (Carlson & Simpson, 1963; Emrich 
et al., 1982).  Until as late as the 1950s their use was recommended in psychiatric 
textbooks  (Mayer-Gross, Slater & Roth, 1956).  Around this time, however, ECT and 
monoamine therapy replaced opiates as the medical treatments of choice for depression, 
to some extent simply because they did not have the same addiction risks (Bodkin et al., 
1995).  Thus despite their apparent efficacy in treating depression, their high addiction 
liability has, in the past, mitigated against empirical investigation of their therapeutic 
effects. 
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It therefore seems well worth investigating the therapeutic potential of new 
generation synthetic opioids, buprenorphine in particular, for treatment of depression.  
Buprenorphine has pharmacological properties that make it far safer than traditional 
opiates.  It is a mixed agonist-antagonist, acting as a partial agonist at mu-receptors, and 
as an antagonist at kappa-receptors.  It is an exponentially more powerful analgesic than 
morphine (Cowan, Lewis & Macfarlane, 1977; Jasinski, Pevnick & Griffith, 1978), and 
yet is safe even in overdosage.  This is due to it being a partial mu-agonist: at high doses 
it acts as an antagonist at mu-receptors, thus the respiratory suppression associated with 
high doses of full mu-agonists does not occur (Galynker et al., 1996).   
Buprenorphine has limited addiction liability (Stefano et al., 2000).  Rather than 
the euphoria associated with opiates such as heroin and opium, buprenorphine has been 
shown to have only modest mood elevating effects in humans, which tend to decline as 
dose increases.  Most subjective effects plateau at a relatively low dose (Ciraulo et al., 
2006; Galynker et al., 1996; McAleer et al., 2003; Zacny, Conley & Galinkin, 1997).  
These ceiling effects on typical opiate effects (euphoria and sedation) increase 
buprenorphine‟s safety and reduce its abuse risk (Walsh, Preston, Bigelow & Stitzer, 
1995).  It is also important to note that in studies using opiate-naïve individuals, subjects 
show high side effects on low doses, including vomiting and incapacitation.  It is argued 
that these aversive effects should also contribute to reducing addiction liability (Zacny et 
al., 1997). 
Some researchers are not convinced that buprenorphine has a low addiction risk, 
however.  For example, Evans (2004) argued that buprenorphine usage may result in 
upregulation of mu-opioid receptors, which may lead to increased tolerance of the drug.  
However, Sittl, Nuitjen and Nautrap (2006) examined escalating doses of buprenorphine 
and fentanyl used for analgesic purposes in patients with severe pain.  Previous clinical 
reports on use of buprenorphine for pain management had suggested that increasing dose 
was not required, and this study confirmed that fact.  The researchers found that, unlike 
fentanyl, buprenorphine doses remained stable over time, indicating that patients did not 
develop tolerance to the medication, and that its analgesic effects continued to be 
effective at the same dose.  These findings argue against concerns regarding high 
addiction liability.   
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Buprenorphine and depression.  Buprenorphine is widely used as the primary 
treatment for opiate dependence, and is known to be safe for use in this context (Johnson, 
Jaffe & Fudala, 1992; Johnson, Strain & Amass, 2003; Ling & Wesson, 2003; Mello & 
Mendelson, 1980; Resnick et al., 1992).  Importantly, studies indicate that in recovering 
addicts its use is associated with substantial improvements in comorbid depressive 
symptoms (Kosten, Morgan & Kosten, 1990; Nunes & Levin, 2004).  Moreover, 
preliminary clinical data support the value of buprenorphine in treating certain cases of 
refractory major depression.   
Emrich et al. (1982) conducted the first published study to investigate the efficacy 
of buprenorphine in treating depression.  Their sample consisted of ten psychiatric 
inpatients with major depression, most of whom had not responded to standard 
treatments.  They used a double-blind, placebo-controlled design, with a low dose of 
buprenorphine (0.2mg p/day), and demonstrated significant improvement in depressive 
symptoms over 5-8 days.  Another small, placebo-controlled study with non-dependent 
depressed psychiatric patients (N = 8) indicated marked improvement in mood and 
behavior in 75% of the sample (Mongan & Calloway, 1990).  Bodkin et al. (1995) used 
buprenorphine to treat 10 psychiatric inpatients with refractory depression over a period 
of 6-8 weeks (with a maximum daily dose of 1.8mg).  Three patients could not tolerate 
the medication and treatment was discontinued.  One of the remaining cases deteriorated.  
However, two cases showed moderate improvement, and four achieved total remission of 
symptoms.  These small studies indicate that for some treatment resistant patients, 
buprenorphine may be able to provide relief.  Systematic investigation of this drug‟s 
efficacy is therefore indicated, perhaps particularly in cases of depression following 
childhood social trauma, as is discussed below. 
 
Childhood Trauma and Depression.   
This research program is based on the idea that early social trauma leads to 
vulnerability to depression at least in part because of mu-opioid dysregulation.  A critical 
study (Nemeroff et al., 2003) indicates that exposure to early childhood social trauma 
may be a factor in poor response to pharmacological treatment of depression.  The 
investigators examined data from 681 cases with chronic forms of major depression, 
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assessing the efficacy of psychotherapy, medication or combination therapy.  They found 
that the results differed markedly once the cases were stratified according to whether or 
not the depressed individuals had experienced early childhood trauma (defined as loss of 
parents, physical or sexual abuse, or neglect).  Those with a history of such trauma were 
significantly less responsive to antidepressant medication (the medication used was 
nefadozone, which acts to inhibit reuptake of serotonin, norepinephrine and dopamine).  
In these cases, targeting the monoamines did not seem to work.  Investigation of the 
efficacy of opioid medication for depression following early social trauma is thus 
necessary.  
There is a well-established literature that clearly shows a strong association 
between early life difficulties and later depression (see, e.g., Bowlby, 1980; Heim & 
Nemeroff, 1999; Heim et al., 2009; Kendler, Thornton & Gardner, 2001; Reite, Short, 
Seiler & Pauley, 1981; Slavich et al., 2010).  Space prohibits a full review of this 
substantial literature, but in brief the key points are as follows: Classic attachment theory 
predicts that bonding experiences with the primary caregiver in the first 2 years of life set 
a template for the individual‟s sense of self, and for all future relationships (Bowlby, 
1969).  The implications for those with problematic attachment experiences are clear; 
even though other bonds and social attachment experiences also exert important 
influences across development (Flinn & Leone, 2006).  A great deal of research supports 
the critical role played by aversive or disrupted early social relational experiences in later 
psychopathology (see, e.g., Flinn et al., 2009; Heim et al., 2000; Heim et al., 2002; Heim 
et al., 2010; Zlotnick, Mattia & Zimmerman, 2001; Zlotnick, Warshaw, Shea & Keller, 
1997).   
Evidence of this association from prospective studies is particulary compelling.  
For example, in a study examining 676 children with confirmed abuse or neglect prior to 
the age of 11 years, researchers found a significantly increased risk for depression in 
adulthood, and earlier onset of depression, in these individuals compared to controls 
(Widom, DuMont & Czaja, 2007).  Research by Flinn and colleagues has illustrated the 
particular role played by social, as opposed to other severe stressors.  They showed that at 
age 11, children in a Dominican village who had been exposed to equivalently severe 
stressors showed a different long-term response depending on the type of stressor: Those 
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who had been exposed to a serious hurricane or political upheaveal in early childhood did 
not have elevated cortisol levels, whereas cortisol levels were elevated in those who had 
experienced early family trauma (defined as parental conflict, parental loss, or abuse; 
Flinn, Nepomnaschy, Muehlenbein & Ponzi, 2011). 
It seems evident that severe and chronic early stress is pathological (Anisman et 
al., 1998; Chrousos, 1998, 2009; Seckl & Meaney, 2004).  The impact of early stressors 
on the HPA axis and stress system has been clearly demonstrated (Champagne, 2010; 
Flinn et al., 2011; Glover, O'Connor & O'Donnell, 2010; Levine, 2001, 2005), and animal 
research on this relationship has been reviewed above.  In humans, early childhood 
appears to be a critical developmental period for the HPA system.  Early trauma, which 
includes problematic social attachment experiences, leads to permanent dysregulation of 
the HPA system, and to elevated levels of CRF and cortisol (Champagne, 2010; Lupien et 
al., 2009; Mirescu, Peters & Gould, 2004; Nepomnaschy & Flinn, 2009).  In the stress 
literature there is also evidence that the HPA axis is particularly sensitive to social 
challenges during development (Flinn & Leone, 2006; Flinn et al., 2009; Hennessey, 
Kaiser & Sachser, 2009; Yim, Quas, Cahill & Haykawa, 2010).   
The links between early stress and dysregulated stress responsivity later in life are 
well-established in the literature, but investigation of the role of the opioid system in 
these stress responses is lacking. The link between the specific stress of early social 
trauma and long-term opioid functioning is of central interest here.  The broader thesis 
under investigation is that stressors that disrupt early social bonding (i.e. that activate the 
separation-distress system, which elicits a strong stress response) may have a particular 
role in the genesis of depression, and that opioid dysregulation is centrally implicated in 
this trajectory.   
 
Specific Aims and Rationale 
 
The literature review has indicated that a satisfactory explanatory model for depression 
has yet to be established.  The disorder is heterogenous, manifesting in a variety of 
clinical presentations, alongside variable responsivity to currently available 
pharmacotherapeutic options.  Of significant concern is the substantial number of patients 
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who are unable to obtain symptom relief.  Investigating the possible therapeutic effects of 
a new generation opioid with low addiction liability thus seems warranted.  My intention 
is that this investigation should not simply test the efficacy of the medication, but should 
aim to elucidate both the neurobiological and emotional mechanisms of its actions.  As 
stated at the start of the Literature Review, I would like to determine not only whether, 
but also how and why this opioid may provide effective treatment for some cases of 
depression. 
For this reason, the current study is grounded in a theory of emotion that views 
social attachment and social loss as primary emotional states, both of which are mediated 
by mu-opioids.  The pain of social loss across the lifespan is viewed as an extension of 
the primary separation-distress response evinced by all infant mammals; a distress 
response as powerful and as critical as that elicited by threats to physical integrity.  
Support for this model comes from evidence that social and physical pain systems 
overlap, both in terms of neuroanatomical substrates, and in neurochemical mediation by 
mu-opioids.  The broad thesis under investigation here is that early experiences involving 
the distress of social loss create a lifelong vulnerability to depression, because they result 
in long-term neurochemical dysregulation, in which the mu-opioid system is implicated. 
In humans, early adverse psychosocial experiences have a clear link to adverse 
outcomes in adulthood, in which mood and anxiety disorders feature frequently.  This 
trajectory has been mapped out to some extent at a neurobiological level, in terms of 
alterations in HPA function.  Both animal models and research in humans indicate that 
early stress results in dysregulated CRF function and in dysregulated glucocorticoid 
signaling.  The contention under examination in the broader research project, within 
which the current study is nested, is that the opioid system is critically involved in this 
developmental trajectory. 
Given the evidence that neurochemistries with which mu-opioids are strongly 
interactive (notably, stress neurochemistries, and the mesolimbic dopamine system) show 
long term changes following early social trauma, and that neuroanatomical changes in 
areas high in mu-opioid receptors are also evident, it seems reasonable to hypothesize 
that early social trauma will also lead to permanent dysregulation in this system.  
Previous studies have shown that mu-opioid function may be dysregulated in depression 
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and in PTSD, but to date, no-one has directly examined the link between early social 
trauma and mu-opioid dysfunction.  This is precisely what the current study set out to do. 
Of course, the question of what exactly constitutes early social trauma is difficult 
to answer definitively.  This study used a very broad definition, based on indications in 
the literature that a range of aversive social experiences can be pathogenic.  It seems that 
various kinds of ill-treatment in childhood, including sexual, physical and emotional 
abuse, as well as physical and emotional neglect, can result in long term HPA alterations, 
and in depression (Bowlby, 1969, 1980; Champagne, 2010; Flinn et al., 2009; Heim et 
al., 2000; Heim et al., 2002; Kendler, Gardner & Prescott, 2002; Mayberg, 2004; 
McGowan et al., 2009; Slavich et al., 2010; Teicher, Andersen, Polcari, Anderson & 
Navalta, 2002; Teicher et al., 2003; Teicher, Samson, Polcari & McGreenery, 2006).  It is 
important to note that all these forms of abuse and neglect involve close social 
relationships, most often within the immediate family.  The trauma focus here is social, 
and concerns disrupted early experiences of attachment and psychosocial relatedness. 
According to the overarching thesis, exposure to early social trauma should result 
in long-term changes to the mu-opioid system.  The aim in the present study was to 
examine the impact of an opioid manipulation in healthy normal individuals.  This choice 
of participants may seem counterintuitive, as the ultimate population of interest is those 
with depression.  However, given the current lack of nosological clarity, the 
heterogeneity of presentations, and the multitude of neurobiological correlates identified 
in major depressive disorder, it seemed premature to include cases of depression at this 
point, as they would most likely cloud the data.  If the overarching thesis is true, even 
psychiatrically healthy individuals who were exposed to early social trauma should show 
some indications of altered opioid function.  Being able to examine this possibility 
„cleanly‟, without the added complexities and possible confounding factors associated 
with depression, seemed the best option for a first step in this research program. 
A further consideration is what exactly is meant by „opioid dysregulation‟.  At 
this point of outset in the research program, it was not entirely clear what form(s) this 
dysregulation would take.  For example, the Kennedy et al. (2006) study showed 
dysregulated mu-opioid activity in depression, but this took the form of increased activity 
during sadnesss.  Given the activity patterns in normals (reduced activity during sadness) 
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one might have expected to see even greater decreases in this population, given their 
propensity to sad mood.  The form of the demonstrated opioid dysregulation was thus 
unexpected.   
The most important goal at this initial stage of the overarching research program 
was to provide some proof of concept – to demonstrate differences in opioid function 
between individuals who had and had not been exposed to early social trauma.  Thus the 
predictions made below are heuristic rather than definitive, based on best guesses given 
what is known about affect and cognitive style in depression.  Of greatest interest is 
whether or not between-group differences in the response to the opioid manipulation can 
be shown – this is the most critical test the data must pass. 
The aim of this study was thus to examine the effects of a once-off low dose 
opioid manipulation in healthy normal subjects with and without a history of exposure to 
early social trauma.  Information regarding changes in affective experience, social 
cognition, and neural activation was obtained.  The following specific questions were 
asked, and heuristic predictions were made: 
 
1) Do the groups of healthy normals differ on key baseline characteristics? 
 
Depression: The groups will not differ significantly on depression scores, as only 
psychiatrically healthy individuals were included. 
 
Hypothesis 1: trauma = control on depression scores 
 
General experience of affect: The groups will differ on general experience of affect.  
Although only individuals who were not depressed were included, I thought it possible 
that in general, the group exposed to early social trauma might experience more negative 
affect, and less positive affect.  
 
Hypothesis 2: trauma > control on negative affect scores 




Personality traits based on core emotion systems: The groups will differ on personality 
traits related to key core emotion systems as follows: 
 
Hypothesis 4: trauma > control on SADNESS  
Hypothesis 5: trauma < control on SEEKING  
 
2) Do the groups differ in their response to opioid manipulation in terms of their 
subjective experience of affect? 
 
Current experience of affect: The groups will demonstrate the same pattern of affect on 
placebo as that predicted for general experience of affect; that is, the control group will 
report greater positive affect, and the trauma group will report greater negative affect.  
Furthermore, the groups will differ in their response to the opioid buprenorphine, in that 
the trauma group will respond more strongly to the medication, showing decreased 
negative affect, and increased positive affect.  
 
Hypothesis 6: On placebo, trauma > control group on negative affect scores  
Hypothesis 7:  On placebo, trauma < control on positive affect scores 
Hypothesis 8:  On medication, trauma = control on negative affect scores 
Hypothesis 9: On medication, trauma = control group on positive affect scores 
 
 
3) Do the groups differ in their response to opioid manipulation in terms of social 
cognition? 
 
Biased judgment of emotional expressions: The groups will differ on placebo, in that a 
negativity bias will be present in the trauma-exposed participants.  These participants will 
be more likely than controls to judge neutral faces as showing negative emotions (anger, 
sadness and fear).  The opioid buprenorphine will reduce this bias.  
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Hypothesis 10: On placebo, trauma > control in judging neutral faces as showing 
negative emotions 
Hypothesis 11: On medication, trauma = control in judging neutral faces as 
showing negative emotions 
 
 
4) Do the groups differ in their response to opioid manipulation in terms of neural 
response to social-emotional stimuli? 
 
Hypothesis 12: For all participants, response to negative social signals (faces 
showing anger and fear) will be reduced on medication compared to placebo. 
Hypothesis 13: This effect will be significantly greater for the trauma group than 























The work reported here constituted a double-blind, placebo-controlled crossover 
design.  It incorporated two groups of healthy individuals – those exposed and those not 
exposed to early social trauma.  None of the participants met diagnostic criteria for any 
major psychiatric disorder, including depression and anxiety disorders.  All participants 
were assessed both on and off the opioid medication, buprenorphine.  The order of 
administration of buprenorphine/placebo was counterbalanced across participants, as the 
small sample size did not permit effective randomization.  Both the participants and the 
researchers involved in data collection were blind to medication condition and to trauma 
status.   
 
Procedure 
Recruitment was initiated by placing poster advertisements across the various 
campuses at the University of Cape Town, and continued for a period of 24 months 
(09/2008 - 08/2010), with participants at various stages of the research protocol 
throughout.  The stages of the protocol are set out in the following figures: Figure 3 
provides an outline of the sequential stages of the protocol and Figure 4 gives details of 
the full protocol (i.e. of the larger study within which this study is nested).  This report 





Sequential stages of protocol. 
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Initially, potential participants were asked to complete an online screening 
battery, that included the Childhood Trauma Questionnaire – Short Form (CTQ-SF; 
Bernstein et al., 2003).  Thereafter, individuals who had completed the online screen 
were contacted telephonically.  Those who were excluded at this stage were informed, 
while those who met preliminary inclusion criteria were asked to provide verbal consent 
to participate, and further screening information was obtained from them (see Appendix 
A).  At the end of the telephonic screen, those who met inclusion criteria were asked to 
come in for a full screening interview.  At that session, they completed the CTQ-SF for 
the second time, and the The Mini-International Neuropsychiatric Interview (MINI; 
Lecrubier et al., 1997; Sheehan et al., 1997) and Beck Depression Inventory-Second 
Edition (BDI-II ; Beck, Steer & Brown, 1996) were administered.   
Again at this stage a number of individuals were excluded from further 
participation (see Figure 5 for details of inclusion/exclusion of participants).  Those who 
continued first completed two cognitive-behavioral assessment sessions, then two 
functional imaging sessions.  In the cognitive-behavioral sessions, a task assessing 
subliminal bias in attributing emotion was administered.  In the functional imaging 
















Table 1  
Screening and Assessment Measures used in the Current Study 
Online Screen 
          Edinburgh Handedness Inventory 
          List of Threatening Events (LTE) 
          Childhood Trauma Questionnaire – Short Form (CTQ-SF) 
Screening Interview 
          Childhood Trauma Questionnaire – Short Form (CTQ-SF) 
          Beck Depression Inventory – 2
nd
 Ed (BDI-II) 
          Mini-International Neuropsychiatric Interview (MINI) 
         Positive and Negative Affect Schedule (PANAS - general ratings)  
          Affective Neuroscience Personality Scales (ANPS) 
Cognitive- Behavioral Assessment Sessions 
          Response Bias Task 
Functional Imaging Sessions 
          Positive and Negative Affect Schedule (PANAS – moment ratings) 




















 Each of these sessions was separated by a period of 10-14 days.  At the start of 
all experimental sessions, participants received either placebo or buprenorphine tablets.  
The medication was administered by a nurse according to a counterbalanced schedule set 
up by the study administrator, thus maintaining the blinding for participants and research 
assistants involved in data collection.  The participants‟ trauma status was also only 
known to the study administrator.   
Due to variable opioid activity across the menstrual cycle, and the menstrual 
cycle‟s impact on closely related reward circuitry, female participants were all assessed 
and scanned during the luteal phase (Dreher et al., 2007; Kraemer et al., 2006; Taylor, 
Goubillon, Broad & Robinson, 2007).  This was accomplished by having female 
participants record their cycles (once they had completed all screening phases, and agreed 
to participate in the experimental sessions), and then scheduling sessions at appropriate 
points in these cycles.  Participants were required to refrain from smoking or consuming 
caffeine on assessment and imaging days (Wewers, Dhatt, Snively & Tejwani, 1999).  
Apart from a light meal at least 2 hours prior to assessment, they were also required not 
to eat or drink before the experimental sessions.  
In order to perform cognitive-behavioral assessments and obtain the functional 
imaging data during the period when the opioid was most active, testing commenced 90 
minutes after the medication had been ingested.  Time to peak plasma concentration for 
sublingual buprenorphine is between 1 and 3 hours (Bullingham, McQuay, Porter, Allen 
& Moore, 1982; McAleer et al., 2003; Mendelson, Upton, Everhart, Jacob & Jones, 
1997).  Subjective effects can be felt within 30 minutes, peak a little later, and remain 
high for up to 6 hours (Harris, Mendelson, Lin, Upton & Jones, 2004).  The timing was 
thus designed to ensure that assessment occurred while the opioid was exerting its 
strongest effect.  Including the waiting period, each experimental session was 3 hours 
long. 
The cognitive-behavioral assessment sessions were carried out first in order to 
ascertain if any participants experienced negative side-effects of the medication (prior to 
placing them in the scanner).  Nausea and vomiting following buprenorphine 
administration do occur in a small percentage of the population, and in fact five 
individuals were not able to continue participation for this reason.    
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Both cognitive-behavioral assessment sessions were conducted at the University 
of Cape Town Department of Psychiatry.  In these sessions, a nurse took blood, and 
research assistants obtained electro-encephalograph recordings, and administered a 
number of computer-based tasks and pencil-and-paper questionnaires (see Figure 4 for 
details of all measures administered in the full protocol). 
The functional imaging sessions were conducted at the Cape Universities Brain 
Imaging Center (CUBIC) at the Stellenbosch University Medical Campus, Tygerberg.  
Again, blood was drawn, and a number of pencil-and-paper questionnaires and tasks were 
administered outside the scanner, before the participant completed several tasks within 
the scanner (see Figure 4 for details). 
 
Sample 
Participants were 32 right-handed volunteers, recruited from the University of 
Cape Town undergraduate student body, and aged 18-25 years.  All of these individuals 
completed two cognitive-behavioral testing and two functional imaging sessions, but only 
22 had usable fMRI data.   
The criteria for inclusion were extremely rigorous, with the aim of controlling for 
as many potential confounding variables as possible (see Table 2 for exclusion criteria). 
The final sample was derived in the following way (see Figure 5 for flowchart): 555 
students performed an online preliminary screening assessment.  Forty-nine were 
excluded immediately due to being left-handed. We were unable to contact 54 of the 
remaining number.  Eleven of the remainder were excluded due to having experienced a 
major stressful life event in the 6 months prior to survey. Furthermore, 38 provided 











Age < 18 or > 25 yrs  
Left handedness 
Asthma; respiratory or hepatic insufficiency 
Any major psychopathology, including affective and psychotic disorders 
Psychoactive medication 
Previous head injury 
Serious medical condition (e.g. renal, cardiac, or  neurological illness)  
Any neurological condition impacting the central nervous system 
Pregnancy or lactation 
Any factors that would preclude scanning (e.g. metal pacemaker or prosthesis) 
Major stressful life-event in past 6 months 
Unsuitable profile on the Childhood Trauma Questionnaire –Short Form 
Note: Use of buprenorphine is contra-indicated in anyone with any respiratory or  
hepatic insufficiency.  Its safety during pregnancy and lactation has not been established. 
 
 
Those meeting preliminary inclusion criteria (N = 403) were contacted 
telephonically.  During that telephone call, a member of the research team obtained 
further screening information from the potential participant.  This information included 
verbal consent to participate further, and details of any medical condition, medication, or 
other factors that would preclude participation (see Appendix A for a copy of the 
telephonic screening questionnaire).   
One hundred and seventy-four individuals consented and were eligible to continue 
participation, but only 165 proved contactable for the next stage.  These 165 students then 
completed a full screening interview, where the CTQ-SF was administered for a second 
time, and the MINI and BDI-II were administered to check for the presence of 
psychopathology.  Only those who provided consistent CTQ-SF reports across both 
administrations (i.e. whose online and interview CTQ-SF profiles fit the same clinical 
interpretations across all subscales), who showed no indication of psychopathology on 
the MINI and BDI-II, and who met all other inclusion requirements continued as 
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participants in the study.  Ninety-four individuals were excluded.  Thus, after the 
screening phase 71 individuals were eligible to participate in the experimental phase of 
the study (see Figure 5). 
During the experimental phase, there was a high attrition rate: 34 participants 
dropped out of study before all four sessions were completed.  Most dropouts (27) 
occurred after the first cognitive-behavioral assessment session, two more occurred after 
the second cognitive-behavioral assessment session, and a further five occurred after the 
first functional imaging session.  Of these 34 participants, only five dropped out due to 
adverse reactions to the medication (nausea, headaches; four after one cognitive-
behavioral session, and one after the first scan).  Feedback from the others indicated 
various reasons for discontinuing.  Prohibitive work commitments, scheduling clashes, 
lengthy research sessions, and distance to the CUBIC facility all appear to have been 
disincentives to continued participation. 
Thirty-seven participants completed all four sessions.  However, data from 15 of 
them had to be excluded from the analysis for the following reasons: on rechecking, four 
participants had inconsistent profiles on the CTQ-SF; one had to be excluded due to 
MINI/BDI scores indicating depression; and 10 sets of scanner data proved unusable (see 
Figure 5 for details). 
Participants were compensated for their time at a rate of ZAR100 per session, and 
were additionally offered a completion bonus (ZAR100) in an attempt to reduce attrition 
across the multiple assessment sessions.  All participants provided written informed 
consent for both the cognitive-behavioral assessment and functional imaging components 
of the study (see Appendix B for information and consent sheets).  Ethical approval for 
the study was granted by the University of Cape Town Faculty of Health Sciences‟ 
Research Ethics Committee, and by Stellenbosch University‟s Committee for Clinical 
Trials.  The study was registered with the South African National Clinical Trials Register. 
We adhered to the principles for research with human subjects outlined in the Declaration 
of Helsinki (2008). 
 
Establishing trauma status.  The CTQ-SF was used to determine trauma group 
assignment (see Appendix C for guidelines to clinical interpretation of CTQ scores).  It 
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was administered twice, and, as noted above, only participants whose reports yielded the 
same trauma profile across all subscales at both administrations were included.  This 
double administration of the CTQ-SF was a conservative check aimed at ensuring that 
participants were reporting reliable information, and that the resulting group allocation 
was thus valid. Given the central nature of exposure to early social trauma to the research 
question, and given that I had to rely on retrospective self-report to gauge exposure, it 
seemed best to err on the side of caution in establishing the two comparison groups. 
The CTQ-SF profiles of all eligible participants had to fall into one of two 
categories: no/minimal exposure to trauma or moderate-severe exposure to trauma.  To 
be considered part of the control group, participants had to have a maximum of a low-
moderate score on a single subscale.  To be considered part of the trauma group, 
participants had to have a moderate-severe score on at least one subscale.  Participants 
whose profiles fell between these two extremes were excluded.  This conservative 
approach was adopted – rather than using a median split on the total score, for example – 
in an effort to maximally differentiate the groups on this central criterion.  
 
Participant characteristics.  The full sample whose behavioral data were used 
for analysis consisted of 32 individuals; 14 had been exposed to early social trauma as 
assessed by the CTQ-SF, and 18 had not.  The groups were matched on age and gender, 
but the race demographic was a little uneven (see Table 3), with a significantly greater 
number of white participants in the control than in the trauma group. 
 
Table 3 
Demographic Characteristics of the Full Sample 
 Trauma group 
(n = 14) 
Control group 
(n = 18) 
Χ
2
 / t p 
Gender (Male:Female) 7:7 10:8 0.1 .76 
Race (White:Indian:Colored:Black)
a
 1:3:6:4 8:0:4:6 8.9 .03 
Age  (Mean (SD)) 20.36 (1.95) 20.94 (2.55) 0.7 .49 
Note: a. In South Africa, due to the legacy of apartheid, census data remains classified in 




Due to the ongoing nature of recruitment and assessment, the study administrator 
was able to manage over time the matching of participants on key factors, such as trauma 
status, gender and race, and attempted to ensure that the matching was particularly good 
for the fMRI sample.  The fMRI subset sample thus comprised 22 individuals, 11 in the 
trauma group and 11 in the control group.  These groups were well matched on age and 
gender.  Although the race composition across the groups remained a little more variable, 
the difference for the subset was not significant (see Table 4).    
 
Table 4 
Demographic Characteristics of the fMRI Subset 
 Trauma group 
(n = 11) 
Control group 
(n = 11) 
Χ
2
 / t p 
Gender (Male:Female) 6:5 6:5 0.0 1.00 
Race (White:Indian:Colored:Black) 1:3:3:4 6:0:2:3 6.9 .08 
Age  (Mean (SD)) 20.46 (2.02) 21.36 (2.87) 0.9 .41 
 
CTQ-SF-based allocation to the trauma and control groups was successful: The 
groups differed significantly on their trauma scores across all subscales.  Effect sizes 













Table 5  
CTQ-SF: Group Differences for the Full Sample on Early Exposure to Social Trauma  
 Trauma group 
(n = 14) 
Control group  
(n = 18) 
t p d 
Emotional Abuse 13.14 (4.99) 6.39 (0.78) 4.46 .001 1.9 
 Mod-Severe None/Minimal    
Physical Abuse 9.50 (3.74) 5.61 (0.78) 3.67 .001 1.4 
 Mod-Severe None/Minimal    
Sexual Abuse 8.36 (4.09) 5.06 (0.24) 3.04 .005 1.1 
 Mod-Severe None/Minimal    
Emotional Neglect 13.14 (5.08) 6.33 (1.71) 4.85 .001 1.8 
 Low - Mod None/Minimal    
Physical Neglect 8.21 (3.33) 5.44 (1.04) 3.07 .005 1.1 
 Low - Mod None/Minimal    
Total Score 52.36 (13.71) 28.83 (2.18) 5.28 .001 2.4 
Note: Means, with standard deviations in brackets, and clinical interpretations are  




CTQ-SF: Group Differences for the fMRI Subset on Early Exposure to Social Trauma  
 Trauma group 
(n = 11) 
Control group 
(n = 11) 
t p d 
Emotional Abuse 13.36 (5.59) 6.09 (0.70) 3.55 .002 1.8 
 Mod-Severe None/Minimal    
Physical Abuse 9.64 (4.15) 5.73 (0.90) 3.25 .004 1.3 
 Mod-Severe None/Minimal    
Sexual Abuse 8.55 (4.23) 5 (0.00) 2.60 .017 1.2 
 Mod-Severe None/Minimal    
Emotional Neglect 11.91 (4.99) 6.27 (1.95) 3.25 .004 1.5 
 Low - Mod None/Minimal    
Physical Neglect 8.09 (3.78) 5.36 (0.67) 2.34 .030 1.0 
 Low - Mod None/Minimal    
Total Score 51.55 (15.38) 28.45 (2.16) 4.00 .001 2.1 
Note: Means, with standard deviations in brackets, and clinical interpretations are  







Measures.  Figure 4 shows the larger study‟s full protocol.  In this section, I 
describe only the measures of direct relevance to the work reported in this dissertation.  
Note also that I provide psychometric detail to substantiate the use of measures central to 
the research question.  
 
Online screening and assessment instruments.  The Edinburgh Handedness 
Inventory (Oldfield, 1971) was developed to provide a brief and simple quantitative 
assessment of handedness for use in clinical and research contexts.  The author explicitly 
aimed to devise an instrument that would be applicable as universally as possible, to 
enable comparisons across gender, nationality, culture and socioeconomic status.  It was 
thus ideally suited as a screening instrument in this study.  Handedness must always be 
taken into consideration in functional imaging studies, as a different functional cerebral 
organization (viz., crossed lateralization or a lesser degree of hemispheric asymmetry) is 
possible in left-handers.  This measure was used to exclude all participants who were not 
right handed. 
 
The List of Threatening Events (Brugha & Cragg, 1990) is a brief screening 
instrument that was used to exclude potential participants who had experienced a major 
life-stressor in the six months prior to survey. The research team reasoned that such a 
recent event might have caused alterations in physiological and neurochemical function 
that could confound our results.  Items include questions about serious illness, financial 
crises, and loss or death of significant individuals.  The measure has good reliability, 
sensitivity and concurrent validity (Brugha & Cragg, 1990; Humke & Radnitz, 2005). 
 
The Childhood Trauma Questionnaire – Short Form (CTQ-SF; Bernstein et al., 
2003) is a widely used retrospective measure that assesses exposure to various kinds of 
trauma during early childhood.  Its popularity is due to the fact that it is almost unique in 
addressing more than a single type of traumatic experience.  It was particularly well 
suited for use in this study, as the domains it assesses, notably emotional and physical 
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abuse and neglect, indicate clearly the absence of appropriate nurturing and caretaking in 
critical early social bonds. 
The CTQ-SF is a 28-item self-report scale, with five clinical subscales: it assesses 
physical, sexual, and emotional abuse, and physical and emotional neglect.  It also 
features a minimization/denial scale that detects under-reporters.  Abuse and neglect are 
identified at three levels – low, moderate and severe.  It is also possible to have a „no 
exposure‟ profile.  Item responses are scored on a 5-point Likert scale ranging from 
„never true‟ to „very often true‟.   
The original CTQ consisted of 70 items.  It has excellent test-retest reliability, and 
demonstrated convergent and discriminant validity.  It has good sensitivity and specificity 
(Bernstein, Ahluvalia, Pogge & Handelsman, 1997; Bernstein et al., 1994).  The short 
form was later developed by the original research group (Bernstein et al., 2003), who 
aimed not only to provide a short yet reliable and valid instrument, but also to establish 
measurement invariance.  The short form has been validated for use in both clinical and 
normal populations.  The validity checks were performed on a sample of 1978 
participants, constituting four groups (three psychiatric, one normal).  Analysis indicated 
measurement invariance is present, with the five-factor structure (corresponding to the 
five subscales) fitting all four groups.  Strong criterion-related validity was also 
demonstrated.  The CTQ-SF has been used effectively across different race and cultural 
groups (Thombs et al., 2007a; Thombs, Lewis, Bernstein, Medrano & Hatch, 2007b), and 
was thus suitable for use in this study.  
 
Telephonic screen.  This instrument (see Appendix A) served to screen potential 
participants for any relevant medical condition (e.g., previous head injury, epilepsy), use 
of medication, or the presence of metal prostheses or objects in the body.  The screen also 
served to exclude any potential female participants who were pregnant or breastfeeding, 
as the safety of buprenorphine has not been established for these conditions.  Participants 
with asthma, and/or respiratory or hepatic insufficiency were excluded, as use of 
buprenorphine is contraindicated in these contexts.  Anyone previously diagnosed with a 
psychiatric disorder was also identified and excluded.   
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Screening interview measures.  The Beck Depression Inventory – 2
nd
 Edition 
(BDI-II; Beck et al., 1996) is one of the most widely used measures of depression in 
research.  It features 21 self-report items. The BDI-II has been well validated, and has 
strong psychometric properties, including very good sensitivity and specificity (Beck, 
Steer & Gabin, 1988; Subramaniam, Harrell, Huntley & Tracy, 2009). This measure was 
included to complement the MINI ratings of depression.  Participants with a score of 14 
or higher – i.e., those who reported the presence of at least mild depressive symptoms – 
were excluded (see Appendix C for guidelines to clinical interpretation of BDI-II scores). 
 
The Mini-International Neuropsychiatric Interview 5.0 (MINI 5.0; Lecrubier et 
al., 1997; Sheehan et al., 1998; Sheehan et al., 1997) is a short structured diagnostic 
interview, and was used to screen participants for DSM Axis I psychopathology, and for 
antisocial personality disorder.  It was developed by psychiatrists and clinical 
psychologists to provide a brief but accurate diagnostic assessment instrument, useful in 
both research and clinical settings.  In its development the authors aimed to create an 
instrument that is highly sensitive, specific, and compatible with international diagnostic 
criteria, including those of the DSM and the International Classification of Diseases 
(ICD).  The instrument was deliberately designed to be conservative with regard to false 
negatives; this means that it is more likely to falsely identify someone as meeting 
diagnostic criteria, than to wrongly miss the actual presence of pathology (Sheehan et al., 
1998).   
The MINI takes approximately 15-20 minutes to administer, and may be 
administered by laypersons who have received appropriate training.  The instrument 
covers 19 diagnostic categories, including mood and anxiety disorders, suicidality, eating 
disorders, psychotic disorders, PTSD, alcohol and substance abuse/dependence, and 
antisocial personality disorder.   
The MINI was validated on sample of 636 participants, from specified clinical 
subgroups.  Its performance was compared with that of two longer, well-established 
structured diagnostic interviews: the Structured Clinical Interview for DSM (First, 
Spitzer, Gibbon & William, 1997) and the Composite International Diagnostic Interview 
(Robins et al., 1989) and with that of expert clinical diagnoses.  The authors found 
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predominantly good or very good correspondence between the instruments.  Specificity 
and positive and negative predictive values were also very good.  Agreement with expert 
diagnosis was found in over 85% of cases.  The authors concluded that the MINI is a 
reliable and valid instrument, capable of appropriately detecting the presence of 
psychopathology as defined by the DSM and ICD (Lecrubier et al., 1997; Sheehan et al., 
1998; Sheehan et al., 1997). 
The MINI has been widely used since its development, and has been translated 
into a number of different languages.  It has proved useful in European, Arabic, South 
American and Japanese populations (de Azevedo Marques & Zuardi, 2008; Kadri et al., 
2005; Otsubo et al., 2005; Rossi et al., 2004), and this applicability across cultures 
suggests that it is suitable for use in South Africa. 
 
The Positive and Negative Affect Schedule (PANAS; Watson, Clark & Tellegen, 
1988) was developed to provide a brief and easy to administer, yet psychometrically 
sound, measure of positive and negative affect.  This measure is very well-validated and 
has been used in over 2000 published studies (Thompson, 2007).  It has been effectively 
used across Europe, as well as in Australia, China and the Middle-East, suggesting that it 
is suitable for use in multiple cultural contexts (Ayyash-Abdo & Alamuddin, 2007; 
Kiernan, Laurent, Joiner, Catazaro & MacLachlan, 2001; Melvin & Molloy, 2000; Shi, 
Wang & Li, 2009).  
The PANAS can measure both state- and trait-related affect (Tellegen, 1985; 
Watson & Clark, 1984).  Positive and negative affect represent distinct domains of 
emotional experience; they are orthogonal rather than inter-correlated.  High positive 
affect indicates that an individual feels energized, and positively engaged, whereas low 
positive affect indicates sadness and a lack of energy.  In contrast, high negative affect 
indicates a range of aversive mood states, including anger, fear and anxiety, whereas low 
negative affect indicates a state of calm or contentment (Watson et al., 1988).  Research 
has indicated that these two dimensions are stable across cultures (Almagor & Ben-
Porath, 1989; Balatsky & Diener, 1993; Melvin & Molloy, 2000).  
The developers of this instrument aimed to select mood descriptors that related 
unequivocally to one or the other affective dimension.  They used factor analysis to 
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identify terms that loaded high only on one factor and had no significant loading on the 
second factor (loadings of less than .25).  The positive affect terms thus derived are 
attentive, interested, alert, excited, enthusiastic, inspired, proud, determined, strong, and 
active.  The negative affect terms are distressed, upset, hostile, irritable, scared, afraid, 
ashamed, guilty, nervous and jittery (Watson et al., 1988).  Participants indicate the 
extent to which they experience each mood state in a given period of time (e.g. in 
general, last week, now) on a 5-point Likert scale, ranging from „very slightly or not at 
all‟ to „very much‟.   
The original psychometric study (which examined both reliability and validity) 
indicated good internal consistency for all time period instructions.  Cronbach‟s alpha for 
positive affect ranged between .86 and .90; for negative affect, it ranged between .84 and 
.87.  The scales were not correlated (r ranged from -.1 to -.2; Watson et al., 1988).  
Independent research has confirmed these statistics (Melvin & Molloy, 2000; Munz & 
Munz, 1997). As is expected in mood measures, test-retest reliability was found to be 
higher for the longer time period instructions (e.g. “how much have you felt anxious  in 
the last few weeks?”); in fact, the measure‟s developers state that the stability coefficients 
of the general ratings are high enough for these to be treated as trait measurements 
(Watson et al., 1988).  Importantly, even the moment ratings were relatively stable, which 
the developers argue reflects the fact that even momentary mood states reflect an 
individual‟s general experience of affect.  The moment measures are, however, capable 
of reflecting changing moods (Watson et al., 1988).  This instrument was thus ideally 
suited to establish participants‟ general experience of affect, and to track changing 
experience of affect on buprenorphine versus placebo.     
 
The Affective Neuroscience Personality Scales (Davis, Panksepp & Normansell, 
2003) were constructed to identify relative strengths and weaknesses in the six core 
emotion systems defined by Panksepp (1998), viz., SEEKING, FEAR, ANGER, 
SADNESS
4
, CARE and PLAY.  The developers report that all items were constructed to 
elicit reports of personal feelings and actual behavior, rather than cognitive social 
                                                 
4
 The term SADNESS is used in this scale. It is a variant of the term SEPARATION-DISTRESS used in 
the literature review and throughout this dissertation.  It refers to the same core emotion system. 
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judgments.   Each core emotion is assessed by 14 items, half of which are reverse scored.  
Filler items are included as validity checks.   
Internal consistency for this measure is good, with Cronbach‟s alpha for the six 
scales ranging from .65 - .86, a range commonly found in the field of personality research 
(see, e.g., Deal, Halverson, Martin, Victor & Baker, 2007; Korner et al., 2008; Tromp & 
Koot, 2008).  Construct validity was assessed by obtaining concurrent measures on a Five 
Factor Model scale.  The „Big Five‟ approach to personality has yielded consistent 
empirical results, and some of the components are thought to be related to underlying 
physiological systems (Coker, Samuel & Widiger, 2002; Goldberg, 1990; Graziano & 
Ward, 1992; Jang, Livesley & Vernon, 1996; Morey, Gunderson, Quigley & Lyons, 
2000; Paunonen, 2003).  SEEKING was found to be significantly associated with the 
Openness to Experience factor (r = .47, p <.001), while SADNESS was strongly 
negatively correlated with Emotional Stability (r = -.68, p <.001).  Confirmatory factor 
analysis affirmed the strong inter-relationships between constructs in the two personality 
measures, with the three negative emotions and emotional stability (inversely) loading 
onto one factor; agreeableness and CARE loading on a second factor; Extraversion and 
PLAY loading on a third; and openness to experience and SEEKING loading on a fourth.  
Inclusion of this scale in the current study enabled detection of possible weaknesses or 
strengths in the key systems of interest (i.e. SEEKING and SADNESS). 
 
Experimental measures.  In the cognitive-behavioral assessment sessions, I used 
an adapted version of a Response Bias Task designed to examine bias in emotion 
recognition  (Arce et al., 2009; Surguladze et al., 2004).  Facial expressions convey 
critical social information, and some evidence suggests that depressed individuals show 
impaired recognition of emotion, with a bias towards negative emotion (Hale, 1998; 
Persad & Polivy, 1993; Rubinow & Post, 1992; Surguladze et al., 2004).  In these healthy 
normal participants, I wanted to examine whether any group difference existed in their 
tendency to perceive others as conveying negative rather than positive emotional 
information, and if this difference changed on opioid medication. 
The specific task I used was developed recently by a research team at the 
Helmholz Research Institute, Utrecht University (J. van Honk, personal communication, 
 71 
16 November, 2009).  It was delivered via EPrime, and featured eight male and eight 
female faces sourced from standard sets of photos of affective faces (Ekman & Friesen, 
1976; Lundqvist, Flykt & Ohman, 1998).  Images were normalized for size and 
luminance, with a standard grey background.  Anger, happiness, sadness, and fear, as 
well as neutral expressions, were included.  Because cognitive processing can over-ride 
or hide automatic response tendencies or biases, stimulus exposure was extremely brief 
(92ms), to prevent conscious recognition of the emotion expressed (Hermans, Nijenhuis, 
van Honk, Huntjens & van der Hart, 2006; Putman, Hermans & van Honk, 2004; 
Putman, Hermans, Koppeschaar, van Schijndel & van Honk, 2007a).     
Each participant saw 96-100 faces, half of which were emotional, and half of 
which were neutral.  The order of presentation was randomized, and differed for each 
participant and across medication conditions.  Participants were asked to guess which 
emotion they had seen after each stimulus presentation, and were given a forced choice 
response format with the options ANGER, HAPPINESS, SADNESS and FEAR.  The 
next stimulus was presented once they had indicated their choice, hence each inter-
stimulus interval depended on their response time.  The question of interest was this: 
what emotion do participants tend to ascribe to the neutral faces?  Following Surguladze 
et al. (2004), responses were normalized to indicate what percentage of the neutral faces 
each participant rated as angry, happy, sad or fearful. 
 
For the functional imaging protocol, I used an adapted version of the Passive 
Viewing of Emotional Expressions protocol developed by Sato and colleagues (2004).  To 
date, most functional imaging studies in this field have used static faces, often in 
conjunction with an active emotion recognition task (see, e.g., Hariri, Tessitore, Mattay, 
Fera & Weinberger, 2002; Morris et al., 1998; Phillips et al., 2001; Whalen et al., 2001). 
The ecological validity of this latter paradigm is open to question.  In the real world, 
facial expressions are dynamic, and we are seldom called upon to make conscious, 
cognitively mediated decisions about which emotion we are seeing.  A strong argument 
can be made that investigation of neural activity in response to these very important 
social signals should use dynamic stimuli that require no cognitive judgment to be made. 
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This approach has been adopted by Sato and his colleagues.  They developed a 
task, using static images taken from standard pictures of affect (Ekman & Friesen, 1976), 
and used computer morphing techniques to create dynamic expressions that transition 
from neutral to an intense emotional expression.  Their work indicates that,  
1) the morphing expressions seem natural to participants, and 2) it is not evident to 
participants that the morphing faces are artificial computer generations (Sato, 2004).  
They have also demonstrated that, compared to static stimuli, this task elicits greater 
neural activity in key regions (Sato et al., 2004).  This greater neural reactivity in key 
regions has been confirmed in independent research using a different set of stimuli 
(Trautmann, Fehr & Herrmann, 2009). 
Stimuli for the current protocol were sourced from standard sets of affective faces 
(Ekman & Friesen, 1976; Lundqvist et al., 1998).  Four female and four male faces were 
used.  Images were normalized for size and luminance, with a standard grey background.  
Starting with static images, computer morphing animation created a dynamic expression 
that started at neutral and used a series of 50 frames to transition smoothly to maximum 






Passive emotion viewing task: faces morph from neutral to intense expression  
in about 1 sec. 
 
Only a subset of basic emotions could be included in the investigation, due to 
time constraints imposed by the larger study.  Fear and anger were selected to represent 
negative emotions, as the processing of these emotional social signals has been 
extensively investigated, and different styles of processing have been identified for 
individuals who are avoidant- rather than approach-oriented
5
 (d'Alfonso, van Honk, 
Hermans, Postma & de Haan, 2000; Putman, Hermans & van Honk, 2006; Putman et al., 
2007a; Putman, Hermans & van Honk, 2007b; Roelofs, Bakvis, Hermans, van Pelt & van 
Honk, 2007; van Honk et al., 2000).  Happiness was selected as a positive control.  
The task was set up as a block design protocol, with epochs of the different 
emotional expressions alternating with rest periods (see Figure 7).  Two blocks of each 
emotion were included to improve power (Liu, 2004; Savoy, 1999).  Anger and happy 
                                                 
5
 This difference in processing was particularly important for the analysis of the affective go/no-go task that 
formed part of the full protocol, and it was decided to use the same set of emotions for both fMRI 
protocols. 
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epochs were presented first, and the fear epochs were presented last.  This approach was 
adopted due to concern that, as fear is a highly salient social stimulus, it might create a 
long-lasting neural response that would then contaminate data from the subsequent 
epochs (Davis & Whalen, 2001; Phan, Wager, Taylor & Liberzon, 2002; Putman et al., 
2006; Putman et al., 2007a; van Honk, Peper & Schutter, 2005).  Because this was the 
first time this particular scanner protocol was used, I was uncertain of the effects the 





fMRI block design protocol sequence and timing. 
 
The length of the epochs was varied slightly on a random schedule, to avoid 
setting any patterned habitual neural response in the participants (Liu, 2004; Savoy, 
2005).  For the rest periods the average epoch length was 26.3s (SD = 0.9, min = 21.4, 
max = 35.5).  For the emotion epochs, the average length was 27.8s (SD = 0.8, min = 
26.5, max = 31.7). 
On average, each run was 350.9s long, and the entire protocol was run twice to 
improve power.  In total both runs took on average 12 minutes. (Note the runs were 
separated in time by a number of runs of the affective go/no-go task which is part of the 
total protocol; see Figure 4). 
 
Medication.  Buprenorphine in the form of 0.2mg sublingual tablets (brand name: 
Temgesic) was used.  Sugar pills of a similar size and color, also taken sublingually, were 
used for the placebo condition.  
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Buprenorphine hydrochloride is a partial mu-opioid receptor agonist and kappa-
opioid receptor antagonist.  It has a particularly long duration of action, dissociating very 
slowly from opioid receptors (Correia, Walsh, Bigelow & Strain, 2006; Harris et al., 
2004).  Time to peak plasma concentration is around one hour, with a half-life of between 
20 and 30 hours (Ciraulo et al., 2006; Harris et al., 2004; McAleer et al., 2003).  
Subjective effects can be felt within 30 minutes, peak a little later, and stay high for up to 
6 hours (Harris et al., 2004).  It is important to note that significant pain and psychomotor 
effects persist for up to 240 minutes despite decreasing plasma levels.  These effects are 
due to very slow dissociation of the drug from brain opioid receptors (Escher et al., 2007; 
Galynker et al., 1996; Zacny et al., 1997). 
It must be noted that in the literature, buprenorphine‟s positive effects seem to be 
ascribed to its actions on mu-receptors, and this is reasonable given the evidence 
(reviewed above) that mu-opioids promote positive opioid effects such as euphoria.  
However, the medication does also act on kappa opioids, blocking their effects.  The 
implications of its kappa opioid effects will be considered in the Discussion. 
Buprenorphine is a registered medicine, and is used as an analgesic for moderate 
to severe pain.  The dose used in this study (0.2mg) is the smallest sublingual dosage 
available in South Africa.  When used for pain, 0.2mg-0.6mg sublingual tablets every 6-8 
hours is a standard dose protocol (Escher et al., 2007).   It is notable that low doses are 
very effective; in fact, 0.3mg of buprenorphine has been found to have greater subjective 
effects than 10mg of morphine (Zacny et al., 1997).   
Buprenorphine is also commonly used in far larger doses to treat opiate 
dependence (Boothby & Doering, 2007).  In such programs, opiate-dependent individuals 
are often started on 8mg of buprenorphine daily, with a maximum daily dose of 32mg. 
These doses are clearly many times greater than those used for analgesic purposes, and 
high-dose pharmacokinetics are not particularly well characterized (Harris et al., 2004; 
McAleer et al., 2003). 
Common side-effects include drowsiness, nausea, and vomiting.  Incidence of 
these effects seems more pronounced in opiate-naïve individuals, and may increase along 
with increased dose (McAleer et al., 2003; Zacny et al., 1997).  Very few studies of 
buprenorphine in opiate-naïve individuals have been conducted, but it appears that 
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tolerability of the medication, even at low doses, may be problematic.  Route of 
administration probably impacts on these effects, but little specific information on 
sublingual buprenorphine is available.  A recent study using low doses (0.002mg/kg 
intravenous) in opiate-naïve individuals (N = 12) found that all participants experienced 
drowsiness, 75% felt nauseous, and 42% vomited (Escher et al., 2007).  Researchers 
using 0.3mg intramuscular dose found that 44% of their sample vomited, while 9 of 12 
participants were too incapacitated to continue (MacDonald, Gough, Nicoll & Dow, 
1989).  In one clinical study of effects on depression, very low oral doses (0.15mg -
1.8mg) were used over a 2-week period.  Nonetheless, 3 of 10 patients dropped out of 
this study due to negative experience of these side-effects (Bodkin et al., 1995).   In 
another study using higher doses (2mg-16 mg oral administration) and again conducted 
with opiate-naïve individuals, 5 of 26 participants withdrew due to aversive effects of the 
medication (McAleer et al., 2003).  The authors found that although standard subjective 
and physiological effects associated with the drug did not increase with dosage, the 
acceptability of the drug decreased, dropping from 68% at 4mg to 25% at 16mg.  Thus, 
with increasing dosage side-effects appear to become more problematic, while standard 
opioid effects appear to plateau (Harris et al., 2004; McAleer et al., 2003). 
Due to concerns around negative experience of the medication in healthy normals, 
and taking into account the sensitivity to low doses seen in opiate-naïve individuals, we 
decided to use the lowest possible dose in this study.  This was, admittedly, a risky 
decision, as the low dose in combination with a novel fMRI protocol might well have 
resulted in null findings.  However, this course of action was highly recommended by one 
of our senior co-investigators who has a great deal of experience with opioids in animal 
work, and given the risks of adverse experience and participant dropout associated with 
higher doses, we thought this was the safest choice.   
 
Data Analysis 
Cognitive-behavioral data analysis.  Analyses were conducted using SPSS 
version 19.  Chi-square tests, independent group t-tests, and mixed-design ANOVA 
analyses were used where appropriate.   
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For analysis of the PANAS ratings of current experience of affect, the factors 
were group (trauma vs. control); medication (buprenorphine vs. placebo) and emotion 
(positive vs. negative).  I was not interested in the independent main effects for 
medication or emotion – the aim of this analysis was to ascertain whether or not group 
differences existed in emotion on and off medication.  I thus combined the two repeated-
measures (RM) factors into a single factor with the following four levels: medication 
positive affect, medication negative affect, placebo positive affect and placebo negative 
affect.  
Similarly for analysis of the response bias task data, the factors were group 
(trauma vs. control); medication (buprenorphine vs. placebo) and emotion (angry, happy, 
sad, fearful).  Again, I was not interested in the independent effects of medication and 
emotion, but wanted to examine group differences in how judgment of emotion changed 
on medication.  I thus combined the two RM factors into a single factor with 8 levels: 
medication anger, placebo anger, medication happy, placebo happy, medication sadness, 
placebo sadness, medication fear, and placebo fear.   
Given that the information provided by the independent main effects of these 
repeated measures in the analyses discussed above was not of interest, reducing the 
number of factors in the analyses had the added benefit of substantially reducing the 
number of post-hoc contrasts required, and hence reduced the associated risk of Type 1 
error.  Fewer RM factors also reduced sphericity demands; where the assumption of 
sphericity was violated, however, Greenhouse-Geisser corrected values are reported. 
Although overall a number of inferential analyses were necessary, the resultant 
increased risk of Type 1 error had to be weighed against two factors: 1) the exploratory 
nature of this research, and 2) the small sample size and consequent high risk of Type 2 
error.  Given these concerns, alpha was not adjusted and remained at the conventional  
.05 level. 
 
fMRI data acquisition.  Data were acquired on a Siemens Allegra Magnetom 3T 
scanner (Siemens Medical Systems, Erlangen, Germany) using a standard single-channel 
head coil.  For each participant a high-resolution T1- weighted magnetization prepared 
rapid gradient echo (MPRAGE) image was acquired with the following parameters: 
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TR/TE/TI = 2300/2.93/1100 ms;  FOV = 256 × 240 mm;  slices = 160; voxel size =  
1.3 × 1 × 1 mm
3
; flip angle = 12 degrees; scan time = 6:28.  
Gradient echo T2*-weighted echo planar images were acquired using the 
following parameters: TR/TE: 2000/30 ms; FOV = 220 × 200 mm
2
; resolution =  
3.4 × 3.4 mm
2
; slices = 34; slice thickness = 3 mm (1.2 mm gap); flip angle = 90 degrees; 
184 volumes.  Slices were interleaved, and head movement was minimized with padding. 
 
fMRI preprocessing and data reduction.  Data preprocessing and analysis were 
completed using BrainVoyager QX, version 2.1.2.  Preprocessing was standard, and 
included correction for different slice acquisition times, motion correction, linear trend 
removal, and high-frequency temporal filtering.  The functional images were corrected for 
different slice acquisition times using cubic-spline interpolation based on TR (2000ms) and 
the order of slice scanning (ascending, interleaved).  Temporal smoothing was done using a 
high-pass GLM-Fourier filter over two cycles.  Motion correction using trilinear 
interpolation aligned all volumes from each subject to the first volume of his/her functional 
run.  For each participant, translation and rotation parameters were inspected, and where 
movement exceeded 3mm displacement or 3 degrees rotation, the data were excluded from 
analysis.  Each participant‟s functional data were co-registered to their high-resolution 
structural MRI, rotated into the AC-PC plane, and normalized to Talairach space 
(Talairach & Tournoux, 1988).  
 
fMRI data analysis.  Analysis was based on the General Linear Model (GLM), 
which, in this context, aims to explain changes in the voxel time courses measured by 
scanning (Friston et al., 1994).  Multiple runs of each condition in the block design 
protocol improved power and increased the ability to distinguish task-related activation 
from potential low-frequency drifts (Liu, 2004).  The block design was set up as a boxcar 
function, convolved with the standard hemodynamic response function implemented by 
BrainVoyager (Boynton HRF: delta = 2.5, tau = 1.25).  Estimated motion parameters and 
drift predictors were z-transformed and then included as predictors of no interest, to 
reduce unexplained error variance in the model.     
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Each participant‟s data were analyzed at the individual level, and were then 
entered into a second-level whole brain analysis using a random effects mixed-design 
ANOVA with two repeated measures [2 (group) x 2 (medication condition) x 3 
(emotion)].  Region of interest (ROI) analysis was then conducted to test specific 
predictions.  ROIs were functionally defined, but were independent of the whole brain 
analysis as orthogonal contrasts were investigated (Friston, Rotshtein, Geng, Sterzer & 
Henson, 2006; Poldrack et al., 2008).  Because BrainVoyager conducts 2-tailed tests by 
default, ROI p values were corrected for the directional hypotheses tested. Anatomical 


























In the following subsections (with the exception of the fMRI results subsection), I report 
results for the full sample (N = 32).  All the full-sample analyses described below were 
also conducted for the fMRI subset sample (N = 22), to establish whether the subgroup 
whose fMRI data were usable for analysis differed from the full sample in any 
appreciable manner.  The results of these analyses are presented in Appendix D.  As 
shown there, the same patterns and significant effects as those found for the full sample 




BDI-II.  The trauma and control groups did not differ significantly on depression 
scores.  Participants‟ scores all fell within the None–Minimal range of depressive 
symptoms (see Table 7). 
 
Table 7 
BDI-II: Group means  
Trauma group 
(n = 11) 
Control group 
(n = 15) 
t p d 
6.00 (4.33) 4.87 (4.72) 0.59 .56 .25 
Note: Means, with standard deviations in brackets, are presented. 
It must be noted that, unfortunately, BDI-II data were missing for 8 participants
6
: five 





                                                 
6
 Where data is missing it is because, due to researcher error, not all measures were collected from all 
participants.  When these omissions were noted, all efforts were made to contact the participants and have 
them complete the outstanding questionnaires/assessments; we were not able to contact some participants, 
however. 
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PANAS – general ratings.  A 2 (group) x 2 (affect type) mixed-design ANOVA 
was conducted on the ratings of general experience of positive versus negative affect.  
Contrary to the a priori predictions, there was no interaction between trauma status and 
type of affect generally experienced, F(1, 29) = 0.57, p = .46, partial eta
2
 = .02.  In fact, 
participants in both the trauma and control groups reported experiencing significantly 
more positive than negative affect, F(1, 29) = 323.97, p < .0001, partial eta
2
 = .92.  (See 
Table 8 for descriptive statistics).   
 
Table 8 
PANAS – General Ratings: Group means   
 Trauma group 
(n = 18) 
Control group 
(n = 13) 
Positive affect 34.08 (5.59) 34.56 (4.37) 
Negative affect 14.31 (3.92) 13.06 (3.28) 
Note: Means, with standard deviations in brackets, are presented. 
Data were missing for one trauma group participant. 
 
 
Affective Neuroscience Personality Scales (ANPS).  The a-priori prediction 
was that group differences would be present on the SEEKING and SADNESS subscales, 
with the control group scoring higher on SEEKING, and the trauma group scoring higher 
on SADNESS.
 7
  Because only these specific predictions needed to be tested, a mixed-
design ANOVA including the other four emotion systems was considered inappropriate.   
A one-tailed t-test for independent groups indicated a significant effect for 
SEEKING, t(28) = 2.15, p = .02, d =.77, with the control group scoring higher, as 
predicted.  However, the prediction that the trauma group would score higher on the 
SADNESS subscale was not supported, t(28) =0.08, p = .47, d =.03.  (See Table 9 for 
scores on all the subscales). 
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ANPS Subscales: Group means  
ANPS Subscale Trauma group 
(n = 13) 
Control group 
(n = 17) 
SEEKING 20.69 (2.66) 22.47 (1.88) 
FEAR 16.92 (1.75) 16.82 (2.79) 
CARE 20.39 (3.50) 18.59 (4.62) 
ANGER 15.39 (4.45) 16.53 (3.12) 
PLAY 20.08 (3.97) 21.18 (2.81) 
SADNESS 16.85 (3.31) 16.77 (2.33) 
Note: Means, with standard deviations in brackets, are presented. 
Data were missing for one participant from each group. 
 
Interim summary: Participant characteristics.  The recruitment strategy 
ensured that the trauma and control groups differed significantly and substantially on 
exposure to early childhood trauma.  These groups of otherwise healthy normal 
participants did not differ on general experience of positive and negative affect, or on 
signs of depression.  The ANPS data indicated a significant difference between the 
groups on the SEEKING subscale, with the control group scoring significantly higher on 
this trait.  There was no between-group difference on the SADNESS subscale. 
 
Impact of Opioid Manipulation on Subjective Experience of Affect 
 
PANAS – current affect ratings.  During both the medication and placebo 
sessions, participants were asked to rate their current affective state.  A 2 (group) x 4 
(medication condition-PANAS rating) mixed-design ANOVA was conducted.  As with 
the baseline general affect ratings, both the trauma and control groups reported far more 
positive than negative affect, F(2.27, 35.22) = 78.13, p < .0001, partial eta
2
 = .74.  
However, for the ratings of current affect (moment ratings), a significant interaction 
between trauma status and medication-PANAS ratings was found, F(2.27, 35.22) = 5.23, 
p < .006, partial eta
2
 = .16 (See Table 10 for descriptive statistics, and Figure 8 for a 
graphical representation of this interaction).   
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Table 10 
PANAS current affect ratings: Group means on and off buprenorphine 
 Trauma group 
(n = 13) 
Control group 
(n = 16) 
Placebo - positive affect 27.39 (9.36) 29.69 (5.67) 
Placebo – negative affect 15.00 (4.93) 11.88 (2.80) 
Medication – positive affect 23.62 (6.91) 30.56 (6.76) 
Medication – negative affect 13.31 (4.29) 12.19 (2.95) 
Note: Means, with standard deviations in brackets, are presented.  













Simple effects analysis of the interaction indicated the following:  First, there 
were no significant within-groups effects.  That is, within the trauma and control groups, 
no significant change in either positive or negative affect on medication versus placebo 
was observed.  One interpretation of this pattern of data is that the opioid manipulation 
was not sufficiently powerful to result in statistically significantly altered experience of 
emotion within either of the groups. 
Second, in terms of positive affect, participants in both the trauma and control 
groups reported very similar scores on placebo (p = .42).  However, on the opioid 
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medication, the control group reported significantly more positive affect than the trauma 
group (p = .011). 
In terms of negative affect, on placebo the trauma group reported significantly 
more negative affect than the control group (p =.04).  However, the between-group 
difference was non-significant in the medication condition (p = .41).  
 
Interim summary: Impact of opioid manipulation on subjective experience of 
affect.  In sum, these results indicate that the groups responded differently to opioid 
manipulation in terms of their subjective experience of affect, albeit not entirely as 
predicted.  The results for negative affect were in the predicted direction.  The trauma 
group reported significantly more negative affect than the control group on placebo, and 
this difference was reduced (to non-significance) on medication.  However, on 
medication, a change in positive affect was seen only in the control group, who moved 
from equivalent scores to the trauma group on placebo to significantly higher scores on 
medication.   
 
Impact of Opioid Manipulation on Social Cognition 
 
Response bias task.  A 2 (group) x 8 (medication condition-emotion) mixed-
design ANOVA indicated a significant interaction between trauma status and types of 
errors made for neutral faces on and off medication, F(2.93, 85.02) = 3.61, p < .017, 
partial eta
2
 = .11.  (See Table 11 for descriptive statistics, and Figure 9 for a graphical 











Response Bias: Emotion choices (as % of all neutral faces) on and off buprenorphine 




Placebo Anger 23.4 (11.7) 25.1 (9.6) 
 Happy 9.4 (8.4) 18.0 (17.6) 
 Sad 57.8 (16.4) 46.2 (14.8) 
 Fear 11.4 (8.3) 9.1 (5.8) 
Medication Anger 20.4 (10.6) 22.4 (10.2) 
 Happy 8.5 (5.8) 20.2 (13.3) 
 Sad 60.5 (18.6) 45.2 (18.2) 
 Fear 10.4 (8.6) 10.1 (7.4) 
Note: Means, with standard deviations in brackets, presented.  










Boxplot illustrating clear trend for the trauma group to judge neutral faces as sad, while 
greater variability is present in the control group. 
 
Simple effects analysis of the interaction indicated the following: First, on 
placebo, the trauma group was significantly more likely than the control group to judge 
neutral faces as sad (p = .049).  Second, on medication, two group differences were 
found: First, the control group was significantly more inclined to judge neutral 
expressions as showing happiness than was the trauma group (p < .006); and second, the 
trauma group was significantly more inclined to judge neutral expressions as showing 
sadness than was the control group (p = .031).  (See Figure 10 for boxplots indicating 
dispersion of the data). 
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Interim summary: Impact of opioid manipulation on social cognition.  In 
sum, these results indicate that the groups responded differently to opioid manipulation, 
but not entirely as predicted.  On both placebo and medication, the trauma group was 
more likely to judge neutral faces as sad.  On medication the control group was 
significantly more likely than the trauma group to judge neutral faces as happy.  
 
Impact of Opioid Manipulation on Neural Activation 
 
The following results are based on data from the fMRI subset sample which 
comprised 22 participants; 11 had been exposed to early social trauma, and 11 had not.  
The results for the fMRI subset on all the measures listed above followed the same trends 
as those for the full sample, and can be found in Appendix D.  
 
fMRI results.  The fMRI protocol featured a three-factor crossover design, with 
one between-group factor (trauma status) and two repeated measures (medication 
condition and emotion). With this complex design, a multitude of contrasts were possible. 
However, I had a very specific set of predictions that I wished to test, which enabled me 
to limit the number of contrasts.  First, it was important to establish whether the low dose 
of buprenorphine resulted in any observable change in brain activation.  Specifically, I 
predicted that relative to placebo, medication would result in reduced activation in 
response to negative social signals (i.e. faces expressing fear and anger). I predicted that 
the response to the control condition (faces expressing happiness) would be unchanged 
from placebo to medication. 
Second, I aimed to investigate whether any change due to medication differed 
across the groups. I predicted that participants who had been exposed to early social 
trauma would show enhanced response to the opioid manipulation. This would mean that, 
on medication, the trauma group would show greater reduction in response to negative 
emotions than the control group. 
 
Whole brain analysis.  A 3-way random effects ANOVA with two repeated 
measures – 2 (group) x 2 (medication condition) x 3 (emotion) – was run, using 
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percentage transformation and separate subject predictors.  Significant effects were 
indicated (q(FDR) < .05).   
With regard to establishing that the dose of buprenorphine resulted in an 
observable change in brain activation, a significant effect for medication was seen for all 
three emotions (see Tables 12, 13, and 14), indicating a difference in neural activation on 
medication relative to placebo for viewing fearful, angry and happy faces.  
The prediction of reduced activation in response to negative emotions on 
medication was not supported in this analysis, however. Although more activations in 
response to fearful faces indicated a reduced response on medication, almost as many 
indicated the opposite (see Table 12, negative activations).  Greater activation on 
buprenorphine was generally observed for angry and for happy faces.  Activations in 
response to the three emotions were seen in a variety of regions, including cortical, 
subcortical, and limbic areas.  The largest areas of activation when viewing fearful faces 
(indicating reduced activation on medication compared to placebo) involved the 
precuneus and anterior cingulate cortex.  The largest areas of activation when viewing 
angry faces (in this instance indicating increased activation on medication compared to 
placebo) also involved the precuneus and anterior cingulate cortex; in addition, a large 
area of activation was evident in the lingual gyrus.  The largest area of activation when 
viewing happy faces (indicating increased activation on medication compared to placebo) 
involved the left middle frontal gyrus.   
With regard to establishing whether any change due to medication differed across 
the groups, the interaction of group by medication was not significant in this analysis. 
Given the unexpected direction of the effects for medication indicated above, and 
the a priori prediction that there would be a between-groups difference in response to the 
opioid manipulation, I considered it possible that group differences were being obscured 
in the whole brain analysis.  It is very likely that the small sample size (only 11 per 
group), the huge number of voxels under analysis, and the rigors of the random effects 
analysis resulted in insufficient power to detect small effects.  I therefore conducted 





Whole brain analysis: Fearful faces elicit greater activation on placebo than buprenorphine (peak voxels reported)  
   Talairach Co-ordinates (mm)   Cluster size 
POSITIVE ACTIVATIONS Side x y z t p (voxels) 
CORTICAL REGIONS        
Superior frontal gyrus R 21 23 46 2.80 0.00762 155 
Middle frontal gyrus R 30 14 49 3.75 0.00053 190 
Superior temporal gyrus
b,1
 R 60 -4 1 3.19 0.00272 163 
Superior temporal gyrus R 45 -46 22 3.59 0.00086 344 
Superior temporal gyrus  R 48 -37 16 3.42 0.00140 115 
Middle temporal gyrus R 39 -61 10 3.42 0.00142 525 
Superior frontal gyrus  L -21 29 43 3.56 0.00093 454 
Middle frontal gyrus L -39 11 37 3.28 0.00208 361 
Frontal - precentral gyrus L -42 -4 37 2.82 0.00726 163 
Middle temporal gyrus L -63 -16 -5 3.45 0.00128 291 
Parietal - precuneus L -9 -49 40 3.62 0.00079 1835 
Parietal - precuneus  L 0 -73 40 2.92 0.00563 253 
Middle occipital gyrus  L -15 -94 7 3.50 0.00110 482 
Middle occipital gyrus  L -42 -64 7 3.14 0.00309 338 
LIMBIC REGIONS        
Anterior cingulate
a
 R 3 5 -5 3.14 0.00306 148 
Anterior cingulate
a
 L -6 23 -2 3.05 0.00393 180 
Caudate
a
 R 18 -10 28 3.01 0.00446 118 
SUBCORTICAL        
Pons
b,2
 L -6 -25 -26 2.97 0.00497 260 
NEGATIVE ACTIVATIONS        
CORTICAL REGIONS        
Inferior frontal gyrus R 42 26 4 3.71 0.00060 269 
Supramarginal gyrus R 51 -34 37 4.19 0.00014 213 
Superior occipital gyrus R 21 -73 34 2.98 0.00471 494 
Occipital - cuneus R 12 -79 1 2.90 0.00590 227 
Frontal - precentral gyrus L -57 5 28 3.49 0.00114 373 
Parietal - postcentral gyrus L -39 -28 34 3.19 0.00268 411 
Inferior parietal lobule L -54 -28 22 4.02 0.00024 524 
LIMBIC REGIONS        
Anterior cingulate
a
 L -3 23 13 3.60 0.00082 2863 
Anterior cingulate
a
 L -21 38 7 3.17 0.00288 1037 
SUBCORTICAL        
Thalamus
a
 R 18 -19 1 3.09 0.00352 139 
Pons
a
 R 6 -37 -29 3.70 0.00062 143 
Note: Uncorrected p values reported. 
a: Regions of interest selected for planned contrasts 
b: Regions of interest featuring significant group differences on planned contrasts.  
1 – 2: The numbers refer to regions in the ROI tables below. 
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Table 13  
Whole brain analysis: Angry faces elicit greater activation on buprenorphine than placebo (peak voxels reported) 
   Talairach Co-ordinates (mm)   Cluster size  
POSITIVE ACTIVATIONS Side x y z t p (voxels)  
CORTICAL REGIONS         
Inferior frontal gyrus R 48 26 7 3.32 0.00188 162  
Orbital frontal gyrus R 39 35 -5 2.67 0.01070 240  
Middle frontal gyrus R 21 44 13 2.88 0.00622 750  
Parietal - precuneus R 21 -46 34 3.75 0.00054 1589  
Parietal - precuneus R 6 -67 37 3.06 0.00387 119  
Occipital - precuneus R 21 -67 28 3.87 0.00037 1553  
Occipital - lingual gyrus R 12 -52 4 4.03 0.00023 422  
Occipital - lingual gyrus R 12 -82 7 3.71 0.00060 1091  
Superior frontal gyrus
b,3
 L -12 5 46 2.76 0.00862 115  
Middle frontal gyrus L -24 47 10 2.95 0.00525 118  
Middle frontal gyrus L -30 26 28 2.70 0.00983 149  
Frontal - precentral gyrus L -57 2 28 3.18 0.00277 254  
Parietal - postcentral gyrus L -54 -28 19 3.05 0.00400 120  
Inferior temporal gyrus L -48 -67 -2 3.45 0.00130 203  
Middle temporal gyrus L -51 -19 -14 3.59 0.00085 125  
Middle temporal gyrus L -57 -52 -8 3.23 0.00242 131  
Occipital - lingual gyrus L -15 -61 1 3.02 0.00427 175  
LIMBIC REGIONS         
Insula
b,4
 R 39 14 -2 3.27 0.00216 458  
Anterior cingulate
a
 L -18 35 16 3.24 0.00235 923  
Parahippocampal gyrus L -27 -40 -5 3.47 0.00120 714  
SUBCORTICAL         
Claustrum
a
 R 27 14 13 2.93 0.00550 108  
Caudate
a
 R 9 20 7 2.61 0.01237 112  
Midbrain
a
 L 0 -10 -8 3.00 0.00449 172  
Head of caudate
a
 L -12 14 -2 2.80 0.00762 148  
NEGATIVE ACTIVATIONS         
Superior temporal gyrus
b,5
 R 60 -4 -2 3.09 0.00355 110  
Cingulate gyrus
a
 R 9 -10 46 3.17 0.00287 198  
Paracentral lobule L -12 -22 49 3.80 0.00046 250  
Superior occipital gyrus L -18 -94 1 3.51 0.00107 705  
 Pons
a
 L 0 -28 -32 3.11 0.00338 415  
Note: Uncorrected p values reported. 
a: Regions of interest selected for planned contrasts 
b: Regions of interest featuring significant group differences on planned contrasts.  





Whole brain analysis: Happy faces elicit greater activation on buprenorphine than placebo (peak voxels reported) 
   Talairach Co-ordinates (mm)   Cluster size 
POSITIVE ACTIVATIONS Side x y z t p (voxels) 
CORTICAL REGIONS        
Superior frontal gyrus R 15 23 49 4.26 0.00011 414 
Superior frontal gyrus
b,6
 R 9 2 52 3.57 0.00091 501 
Middle frontal gyrus R 36 20 34 3.66 0.00070 392 
Middle frontal gyrus R 24 -10 49 3.96 0.00029 913 
Frontal - paracentral lobule R 6 -31 46 3.87 0.00038 503 
Parietal - postcentral gyrus R 33 -22 46 4.34 0.00010 329 
Parietal - postcentral gyrus R 51 -25 40 3.74 0.00055 233 
Parietal - precuneus R 18 -79 34 3.44 0.00132 513 
Occipital - cuneus R 12 -52 4 3.57 0.00091 119 
Occipital - lingual gyrus R 9 -76 -2 3.81 0.00045 165 
Superior frontal gyrus L -12 -22 64 4.99 0.00001 384 
Middle frontal gyrus L -21 2 61 4.98 0.00001 1910 
Middle frontal gyrus L -33 20 40 3.07 0.00378 206 
Frontal - precentral gyrus L -28 -16 67 3.46 0.00124 171 
Superior temporal gyrus L -39 -52 28 3.55 0.00095 349 
Parietal - postcentral gyrus L -21 -37 52 4.15 0.00016 210 
Parietal lobule L -6 -7 55 4.64 0.00003 421 
Occipital - precuneus L -15 -55 16 3.22 0.00246 261 
LIMBIC REGIONS        
Cingulate gyrus
a
 R 9 -16 34 3.92 0.00032 247 
Cingulate gyrus
a
 R 15 -1 46 3.45 0.00129 242 
Cingulate gyrus
a
 R 6 -1 28 4.07 0.00020 116 
Posterior cingulate R 12 -67 7 3.31 0.00190 166 
Insula
b,7
 R 45 -7 22 3.63 0.00077 322 
Anterior cingulate
a
 L -3 23 16 3.10 0.00346 109 
Insula
a
 L -36 -7 10 3.71 0.00061 505 
Insula
b,8
 L -45 -13 19 3.53 0.00101 127 
SUBCORTICAL        
Caudate
a
 L -18 26 1 4.22 0.00013 540 
NEGATIVE ACTIVATIONS        
CORTICAL REGIONS        
Superior frontal gyrus L -9 59 13 3.47 0.00121 186 
Middle temporal gyrus R 48 -61 10 3.57 0.00092 353 
Note: Uncorrected p values reported. 
a: Regions of interest selected for planned contrasts 
b: Regions of interest featuring significant group differences on planned contrasts.  




Region of interest analysis.  The key question to be addressed in the functional 
imaging analysis was whether group differences in the response to the opioid medication 
could be established, particularly with regard to the negative social signals conveyed by 
fearful and angry faces.  ROI analysis provided greater power for this critical between-
groups comparison, as exponentially fewer voxels were included in each analysis.  ROIs 
were functionally defined: Areas of theoretical interest that reached significance in the 
whole brain analysis were selected as ROIs, within which specific contrasts were 
investigated. These areas of theoretical interest were, chiefly, anterior limbic and 
subcortical structures (Alcaro & Panksepp, in press; Braun et al., 2000; Damasio et al., 
2000; Eisenberger et al., 2006; Eisenberger et al., 2003; Panksepp, 1998; Panksepp, 
2005a; Poeggel et al., 1999; Ziabreva et al., 2003; Zubieta, Dannals & Frost, 1999; 
Zubieta et al., 2003).  Only two posterior cortical regions were included: these were both 
anterior temporal regions that are high in mu-opioid receptors, and that are often 
implicated in limbic/emotional function (Maurer et al., 1983; Pfeiffer et al., 1982; Phan et 
al., 2002).  I also included regions falling in ventral and mesial (as opposed to dorsal and 
lateral) prefrontal areas (see Tables 12, 13 and 14; Kennedy et al., 2006; Liberzon et al., 
2007; Northoff et al., in press).  These regions are all important in processing social-
emotional information or mood states, or are part of the SEPARATION-DISTRESS or 
SEEKING systems.  
The subsequent ROI analyses were independent of the original whole brain 
analysis, consisting of orthogonal planned contrasts.  Random effects general linear 
model regressions tested the overall contrasts, followed by t-tests to examine possible 
group differences in the specified pattern of response.  Once again for the ROI analysis, a 
number of comparisons were possible.  I restricted the analysis to the following three 
contrasts that seemed particularly important to the research question under examination.   
 
1) Anger + Fear (medication) < Anger + Fear (placebo) 
This contrast tested the most critical prediction that compared to placebo, reduced 
response to negative social signals would be seen on buprenorphine.  I predicted that this 
effect would be significantly greater for the trauma group than for the control group in 
key regions.  
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Table 15 
Region of interest analysis: Response to negative social signals is reduced on 
buprenorphine compared to placebo 
Region Cluster size 
(voxels) 




  Trauma group Control group   
  (n = 11) (n = 11)   
R Insula
4
 458 -0.05 -0.54 2.3 .02 
L Insula
8
 505 0.18 -0.32 2.2 .02 
 Note: The numbers refer back to the regions selected from the whole brain analysis.   
Uncorrected p values reported. 
 
 
The ROI in the right insula extended over the anterior region of the insula.  The 
ROI in the left insula included activation in the orbital region of the inferior frontal gyrus, 
which extended to include the short gyri of the anterior insula (triangular part; see Figures 
11 and 12). 
The contrast means for the between-groups t-tests represent average percent 
signal change as weighted by the specified linear combination.  They should be 
interpreted as follows: a positive group mean indicates that the change in activation is in 
the direction specified by the linear contrast.  In this instance, a positive mean thus 
indicates that activation in response to negative social signals is less on medication than 
on placebo. A negative mean indicates the opposite pattern of activation to that specified 
in the linear contrast.  In this instance, a negative mean indicates that activation in 
response to negative social signals is greater on medication than on placebo.  
In both regions where a significant group difference was found, the difference 
was in the direction predicted (see Table 15).  That is to say, the trauma group showed a 






ROI analysis: Group difference in reduced response to negative social signals on 
buprenorphine compared to placebo in the right anterior insula (peak voxels 39, 14, -2); 





ROI analysis: Group difference in reduced response to negative social signals on 
buprenorphine compared to placebo in the left anterior insula (peak voxels -45, -13, 19); 
t = 2.2, p < .02 (uncorrected); cluster size (voxels) = 505 
 
With regard to the remaining contrasts, I predicted that, on placebo and compared 
to the control group, the trauma group would show greater reactivity in response to 
negative than positive social signals; a pattern of response that is, arguably, similar to or 
indicative of their normal, unmedicated response to such social signals.  I also predicted 
that opioid manipulation would attenuate this effect.  
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2)  Anger + Fear (placebo) > Happy (placebo) 
This contrast tested the prediction that on placebo, greater activation would be 
seen in response to negative compared to positive social signals.  I predicted that this 
effect would be significantly greater for the trauma group than for the control group.  
Group differences were found in six regions (see Table 16). 
 
3) Anger + Fear (medication) > Happy (medication) 
This contrast was conducted only in the six regions where group differences on 
response to negative social signals on placebo were found, to examine whether this effect 
was also evident on opioid medication.  Group differences in response to negative social 
signals were not evident on buprenorphine (see Table 16). 
 
Table 16 
Region of interest analysis: Greater response to negative than to positive social signals 
on placebo (Contrast 2) and on medication (Contrast 3). 
Region Cluster size 
(voxels) 
Contrast 2 Means t p 
 
Contrast 3 Means t p  
 
  Trauma  Control    Trauma  Control    
  (n = 11) (n = 11)   (n = 11) (n = 11)   
R Superior frontal gyrus
6
 501 0.17 -0.07 2.0 .03 -0.09 0.01 1.1 .15 
L Superior frontal gyrus
3
 115 0.07 -0.10 2.4 .01 -0.01 -0.09 1.0 .16 
R Superior temporal gyrus
5
 110 0.64 0.10 2.3 .02 -0.07 -0.08 0.1 .49 
R Superior temporal gyrus
1
 163 0.59 0.15 2.0 .03 -0.12 -0.01 0.4 .33 
R Insula
7
 322 0.17 -0.05 1.9 .04 -0.01 -0.07 0.7 .25 
L Pons
2
 260 0.07 0.33 2.5 .01 -0.05,  -0.04 0.2 .40 
Note: The numbers refer back to the regions selected from the whole brain analysis. 
Uncorrected p values reported. 
 
Areas in the right and left superior frontal gyrus activated on Contrast 2; the left 
lateralized region involved the medial region of the superior frontal gyrus.  Two rostral 
regions of the right superior temporal gyrus were implicated.  In the first of these regions, 
the activation incorporated the superior temporal gyrus and superior temporal sulcus, but 
 98 
did not extend to the middle temporal gyrus.  In the second right temporal region, the 
activation also included superior temporal gyrus and sulcus, and did extend to the middle 
temporal gyrus.  The right insula activation included the inferior border of the inferior 
frontal gyrus (posterior to orbital region), and extended to the long gyrus of the insula.  
The region of activation in the left pons encompassed a large area; any number of nuclei 
could be involved, including the ARAS, raphe nuclei and the trigeminal nerve. 
In all five cortical regions where significant group differences were indicated, the 
trauma group showed the pattern predicted by the contrast – i.e., on placebo they showed 
greater activation than the control group in response to negative than positive social 
signals.  In the pons, the trauma group again evidenced greater activation in response to 
negative than positive signals; however in this region this effect was greater in the control 
group.  Group differences were not evident on opioid medication (see Table 16). 
The patterns of activation shown by the control group were more variable: In 
three regions, the control group showed the opposite pattern to that predicted – i.e. on 
placebo, they showed reduced activation in response to negative compared to positive 
social signals.   
In three regions the control group showed the same pattern as the trauma group 
(i.e. the pattern predicted by the contrast); in two of these regions the effect was 
significantly less pronounced in the control group than in the trauma group.  In only one 
region (left pons) where both groups showed the predicted pattern of increased activation 
in response to negative emotions, was this effect greater in the control than the trauma 
group. 
 
Interim summary: Impact of opioid manipulation on neural activation.  In 
summary, the fMRI results indicate that the low dose opioid was sufficient to produce 
observable changes in neural activation relative to placebo.  The ROI analysis confirmed 
that the groups responded differently to opioid manipulation, with reduced response to 







This study constitutes the first step in an investigation of the premise that opioid 
dysregulation following early social trauma plays a key role in the etiology of certain 
cases of unipolar depression.  By examining baseline characteristics, and the impact of 
opioid manipulation on subjective affective states, social cognition, and neural activation 
in medically and psychiatrically healthy normal participants who differed only in terms of 
exposure to early social trauma, I hoped to find indications that opioid function differed 
across these individuals.  Although not all predictions were upheld, I found between-
group differences in all measured domains.  The most important indication that opioid 
function may be dysregulated in trauma-exposed, but psychiatrically healthy individuals 
is the fact that those participants consistently differed from controls in terms of their 
response to the opioid manipulation. 
 
Participant Characteristics 
The sample consisted of psychiatrically healthy young adults.  Participants 
differed primarily on one key variable: exposure to early social trauma.  As indicated in 
the rationale for this study, this construct was very broadly defined, due to clear 
indications in the literature that various interpersonal social traumas are associated with 
negative outcomes (see, e.g., Flinn et al., 2011; Heim & Nemeroff, 1999; Heim et al., 
2010; Nepomnaschy & Flinn, 2009; Slavich et al., 2010; Widom et al., 2007).  Early 
social trauma was operationalized using the Childhood Trauma Questionnaire – Short 
Form (CTQ-SF; Bernstein et al., 2003), which measures childhood exposure to physical 
and emotional neglect, as well as to sexual, physical and emotional abuse.  
The trauma and control groups differed significantly on all five CTQ-SF 
subscales.  Estimated effect sizes indicated substantial between-group differences on all 
subscales.  The control group‟s subscale scores all fell within the none-minimal clinical 
range, whereas the trauma group‟s scores fell in the low-moderate range for physical and 
emotional neglect, and in the moderate-severe range for sexual, physical and emotional 
abuse.  I was thus successful in using recruitment and exclusion criteria to set up 
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comparison groups with real differences in their exposure to relevant early social 
traumatic experiences.   
The Mini International Neuropsychiatric Interview (MINI; Lecrubier et al., 1997; 
Sheehan et al., 1997) was used to screen out participants with any psychopathology, 
including anxiety disorders and depression.  The Beck Depression Inventory-Second 
Edition (BDI-II ; Beck et al., 1996) was used to complement the MINI in screening for 
depression, and any individual who scored in the mild symptom range, or higher, was 
excluded.  The groups were thus equivalent on BDI-II depression scores, scoring in the 
none-minimal symptom range on this measure.   
It is true that a number of participants did not complete the BDI-II, and that of 
these, disproportionately more were from the trauma than from the control group.  The 
data collected showed that, although no significant between-group differences were 
present, the trauma group scored slightly higher than controls.  It is thus possible that this 
difference might have been more pronounced had all the trauma group participants 
completed the BDI-II.  In other words, it is possible that some of the trauma group 
participants who did not complete this measure might have been depressed.  However, 
this scenario is unlikely, as I also screened for depression using the MINI, a sensitive 
measure of psychiatric dysfunction that errs on the side of false positives (Sheehan et al., 
1998).  The missing data are therefore unlikely to have impacted unduly on participant 
inclusion, or on between-group differences in depression scores.   
That being said, it is not unreasonable to think that even psychiatrically normal 
individuals who have had difficult childhoods might have a tendency to experience more 
negative affect than controls.  This indeed was hypothesized for negative affect on the 
Positive and Negative Affect Schedule (PANAS; Watson et al., 1988) and for the 
SADNESS subscale on the Affective Neuroscience Personality Scales (Davis et al., 
2003).  However, as is made evident below, the trauma and control groups showed no 
signs of differing on any baseline measures of negative affect.   
I used the PANAS-general ratings to obtain a measure of participants‟ everyday 
emotional experience.  I predicted that the trauma group would experience more negative 
emotion, and less positive emotion, than the control group.  These predictions were not 
supported.  There were no between-group differences on experience of either positive or 
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negative affect, and both groups reported experiencing significantly more positive than 
negative affect.  Given that our trauma group participants were selected specifically for 
being psychiatrically healthy (and even more specifically, for not being depressed), this 
lack of a between-group difference is, perhaps, unsurprising.  It is entirely possible that, 
in terms of the hypothesized mechanisms of depression, this group represents atypical 
and especially resilient individuals.  The implications of this possibility are discussed 
further below. 
The only baseline group difference I did find was on the ANPS – notably, the 
only measure designed specifically to measure long-term differences in the key core 
emotion systems that are the focus of interest in this study.  As with negative affect on the 
PANAS, I predicted that the groups would differ on the ANPS SADNESS subscale, with 
the trauma group scoring higher than the control group.  However, this prediction was not 
confirmed; the groups obtained similar scores on the SADNESS subscale.  The predicted 
group difference on the SEEKING subscale was, however, confirmed; the control group 
scored significantly higher than the trauma group, and the estimated effect size indicated 
that a large between-group difference was present.  This result indicates that general 
motivational and positive expectancy states were greater in the control than in the trauma 
group.   
As mentioned above, the groups were both psychiatrically healthy, so once again 
finding no between-group difference on negative feelings, in this case SADNESS, should 
perhaps not be surprising.  The groups also scored very similarly on the other negative 
emotion subscales (FEAR and ANGER).  The possibility, outlined briefly above, that the 
trauma group is perhaps atypical and resilient in terms of the hypothesized mechanisms 
of depression under investigation here, is one that must be considered.  The broad thesis 
is that early separation-distress may lead to dysregulation of opioid function, which then 
plays a causal role as a mechanism underlying depression; yet the current study‟s sample 
was comprised of only non-depressed trauma-exposed individuals.  As discussed in the 
rationale for this research, there was good reason to include only healthy individuals at 
this point in the research program, but the fact remains that I have assessed an atypical 
and perhaps very resilient group.  These participants were not depressed, they did not 
experience more negative affect in general, and they specifically did not differ from the 
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control group on the SADNESS subscale.  The fact that the data were able to demonstrate 
a between-group difference on SEEKING, however, is most encouraging. 
These ANPS results can be explained in terms of the most recent articulations of 
how early separation-distress feeds into depression.  As indicated in the literature review, 
from this perspective depression is conceptualized as resulting from an evolutionarily 
conserved mechanism that serves to end ongoing activation of the SEPARATION-
DISTRESS system.  In Bowlby‟s (1969) terms, separation-distress constitutes a „protest‟ 
phase that can be observed in the vocalizations of young animals and children.  This 
social pain motivates the animal or child to attempt to re-establish vital social contact.  
However, if this contact is not achieved, a second phase – „despair‟ – sets in. 
The despair phase is characterized by the shutdown of SEPARATION- 
DISTRESS behavior and chemistries.  As explained in the review above, this shutdown 
doubtless has benefits in evolutionary terms, as the youngster does not stray too far, 
avoids metabolic exhaustion, and ceases to announce its vulnerability to potential 
predators.  The shutdown state is characterized by the abandonment of goals, viz., 
reduced SEEKING.  A key point made in the recent papers (Alcaro & Panksepp, in press; 
Panksepp & Watt, 2011; Watt & Panksepp, 2009) is that, although this shutdown is 
usually self-limiting, it can become released from normal control mechanisms.  In this 
instance it can become pathologically active in response to even mild stressors, which can 
result in depression This new articulation of the separation-distress model of depression 
thus directly links the SEPARATION-DISTRESS and SEEKING systems in the genesis 
of depression. 
This recent work also elucidates the chemical mechanisms that accomplish the 
switch from distress or protest to despair.  The neurochemical underpinnings of this 
switch are thought to involve, primarily, raised levels of kappa-opioids, particularly in the 
nucleus accumbens and ventral tegmental area.  Kappa-opioids promote dysphoria and 
reduce pleasure by inhibiting SEEKING – they downregulate mesolimbic dopamine 
expression and transmission (Alcaro & Panksepp, in press; Zellner et al., in press).  
 It may thus be that the experience of early social trauma in the healthy 
participants in the current study has led to long-term downregulation of this system – not 
at a pathological level, as they have no psychiatric disorder – but at a level sufficient to 
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be discernible on a trait measure of this SEEKING disposition.  Because they are atypical 
and resilient, elevated negative affect and signs of depression are not evident.  However, 
we do see a reduction in motivation to engage with the world, and in pleasurable 
expectancy and anticipation states.  In a sample of depressed participants, we might 
expect to see elevated negative affect, along with more profound inhibition of the 
SEEKING system. 
In terms of limitations, it may seem problematic that I chose to begin the 
examination of a broad thesis proposing that early social trauma plays a role in the 
etiology of depression by assessing only non-depressed, psychiatrically healthy 
participants.  In terms of this broad thesis, these participants constitute an atypical group.  
However, I must reiterate that there were sound scientific reasons for beginning the 
investigation in healthy, normal individuals.  Exposure to early social adversity is not 
synonymous with depression.  It is important to investigate opioid function following 
such exposure in its own right, prior to investigating it in the clinical population.  The 
heterogeneity (of both clinical presentations and neurobiological correlates) that exists 
within major depressive disorder presents a significant challenge when conducting 
research with this population.  The information regarding the nature of opioid 
dysregulation subsequent to early social trauma that has now been provided by using a 
„clean‟ population gives a basis from which to build, and will inform future work that 
does include individuals with depression.  
Two ethical concerns were also accounted for, given this choice of participants: 1) 
Little work using buprenorphine has been done in opiate-naïve participants; it was thus 
important to be sure of the medication‟s effects and tolerability at the chosen dose, before 
administering it to individuals from a clinical population.  2) The study featured a novel 
fMRI protocol and a very low-dose pharmacological challenge; it was important to 
ascertain whether these methods could yield any discernible effects, prior to 
implementing them in a clinical population.  
Although in using non-depressed participants I incurred the risk of seeing weaker 
effects than would be present in depressed participants, it was nonetheless possible that 
some difference in opioid function would be discernible in this group of trauma-exposed 
participants.  Given that this group was probably atypical and resilient, the fact that a 
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substantial between-group difference on SEEKING was evident, is a very promising sign 
that effects of early social trauma on opioid function are indeed present and well worth 
investigating further. 
Another interesting observation is that the groups seem to score differently on the 
CARE subscale, with the trauma group scoring higher on this dispositional trait.  Recent 
papers suggest that prosocial activities involving the CARE and PLAY systems may act 
to protect against the effects of early social losses, and may have therapeutic effects in 
depression, as they result in the release of neurochemistries that promote positive social-
affective states (Panksepp, 2010; Panksepp & Watt, 2011; Watt & Panksepp, 2009).  In 
the trauma group, elevated CARE subscale scores thus might reflect a resilience factor.  
This possibility should certainly be pursued in future work.   
 
Impact of Opioid Manipulation on Subjective Experience of Affect 
I used the PANAS-moment ratings (i.e., participants self-ratings of how they felt 
in the moment) to assess whether the administration of buprenorphine had any observable 
impact on current experience of affect.  I predicted that on placebo, the groups would 
show the same pattern of affective experience as that predicted for general experience of 
emotion: that is, the trauma group would experience greater negative affect and less 
positive affect than the control group.  I also predicted that the groups would differ in 
their response to the opioid manipulation, with the trauma group responding more 
strongly.  I predicted that this stronger response to the opioid manipulation in the trauma 
group would result in the experience of positive and negative affect being equalized 
across the groups; that is, on medication the trauma group would not differ from the 
control group on negative or positive affect.  Overall, the results indicated that the trauma 
group did respond more strongly to the medication, but not in a straightforward way. 
There was a significant interaction between trauma status and the combined 
medication-condition/affect factor.  Simple effects analysis of this interaction indicated 
the following with regard to positive affect: on placebo, the groups reported experiencing 
similar levels of positive affect.  However, on medication, the control group reported 
experiencing significantly more positive affect than did the trauma group.  With regard to 
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negative affect, on placebo the trauma group reported significantly more negative affect 
than did the control group.  However, on medication, this difference was not evident.   
It must be noted that there were no significant within-group effects.  In other 
words, the opioid manipulation did not result in a significant change in the experience of 
either positive or negative affect in either group.  This may well be due to the small sizes 
of the groups, and resultant low power. (Post-hoc power calculations for this sample size 
indicate a < 30% chance of detecting small effects; and as indicated below, a small effect 
may have been present in the trauma group).  
Close inspection of the data indicates that the between-group interaction effects 
were largely due to decreases in the trauma group scores on medication.  The observed 
interaction effect where the control group reported significantly more positive affect on 
medication is in fact a function of the trauma group‟s score dropping by almost 4 points 
(on a scale with a maximum of 50), and the control group going up very slightly (almost 
1 point) on medication.  The observed interaction effect where the between-group 
difference in negative affect on placebo disappeared on medication is again due to the 
trauma group‟s score dropping (by nearly 2 points), and the control group going up very 
slightly (nearly 0.5 points).  
Thus, the opioid manipulation did not have a straightforward effect of increasing 
positive affect and reducing negative affect in either group.  It seems that buprenorphine 
reduced the experience of both positive and negative emotion in the trauma group, and 
had little effect on emotional experience in the controls.  Two points are worth 
considering with regard to these results: first, buprenorphine is an analgesic, so as part of 
its sedative effect a general dampening of emotional experience is possible (Boothby & 
Doering, 2007; Greenwald et al., 2007).  However, this pattern was only evident in the 
trauma group, so it being the result of a general sedative effect is unlikely.  Perhaps the 
important observation here is that the groups responded differently to the opioid 
manipulation.  One might argue that this difference reflects different functioning of the 
opioid system across the groups, and in fact supports the hypothesis that individuals 
exposed to early social trauma would be more sensitive to opioid manipulation.   
Second, the effects of buprenorphine on mood in opiate-naïve participants are not 
unequivocal.  Buprenorphine is not a full mu-opioid agonist, and so it does not create the 
 106 
marked euphoria characteristic of those substances; it generally has only modest mood 
elevating effects (Ciraulo et al., 2006; Stefano et al., 2000).  The documented mood 
improvements in recovering addicts and in small clinical trials using buprenorphine occur 
following periods of consistent administration, from 5 days to several weeks (Bodkin et 
al., 1995; Emrich et al., 1982; Kosten et al., 1990; Mongan & Calloway, 1990; Nunes & 
Levin, 2004).  It is thus possible that the ameliorative effects on mood are not evident 
during a once-off pharmacological challenge, and only occur following repeated 
administration.  
With regard to limitations, the very stringent inclusion/exclusion criteria 
employed resulted in very small comparison groups, despite prolonged recruitment 
efforts.  Having small groups impacts on results not only in the simple terms of reduced 
statistical power; it in fact affects the likelihood that the patterns seen in the data are 
reliable.  Those described here thus need to be confirmed in future work.  One 
encouraging sign that these results may reflect reliable data patterns is that the same 
patterns were found for both the full sample and the fMRI subset: if unusual individuals 
in the small sample were skewing the data, it would be more likely that data patterns 
would be unstable across the samples. 
 
Impact of Opioid Manipulation on Social Cognition 
Subliminal presentation of faces showing four basic emotions (anger, fear, 
sadness, and happiness) was used to evaluate bias in assigning one of these four emotions 
to the presentation of neutral faces.  The opioid system is strongly implicated in social 
functioning.  If the idea is correct that exposure to early social trauma leads to opioid 
dysfunction, which in turn contributes to depression, negativity biases in processing 
social-emotional information might exist in the trauma group.  Negativity biases exist in 
depression, and are evident, for example, in tendencies to have better recall for negatively 
valenced material, and to attend more closely to negative stimuli (Beck, 1967, 1987; 
Matt, Vazquez & Campbell, 1992).  They are also evident in processing social and 
emotional stimuli (Gilboa-Schechtman, Erhard-Weiss & Jecsemien, 2002; Miskowiak et 
al., 2007; Poulsen, Luu, Crane, Quiring & Tucker, 2009).  A specific bias towards 
interpreting neutral faces as showing negative emotions has been documented in 
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depression (see, e.g., Bouhuys, Geerts, Mersch & Jenner, 1996; Gur, Erwin, Gur & Zwil, 
1992).  Thus I predicted that this bias would be present, to some extent, in these 
psychiatrically healthy trauma-exposed participants. 
I predicted that on placebo, a negativity bias would be evident in the trauma 
group.  These participants would thus be more likely than controls to judge neutral faces 
as showing negative emotions (anger, sadness or fear).  I predicted that the opioid 
manipulation would attenuate this bias, and that therefore, on medication, this tendency 
would no longer be evident in the trauma group. 
Results showed a significant interaction between trauma status and the combined 
medication condition/emotion factor.  Simple effects analysis indicated that on both 
placebo and medication, the trauma group was more likely than the control group to 
judge neutral faces as showing sadness.  On the opioid medication, the control group was 
more likely than the trauma group to judge neutral faces as showing happiness. 
The predicted negativity bias in the trauma group on placebo was thus only 
evident for sadness; both groups judged similar proportions of neutral faces as showing 
anger or fear.  Contrary to prediction, buprenorphine administration did not reduce the 
bias in the trauma group: these participants also judged significantly more neutral faces 
as sad on medication.   
Buprenorphine administration did result in a significant between-group difference 
in the proportion of neutral faces judged to be showing happiness: the control group made 
significantly more of these judgments on medication than did the trauma group. This 
trend was present on placebo (9.4% vs. 18% of neutral faces judged happy by the trauma 
and control groups respectively), but the difference became statistically significant on 
medication (8.5% vs. 20.2%). 
It should be noted that there were no within-group differences, so there is no 
direct evidence of the opioid medication producing marked changes in each group‟s 
interpretation of the neutral faces.  Once again, this is perhaps due to the impact of the 
small group sizes on statistical power to detect small effects; alternatively, there is the 
possibility that consistent administration of buprenorphine might be required to produce 
significant effects. 
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It should also be noted that the greatest proportion of all judgments for both 
groups on and off opioid medication featured sadness (58.7% and 60.5% for the trauma 
group and 46.2% and 45.2% for the control group, respectively).  It thus seems that 
neutral expressions were most easily mistaken for sadness by all participants.  A number 
of earlier studies have reported similar findings (Arce et al., 2009; Gur et al., 2002; 
Rojahn & Warren, 1997).  In those studies, the tendency to attribute sadness at greater 
rates than other basic emotions to neutral faces was found in both normal and psychiatric 
populations.  This tendency to perceive neutral faces as sad is arguably due to the fact 
that sad facial expressions are least distinctive when compared to angry, fearful or happy 
expressions, and hence closest to neutral. 
However, the increased tendency to interpret neutral faces as sad was clearly 
more pronounced in the trauma group (Figure 10 clearly illustrates this point).  
Difficulties recognizing facial emotions and a bias towards interpreting neutral faces as 
showing negative emotions have been documented in depression (Bouhuys et al., 1996; 
Gur et al., 1992), but are also evident in subclinical cases of depression, and in highly 
neurotic individuals who are not depressed (Arce et al., 2009; Chan, Goodwin & Harmer, 
2007; Williams, Watts, MacLeod & Mathews, 1997).  It has thus been argued that the 
negativity bias precedes and is a risk factor for depression (Chan, Harmer, Goodwin & 
Norbury, 2008).  Because interpreting ambiguous facial expressions is thought to play an 
important role in social and interpersonal relationships, examining the way in which 
individuals interpret neutral expressions gives insight into how they are likely to respond 
in complex social situations (Arce et al., 2009; Bouhuys et al., 1996; Gilboa-Schechtman 
et al., 2002; Gur et al., 1992; Surguladze et al., 2004).  As indicated above, negativity 
biases, including a tendency to interpret ambiguous social situations in a negative light, 
are thought to represent a vulnerability factor for depression.  The trauma group‟s 
tendency to interpret ambiguous social signals as negative might thus represent such a 
vulnerability factor in this group of participants.   
On medication, there was an increased bias in the control group towards judging 
neutral faces as happy.  This bias has previously been documented in highly resilient 
individuals (Arce et al., 2009), and tends to be interpreted as supporting the argument that 
resilient individuals are able to focus on and generate positive emotions, which helps 
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them cope successfully with stress (Ong, Bergman, Bisconti & Wallace, 2006; Tugade, 
Fredrickson & Barrett, 2004; Werner & Smith, 1992).  This data thus suggests that opioid 
manipulation strengthens a positivity bias in interpreting ambiguous social signals in 
individuals who have not been exposed to early social trauma.   
Overall, the data thus support the contention that exposure to early social trauma 
has a long-term effect on social cognition, even in psychiatrically healthy individuals.  
Trauma-exposed participants showed a persistent negative bias towards sadness, which 
was not attenuated by opioid medication.  These participants showed no sign of the 
positive bias exhibited by the controls.  A negative bias in interpreting complex social 
emotional information may have important effects in social interactions, and may 
represent a vulnerability factor in the trauma group.  Importantly, these data again 
indicated that the groups responded differently to the opioid manipulation, supporting the 
contention that opioid function is dysregulated in individuals exposed to early social 
trauma.  
In terms of limitations, why did the medication not attenuate the negativity bias 
towards sadness evident in the trauma group?  Perhaps, as argued in the section above in 
relation to mood, longer periods of consistent administration of buprenorphine might be 
required to restore the opioid system to relatively normal functioning.  Long-term 
treatment of depression with SSRIs can reduce negativity biases (Curry et al., 2006; 
Simons, Garfield & Murphy, 1984), and there are indications in the literature that even 
once-off administration of SSRIs can reduce such biases in processing emotional material 
(Browning, Reid, Cowen, Goodwin & Harmer, 2007; Miskowiak et al., 2007; Norbury, 
Mackay, Cowen, Goodwin & Harmer, 2008).   
However, although SSRI treatment may reduce the negativity bias, this bias may 
exist independently of diagnosable depression.  It is seen in subclinical cases and in 
highly neurotic never-depressed individuals; it may remain present even when depressive 
symptoms remit following treatment (Bouhuys et al., 1996; Mayberg, 2004; Williams et 
al., 1997).  It could be that medications targeting chemistries that primarily mediate affect 
have limited impact on eradicating negative cognitive biases – these might need to be 
unlearned in a structured way.  Further work will be needed to ascertain whether the 
negativity bias demonstrated here responds to consistent administration of buprenorphine, 
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and to what extent this bias acts as a vulnerability factor for increased negative affect or 
depression in individuals exposed to early social trauma.  
 
Impact of Opioid Manipulation on Neural Activation 
The main goal of the fMRI investigation was to establish whether or not the 
opioid manipulation led to observable between-group differences in neural activation, 
particularly in response to negative social signals.  I used a neuroimaging task that 
featured dynamic morphing of facial expressions, from neutral to extreme emotion, to 
investigate this possibility.  In the following subsections, I will first discuss this 
neuroimaging task, then the whole brain analysis, and then the ROI analysis, before 
moving on to a consideration of limitations of the neuroimaging component of this study.    
 
The passive viewing of emotions protocol.  Because the use of passive viewing 
of dynamic stimuli is fairly unusual, and because the use of a novel fMRI protocol can be 
problematic, it seems important to justify the selection of this particular protocol.  The 
aim of the task was to expose participants to powerful negative social stimuli in the form 
of faces that morphed quickly from neutral to extreme fearful or angry expressions (with 
happiness serving as a positive control).
8
  I wanted to access participants‟ unmediated 
automatic responses to these signals, and thus no cognitive task was involved.  
Participants were not required to perform an explicit emotion recognition task; they 
simply watched the stimuli.   
As mentioned briefly in the Methods section, the bulk of functional neuroimaging 
work investigating the processing of facial emotion has used static images (see, e.g., 
Costafreda, Brammer, David & Fu, 2008; Habel et al., 2007; Hariri et al., 2002; Morris et 
al., 1998; Norbury, Mackay, Cowen, Goodwin & Harmer, 2007; Phillips et al., 2001; 
Whalen et al., 2001).  In real life, however, dynamic changes in expression provide vital 
social information in that they give us immediate indications of changes in others‟ 
emotional states.   
                                                 
8
 As indicated in the Methods section, time constraints and considerations from the larger study mandated 
that only these emotions could be included in the protocol.  Given the results regarding sadness in the 
previous section, it would be most beneficial to include this emotion in this task in future work. 
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A small body of research shows that using dynamic stimuli to present facial 
expressions has important consequences.  These dynamic stimuli evoke different 
perceptual, cognitive and emotional processing (Pelphrey, Singerman, Allison & 
McCarthy, 2003; Puce, Allison, Bentin, Gore & McCarthy, 1998; Wicker, Michel, 
Henaff & Decety, 1998).  They have been shown to 1) improve emotion recognition (de 
Gelder, Vroomen, Pourtois & Weiskrantz, 1999; Harwood, Hall & Shinkfield, 1999); 2) 
improve the ability to distinguish actual from posed emotional expressions (Hess & 
Kleck, 1990); and 3) improve age and familiarity judgments (Berry, 1990; Lander, 
Christie & Bruce, 1999).  Furthermore, a handful of neuroimaging studies have indicated 
that the use of dynamic facial expressions results in both increased activation in the 
regions known to activate in response to static faces, and in the activation of a more 
widespread network that includes these regions (Kilts, Egan, Gideon, Ely & Hoffman, 
2003; LaBar, Crupain, Voyvodic & McCarthy, 2003; Sato et al., 2004; Trautmann et al., 
2009).  Some researchers thus regard the use of dynamic rather than static stimuli in 
studying responses to facial emotion as a more ecologically valid method, particularly 
when studying social functioning.  As my interest was to see the spontaneous emotional 
responses elicited by these negative social stimuli, it was important to use the most 
sensitive protocol.   
Passive viewing, rather than a protocol featuring an explicit emotion recognition 
or other active cognitive task was chosen deliberately in an attempt to exclude conscious 
cognitive processing.  Researchers argue that cognitive demands result in the inhibition 
of deeper emotion processing structures or systems by the prefrontal cortex (Blair et al., 
2007; Ochsner & Gross, 2005; Rosenkranz, Moore & Grace, 2003), and a number of 
functional imaging studies support this contention (Hariri, Mattay, Tessitore, Fera & 
Weinberger, 2003; Ochsner, Bunge, Gross & Gabrieli, 2002; Pezawas et al., 2005).  In 
fact, a meta-analysis of 385 neuroimaging studies indicated that increased amygdala 
activation was evident for passive, compared to active, viewing tasks (Costafreda et al., 
2008).  The passive viewing of emotions thus seemed a better choice in terms of its 
ability to strongly elicit emotional processing, and also because I wanted to examine 
emotional, rather than cognitively mediated, responses to negative social stimuli.   
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Whole brain analysis.  Given the very low dose of buprenorphine used, it was 
possible that the opioid manipulation would not be strong enough to produce any 
detectable differences in neural activation.  The whole brain analysis was able to show, 
however, that the medication had a significant effect across all three emotions included in 
the protocol.  Although the general response of all participants to the opioid manipulation 
was not the focus of this investigation, it was encouraging to note that several regions 
flagged as important in the literature review demonstrated differences in activation on 
and off medication.  These included various regions in the prefrontal cortex, anterior 
cingulate, basal ganglia, midbrain and pons – areas implicated in the SEPARATION-
DISTRESS and SEEKING systems.   
Given that buprenorphine is an analgesic with mild mood-elevating properties, I 
predicted that on medication compared to placebo, both groups would show reduced 
neural activation in response to negative social signals (fearful and angry faces).  Because 
the hypothesis was that exposure to early social trauma has a long-term effect on opioid 
circuitry and opioid function, I predicted that the trauma group would show a different 
pattern of response to the opioid manipulation when compared to the control group: 
specifically, that significantly greater reduction in neural response to negative social 
signals would be evident in the trauma group compared to controls.   
When examining the impact of buprenorphine without taking trauma status into 
consideration, the prediction that medication would reduce response to negative social 
signals was not supported.  In response to viewing fearful faces on medication, more 
regions showed reduced than increased activation.  This does fit the prediction.  
However, increased activation was also fairly common in response to fearful faces (as 
illustrated in Table 12, which shows 18 areas of reduced activation, and 11 areas of 
increased activation on medication).  In response to both angry and happy faces, 
predominantly increased activation was seen on medication.  
What could account for this unexpected direction of the effect for medication?  It 
seems that, overall, participants in the two groups responded similarly to anger and 
happiness on medication, but showed a different pattern of response to fearful faces.  
Different processing styles for fear and anger stimuli are known to exist: a well-
established body of research indicates that socially dominant, approach-oriented 
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individuals respond similarly to angry and happy faces, whereas those who are more 
avoidant are likely to react strongly to fear stimuli, but to avoid anger stimuli.  This 
literature uses a model that conceptualizes emotions and their associated behavioral 
tendencies in terms of a dichotomy: they are all related to either approach or withdrawal 
tendencies.  Research seems to support the contention that many individuals develop 
personality traits that are either predominantly approach-oriented, motivated by reward-
seeking, or avoidant, motivated by the desire to escape punishment (Allen, Coan & 
Nazarian, 2004; Allen & Kline, 2004; Davidson, 1995; Pizzagalli, Sherwood, Henriques 
& Davidson, 2005).  Critically, this work indicates that those who are more approach-
oriented and reward-sensitive will respond differently to anger stimuli than those who are 
more avoidant-oriented and punishment sensitive.  Specifically, approach-oriented 
individuals attend to and hence respond strongly to anger, whereas avoidant individuals 
attend to and respond strongly to fear, while avoiding attending to and processing anger 
stimuli.  The idea is that approach-oriented, dominant individuals see anger as a 
challenge, with reward following if the challenge is successfully handled; in contrast, 
avoidant, submissive individuals experience anger as punishing, while fear is the most 
salient social signal (Hermans, Ramsey & van Honk, 2008; Putman et al., 2004; Putman 
et al., 2007a; van Honk et al., 2002; van Honk & Schutter, 2006; van Honk et al., 2004; 
van Honk et al., 2000).   
It is thus possible that buprenorphine increased the tendency in all participants to 
respond in approach-related ways; therefore they showed greater activation in response to 
angry and happy faces on medication.  It is, of course, also possible that personality 
differences of this nature (participants with greater approach or avoidant tendencies) were 
present in this sample, which could result in very different patterns of neural response in 
different individuals, thus confounding the analysis.  Within-group personality 
differences of this kind might account for the variable pattern of response to fearful faces, 
where there were both increases and decreases of activation on medication, in some 
instances in areas of the same structure (e.g. anterior cingulate and pons); however this 
line of reasoning is only speculative.  What must be considered is the fact that, given that 
the trauma group probably comprised an atypical set of resilient individuals, it is unlikely 
that all these participants were avoidant, or that all the participants in the control group 
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were approach-oriented.  This factor could thus constitute an important confounding 
variable in the between-groups fMRI analysis discussed below.  It would be highly 
advisable to include examination of approach/avoidance tendencies in future work.
9
 
Turning to the between-groups comparison, which takes trauma status into 
account in the examination of the impact of buprenorphine on neural activation, I found 
no significant interaction between group and medication condition in the whole brain 
analysis.  Thus, the prediction that the groups would respond differently to opioid 
medication was not supported, and post-hoc investigation of possible different responses 
to the different emotions (especially the combined negative emotions) could not be 
conducted. 
A primary concern regarding this result was that the rigors of the random effects 
method in the whole brain analysis, especially given the very small group size (n = 11 per 
group), resulted in group differences being undetectable.  Given the unexpected direction 
of the effect for medication discussed above, and the power problem in the whole-brain 
analysis, group differences that consisted of small effects might well have gone 
undetected.  Hence, I turned to the more powerful ROI analysis, and examined very 
specific planned contrasts. 
 
Region of interest analysis.  The ROIs included in the analysis were functionally 
defined: areas that showed significant activations in the whole brain analysis were used 
for the ROI analysis.  I restricted this exploratory analysis to regions that the literature 
review had indicated were likely to be of importance: anterior subcortical, anterior limbic 
and paralimbic, anterior temporal, and prefrontal regions (the latter consisting of ventral 
and medial areas, rather than dorsal and lateral areas).  These are all areas involved in 
emotion, and more specifically many are implicated in the SEPARATION-DISTRESS 
and SEEKING systems (Panksepp, 1998; 2005a).  In the ROI analysis, I carried out three 
planned contrasts. 
                                                 
9
 Individual differences in these personality traits are tapped by the BIS/BAS scale and differences in 
baseline lateralized prefrontal activity as measured by EEG.  These measures are not part of the study 
reported here – they do, however, form an integral part of another PhD being written up on other parts of 
the dataset from the full protocol.  It is for this reason that this analysis is not included in this thesis, despite 
its obvious relevance. 
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The first contrast examined the most critical prediction: that opioid manipulation 
would reduce the trauma group‟s response to negative social signals significantly more 
than it would that of the control group.  This prediction was confirmed in two anterior 
regions of the insula. The left-sided region of activation included the short gyri of the 
anterior insula, and extended to the orbital region of the adjacent inferior frontal gyrus.  
The right-sided region of activation extended over the anterior region of the insula.  In 
these regions, the opioid manipulation (in comparison to placebo) resulted in the trauma 
group showing significantly less reactivity to negative social signals than the control 
group.   
It should be noted that the region of activation in the left anterior insula extended 
to include part of the adjacent inferior frontal gyrus (orbitofrontal region).  Previously, 
opposing patterns of mu-opioid activity in the insula and orbitofrontal cortex have been 
found (Kennedy et al., 2006; these were interpreted as the insula and orbitofrontal region 
exerting different influences).  In this instance, however, the activation represents a single 
cluster.  A number of authors have noted that spillover of anterior insula activation into 
this region is in fact common.  For example, Ochsner et al. (2006) indicated that the 
orbitofrontal cortex adjacent to the anterior insula activated in concert with the latter 
structure during the experience of the affective component of physical pain.  In a review 
of insula function, Craig (2003) stated that insula activation during the experience of 
emotion often extends to the neighbouring inferior frontal gyrus, and terms this region the 
fronto-insula junction.  It is therefore not unusual to see joint orbitofrontal and anterior 
insula activation representing a single response or function. 
How does this group difference in response to negative social signals in these 
anterior insular regions fit with (a) reasoning around the overlap between physical and 
social pain, and (b) the role of the mu-opioid system in these affective states?   
The insula is best known for its role in interoception: the representation of the 
visceral, physiological state of the entire body, which is primarily carried out in the 
posterior regions (Craig, 2003).  The fact that the insula is also implicated in emotion is 
clear, with work around its role in disgust being best known (see, e.g., Jabbi, Bastiaansen 
& Keysers, 2008; Phillips et al., 1997; Rozin & Fallon, 1987; Rozin, Haidt & McCauley, 
1993).  However, the insula does appear to participate in emotion more broadly.  Various 
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studies have indicated that the insula, particularly anterior regions, is activated during the 
experience of emotions, especially sadness (Damasio et al., 2000; George et al., 1995; 
Reiman et al., 1997).  If we consider Damasio‟s (1999) conception of emotions as 
readouts of the body‟s current state in the world, the insula‟s involvement in emotion is 
certainly coherent with its interoceptive functions.   
Both areas of significant activation in this analysis fell in the anterior insula.  This 
region has extensive connections to areas of the brain known to be involved in emotion 
(Craig, 2003, 2009).  The right anterior insula seems to have a very particular role.  In his 
reviews of insula function, Craig states that the right anterior insula re-represents 
interoceptive activity from posterior insula regions, and that this re-representation 
correlates with subjective awareness of feelings.  Insula regions are thus associated with 
conscious awareness of affective states (see also Damasio, 1999; Damasio et al., 2000). 
Furthermore, the insula has a specific role in pain.  As part of its interoceptive 
function, it represents both the sensory and affective components of physical pain 
(Brooks, Nurmikko, Bimson, Singh & Roberts, 2002; Petrovic, Kalso, Petersson & 
Ingvar, 2002; Peyron et al., 2000; Price, 2000).  It forms part of a descending pain 
modulation system (incorporating the prefrontal cortex, anterior cingulate cortex, insula, 
amygdala, hypothalamus, and various brainstem regions including the periaqueductal 
grey) that can also enhance bottom-up pain signalling, and that appears to have a role in 
the emotional modulation of pain (Wiech & Tracey, 2009). 
Given the evidence of the overlap between brain systems for physical and social 
pain reviewed earlier, it is unsurprising that the insula plays a role in representing social 
pain.  The insula is involved in empathy for both physical pain (Gu & Han, 2007; 
Jackson, Brunet, Meltzoff & Decety, 2006; Singer et al., 2004) and empathy for social 
pain (Masten, Morelli & Eisenberger, 2011).  The latter study in fact found anterior 
insula activation during empathy for social rejection.  Moreover, studies investigating the 
pain of loss have shown that the insula is activated during the experience of grief (Gundel 
et al., 2003; O'Connor et al., 2008).  A recent meta-analysis of functional imaging work 
on emotions confirmed that the insula is particularly active during the experience of 
negative emotions (Wager, Phan, Liberzon & Taylor, 2003), and that, as indicated above, 
it is particularly involved in sadness.  Recent work indicates that the insula, and perhaps 
 117 
particularly the right anterior insula, is activated during the experience of social rejection, 
and that this activation correlates with increased self-reported distress (Masten et al., 
2009; Way, Taylor & Eisenberger, 2009). It thus seems that the insula may be an 
important part of the human sadness, or SEPARATION-DISTRESS system. 
Moreover, there is evidence of mu-opioid involvement in insula regions during 
the experience of negative emotions.  Studies have found an association between mu-
opioid activity in both the left (Zubieta et al., 2003) and right (Kennedy et al., 2006) 
insula and heightened feelings of sadness.  These studies have demonstrated that in 
healthy controls, mu-opioid activity decreases during feelings of sadness, but that in 
depressed individuals, opioid function appears to be dysregulated.  Critically, Kennedy et 
al. (2006) found that in participants with major depressive disorder, increased mu-opioid 
activity was evident in the right anterior insula during sadness.  Other work has indicated 
that heightened activity in the anterior insula is greater in individuals who are prone to 
anxiety when processing emotionally aversive stimuli (Paulus, Feinstein, Castillo, 
Simmons & Stein, 2005; Simmons, Matthews, Stein & Paulus, 2004; Stein, Simmons, 
Feinstein & Paulus, 2007). 
Another important line of evidence comes from a study that examined baseline 
mu-opioid activity in groups with exposure to war trauma and in healthy controls 
(Liberzon et al., 2007).  The authors found that all those exposed to trauma had reduced 
baseline mu-opioid binding potential in the insula bilaterally.  The authors suggested that 
trauma exposure leads to functional changes in the mu-opioid system, and that these 
changes consist of downregulation of activity in the limbic forebrain and associated 
cortical areas, including the insula.  Given these findings, they also raised the possibility 
that early trauma may alter the development of the endogenous opioid system. In all the 
papers investigating the mu-opioid system cited above, the authors regard mu-opioid 
activity as responsive to negative emotional states; its purpose being the regulation or 
inhibition of these negative emotions.  This function appears to be dysregulated in major 
depression and in individuals exposed to trauma. 
In sum, it seems that the insula is involved in representing and regulating both 
physical and social pain.  We know that the insula is strongly activated during negative 
emotions, and there are indications that this responsivity is dysregulated (heightened) in 
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individuals with negative mood states, such as major depression and anxiety.  
Furthermore, individuals exposed to trauma show reduced baseline mu-opioid activity in 
this region. 
In the current study, buprenorphine administration led to reduced responsivity to 
negative social signals in trauma-exposed individuals compared to controls.  I suggest it 
is possible that, due to their exposure to early social trauma, mu-opioid function was 
downregulated in these regions in the trauma group.  Given what the literature reviewed 
above indicates, the observed effect could have come about as follows: exposure to 
negative social signals could have resulted in activation here, and due to mu-opioid 
downregulation, trauma-exposed participants could have been less able to adequately 
self-regulate or inhibit this negative emotional response via mu-opioid release.  
Buprenorphine administration could thus have had a disproportionate effect on 
individuals in this group, in reducing insula reactivity, and hence reducing the negative 
affective state. 
 
Two subsequent contrasts served to explore further the impact of the opioid 
manipulation on the groups‟ responses to social signals.  First, I hypothesized that the 
trauma group would be more reactive than the control group to negative than positive 
social signals.  This pattern of response would be another instance of the negativity bias 
that can be seen in even in subclinical depression and in highly neurotic, never-depressed 
individuals (Bouhuys et al., 1996; Mayberg, 2004; Williams et al., 1997).  I used 
activation on placebo as a marker for this, reasoning that those responses should 
approximate normal neural responsivity.  Next, I did an indirect contrast aimed at 
investigating whether or not any such effects seen on placebo were also present on opioid 
medication.  In other words, did the trauma group remain more reactive than controls to 
negative compared to positive social signals on opioid medication? 
The prediction that, on placebo, the trauma group would be more responsive than 
the control group to negative than positive social signals was confirmed.  Significant 
between-group differences on this contrast were found in five regions: the right and left 
superior frontal gyrus; two areas of the right superior temporal gyrus; and the right insula. 
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The superior frontal gyrus activation was not bilateral; different regions were 
implicated.  The activations in the right superior temporal gyrus were both rostral.  In the 
first of these temporal regions, the activation incorporated the superior temporal gyrus 
and superior temporal sulcus, but did not extend to the middle temporal gyrus.  In the 
second of these regions, the activation again included the superior temporal gyrus and 
sulcus, and extended to the middle temporal gyrus.  It must be noted that these regions 
seem to be more anterior than the regions of superior temporal gyrus/sulcus that are 
typically implicated in the processing of facial movement (Haxby, Hoffman & Gobbini, 
2000; Sato, 2004; Trautmann et al., 2009).  The right insula region of activation extended 
to include the inferior border of the inferior frontal gyrus (posterior to the orbital region).   
As indicated by various meta-analyses, these cortical regions are activated when 
processing emotional faces (Fusar-Poli et al., 2009; Phan et al., 2002; Sabatinelli et al., 
2011; Trautmann et al., 2009; Wager et al., 2003).  Emotional face processing is known 
to activate areas, such as these, that are themselves involved in the experience of emotion 
(Adolphs, 2002; Davidson & Irwin, 1999; Haxby et al., 2000; Murphy, Nimmo-Smith & 
Lawrence, 2003).  In all these cortical areas, on placebo, the trauma group exhibited a 
significantly greater response to angry and fearful faces (compared to happy faces) than 
did the control group.     
Subcortically, there was a significant between-group difference in response to 
these social signals in the left pons; however, here the predicted pattern was reversed.  In 
this area, on placebo, the control group showed greater activation than the trauma group 
in response to negative compared to positive social signals.  It is not entirely clear what 
this pattern of activation in the pons means.  The area covers a large region and could 
involve a number of pontine nuclei, which serve very different functions (e.g., it might 
encompass a portion of the reticular activating system, the trigeminal nerve, and the 
raphe nuclei).  In terms of emotion processing, Damasio et al. (2000) found that the 
dorsal and anterior pons activated during the experience of anger of sadness, but that the 
anterior pons was relatively deactivated during the experience of happiness and fear.  A 
study of grief also found dorsal pons activation during the experience of this emotion 
(Gundel et al., 2003).  Pons activation is also, however, associated with laughter and 
feelings of happiness (Wild, Rodden, Grodd & Ruch, 2003).  Pontine activation thus 
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appears to occur during the experience of various emotions, but there is no clear 
overarching theoretical framework to explain the pons‟ function in this regard. 
The third contrast tested the prediction that the trauma group would show greater 
responsivity to negative than positive social signals, this time on medication.  The aim 
was to establish whether any negativity bias evident in the trauma group on placebo 
would remain evident on the opioid medication.  This contrast was thus conducted only 
in the six regions where significant between-group differences were found on placebo.   
No significant effects were found. 
What the second and third planned contrasts illustrate is that perhaps 
buprenorphine attenuates the exaggerated cortical-limbic responsivity to negative social 
signals present in the trauma group.  I qualify this statement because this is an indirect 
contrast – the comparison is so complicated that I could not set up a direct contrast in 
BrainVoyager.  What these contrasts also illustrate is that, once again, the effect of the 
opioid manipulation on the two groups differs.  If both groups changed equally on the 
medication, the effects should still be present.  However, this was not the case.  The fact 
that the trauma and control groups responded differently to the opioid manipulation 
supports the idea that exposure to early social trauma may lead to long-term 
dysregulation of opioid function.   
 
Interim summary: Impact of opioid manipulation on neural activation.  I was 
able to demonstrate that the low dose of buprenorphine resulted in observable changes in 
neural activation, many of these occurring in brain areas marked as theoretically 
significant in the literature review.  In the region of interest analysis, I was able to 
demonstrate between-group differences in the response to the opioid manipulation.  Most 
interestingly, buprenorphine had a greater impact in reducing response to negative social 
signals in the trauma group, in anterior regions of the insula, which appear to be part of 
the social pain, or SEPARATION-DISTRESS system in humans.  A further set of 
contrasts indicated that buprenorphine was able to attenuate a negativity bias (greater 
response to negative than positive social signals) evident in the trauma group on placebo.  
Although obviously preliminary, these findings are very encouraging.   
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Limitations of the neuroimaging component of this study.  The research 
reported here constituted an exploratory pharmacological challenge study, using a low-
dose buprenorphine manipulation in combination with a small sample size: There was 
thus a real risk of obtaining null findings.  The reasons for using a low dose of 
buprenorphine have been discussed above, and in opiate-naïve individuals small amounts 
of buprenorphine seem capable of having marked effects (see, e.g., Bodkin et al., 1995; 
Emrich et al., 1982; Escher et al., 2007; McAleer et al., 2003).   
The fact that a group-by-medication interaction was not evident in the whole brain 
random effects analysis could well be due to the small sample size (n = 11 per group). 
The random effects analysis method is the preferred method in fMRI research, largely 
because although fixed effects analysis is more powerful and better suited to small 
samples, it does not permit generalization beyond the sample used.  Twelve participants 
per group are the minimum recommended number when using random effects analysis 
(Savoy, 1999), and 15 per group is becoming the new minimum guideline in the field (E. 
Meintjes, personal communication, 11 March 2011).  Given the extremely stringent 
inclusion/exclusion criteria employed and hence the difficulty finding appropriate 
participants, ongoing recruitment would have been an extremely time-consuming 
process, and of course the financial implications would have been substantial. Most 
importantly, a number of pharmacological challenge studies using only 12 participants 
per group had been published, indicating that it should be possible to see effects at the 
sample size reported here (see, e.g., Harmer et al., 2003; McKie et al., 2005; Miskowiak 
et al., 2007; Norbury et al., 2007).  For future work, a larger group size would be most 
beneficial, of course.   
It was possible to demonstrate effects resulting from the opioid manipulation, but 
not between-groups effects in the whole brain analysis; hence the need for the ROI 
analysis.  Because of concerns regarding the small sample, and the exploratory nature of 
this research, I did not correct for Type 1 error, which represents a very real threat in 
fMRI work (Amaro & Barker, 2006; Poldrack et al., 2008).  The fMRI results must thus 
be regarded as tentative, requiring further confirmation.  However, I regard the results 
from the region of interest analysis as most encouraging, and with larger groups in the 
follow-up study (discussed below), I hope to demonstrate robust effects.   
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There are also concerns around whether or not fMRI is suited to capturing the 
(probably) relatively slow and large scale dynamics that represent emotional changes in 
the brain (Liotti & Panksepp, 2004).  For this reason, a repeated block-design protocol 
was selected above an event-related design.  Although event-related designs allow better 
temporal resolution, they are best suited to capturing rapid neural responses.  Block 
designs allow a stable neural state to be set up, which to my thinking was more likely to 
represent the sort of emotional changes that are of interest.  Furthermore, block designs 
are much more sensitive to small effects, establishing a far better signal-to-noise ratio 
than event-related designs (Amaro & Barker, 2006; Cacioppo et al., 2003; Friston, 
Zarahn, Josephs, Henson & Dale, 1999; Savoy, 1999).  They are generally regarded as 
yielding robust results.  One of their flaws is setting up neural expectancy or habituation 
patterns, and I attempted to avoid this by using random (within set limits) epoch timing, 
and limiting the block repeats to two (Liu, 2004; Savoy, 2005).  It seems that, for 
capturing responses to emotional facial expressions, this was the best format choice. 
In terms of interpreting activations, it would be most helpful in future to include 
an emotion check after each block of faces.  This would provide information on the actual 
feeling states invoked in participants while watching the different emotions, and thus add 
to the interpretation.  Another concern is that in passive tasks, there is no measure of the 
participants‟ attention to the stimuli.  This could also perhaps be checked by a simple 
post-block question assessing to what extent the stimuli demanded attention, or if the 
participant was thinking about something else.  This would enable exclusion of data 
where participants were not attentive.   
One final concern, and one that has no simple resolution, is that of a possible 
cross-race effect in processing faces.  The marked benefit for own-race face recognition 
is a very strong finding in cognitive psychology (for a review, see Meissner & Brigham, 
2001), and recent neuroimaging work has indicated that processing other-race faces may 
elicit different neural activity that represents automatic, unconscious responses.  For 
instance, in the United States, enhanced amygdala response has been documented in 
response to other-race faces (see, e.g., Cunningham et al., 2004; Lieberman, Hariri, 
Jarcho, Eisenberger & Bookheimer, 2005; Phelps et al., 2000).  There is also recent 
evidence suggesting that different neural responses are elicited when processing emotions 
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in own- versus other-race faces (Lee et al., 2008).  The set of emotional faces that we 
used featured only Caucasian faces, while our participants were of various races.  What 
impact this could have on our results is unknown, given the findings mentioned above.  
Fortunately, the groups in the fMRI subsample were well matched on race (no significant 
difference), so whatever effect may have been present, would have been present to a 
similar extent in both groups, and thus would not have impacted unduly on the results.   
There are also indications in the literature that the effects seen with other-race 
stimuli may be linked to social categorization and prejudice, and can be attenuated by 
increased contact between races (see, e.g., Bernstein, Young & Hugenberg, 2007; 
Hancock & Rhodes, 2008).  It is therefore very difficult to predict how young South 
African university students might respond to faces of different races.  Moreover, how to 
control for these effects is also not clear: would using a set of emotional faces featuring a 
variety of races be able to statistically „shuffle out‟ the effect across participants of 
different races, or, given the small samples typically used in neuroimaging, would it 
simply increase the confound?  Recruiting participants only from one race is an obvious 
solution, but in the long term this has ethical implications, particularly in the South 
African context, where broad concerns around race and knowledge production remain 
highly pertinent.  It is not clear to me how best to address this problem.  Despite its 
obvious relevance, it does not seem to be a factor that is generally given consideration in 





Overview of Results 
This study constitutes a first step in examining the broad thesis that early social 
trauma may lead to depression, at least in part, because it results in opioid dysregulation.  
I examined certain baseline characteristics, and the response to a once-off 
pharmacological challenge using the opioid buprenorphine, in medically and 
psychiatrically healthy young adults who differed only in terms of exposure to early 
social trauma.  With regard to baseline characteristics, the groups did not differ on 
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general experience of positive or negative effect, or on depression scores.  They did, 
however, differ significantly and substantially on scores reflecting a trait disposition on 
the SEEKING system.  This result indicates that even psychiatrically healthy young 
adults who have been exposed to early social trauma show reduced tendencies to engage 
with the world in a positive, expectant, and motivated way.  The neurochemical and 
psychological links between social bonding/attachment and SEEKING system activation 
will be discussed further below. 
Importantly, this study demonstrated clearly that trauma-exposed and control 
participants responded differently to the opioid manipulation, at all the levels measured 
(affective, cognitive, and neural).  With regard to the measures of subjective affect and 
social cognition, this altered response in the trauma group was not straightforward, and 
did not directly match the predictions made.  However, this was not entirely 
unanticipated.  As stated in the Introduction, at this initial, exploratory stage of the 
investigation, it was difficult to predict the precise form that opioid dysregulation would 
take, and the specific predictions made in this study, particularly for the affective and 
social cognitive domains, were heuristic, based on what is known regarding affect and 
cognition in depression.  The key finding is that the groups responded differently: with 
regard to subjective affective states, buprenorphine reduced the experience of both 
positive and negative affect in the trauma group, but had little impact on affect in the 
control group.  With regard to social cognition, the trauma group showed a negativity 
bias in interpreting ambiguous social information, perceiving neutral faces as sad.  This 
bias was not attenuated by buprenorphine administration.  However, buprenorphine 
enhanced a positivity bias in the control group – these participants were more likely to 
interpret neutral faces as happy.  There was no sign of a positivity bias, or of 
enhancement of positive interpretations on medication, in the trauma group.  These 
markedly different patterns of response to the opioid manipulation suggest that the opioid 
system was functioning differently in the two groups.  
As mentioned above, it is possible that longer periods of consistent buprenorphine 
administration might be required to restore the opioid system to normal functioning, at 
which point equivalent affective experience and social cognition might be seen across the 
trauma and control groups.  However, given the clear changes in neural activation 
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demonstrated in the fMRI analysis, we can be certain that the medication did have 
immediate effects – these may simply need more time and amplification in order to 
manifest at the affective and social cognitive levels. 
The fMRI analysis indicated that even a low dose of buprenorphine was able to 
produce observable alterations in neural activity.  Due to the small group sizes, the 
critical group by medication interaction was not evident in the whole brain analysis.  
However, in the more powerful ROI analysis, this study was able to demonstrate 
important effects.  Most critically, it demonstrated reduced activation on medication in 
the anterior insula in response to negative social stimuli.  This reduction was significantly 
greater in the trauma group than in controls.  The anterior insula has been shown to be 
critically involved in both physical and social pain, and should perhaps be considered part 
of the SEPARATION-DISTRESS system in humans.  This result is in line with 
Panksepp‟s model (Panksepp et al., 1997; Watt & Panksepp, 2009), which proposes that 
social pain mechanisms evolved from pre-existing mechanisms for physical pain; it is 
also consistent with a body of human neuroimaging work demonstrating that physical and 
social pain share neural substrates, and are both mediated by mu-opioids (DeWall et al., 
2010; Eisenberger et al., 2006; Eisenberger et al., 2003; Kennedy et al., 2006; Liberzon et 
al., 2007; Masten et al., 2009; Zubieta et al., 2005; Zubieta et al., 2003; Zubieta et al., 
2001).  Moreover, this analysis, indicating a greater sensitivity to the opioid manipulation 
in the trauma group in such a key region, is most encouraging, as it supports the 
contention that opioid function is dysregulated subsequent to early social trauma.  The 
final two ROI analyses again provided evidence of a greater sensitivity to opioid 
manipulation in the trauma group.  The two contrasts indicated that buprenorphine 
appears able to attenuate heightened responses to negative social signals in the trauma 
group.  An equivalent change in the controls was not evident.   
In total, the results from this first study provide critical proof of the key concept 
under investigation – the opioid system does seem to be functioning differently in 
medically and psychiatrically healthy young adults who have been exposed to early social 
trauma.  I now turn back to the literature to consider the implications of these findings in 





An interactive matrix of chemistries underlies the disorder.  As emphasized in 
the literature review, depression remains poorly understood.  Despite the identification of 
multiple neuroanatomical and neurochemical correlates of depression (or perhaps 
because of it), a single coherent unifying explanation of major depression has yet to 
emerge.  Since the commencement of the study reported here, there has been a move in 
the literature towards developing more complex, systems-level models of the disorder 
(see, e.g., Anisman, 2009; Giacobbe et al., 2009; Mayberg, 2009; Northoff et al., in 
press).  It seems clear that single factor theories are unlikely to be able to explain 
depression (Watt & Panksepp, 2009).  Increasingly, major depression is seen as a 
multifactorial disorder, manifesting in different clinical presentations depending on which 
factors are most strongly implicated.  Several authors are focusing on more pluralistic 
modeling of the neurochemistries involved, with an emphasis on the way in which these 
chemistries interact with and regulate each other.  These inter-connections have been 
conceptualized in terms of a matrix of interactive factors (see, for e.g., Table 17).  The 
argument is that without such a multifactorial understanding, it is unlikely that the 
etiology of depression will be able to be explained (Panksepp & Watt, 2011; Zellner et 





Neurobiological Factors Forming an Interactive Depressive Matrix 




cholecystokinin and reduced 
BDNF 
Multifactorial limbic influences 
on paraventricular nucleus 
promoting activation of HPA 
stress axis. 
Increased dynorphin, decreased 5-HT, reduced 
neuroplasticity/HC atrophy. Intensification of 
separation distress. Disrupted ventral HC feedback 
on core affective regions. 
Dysphoria, sleep and appetite loss. 
Reduced short-term memory, and other 
cognitive deficits. 
Increased acetylcholine Reduction of social and other 
rewards, declining opioid tone, 
and any other social 
punishment. 
Facilitation of separation distress circuitry and 
other negative emotions. Effects on other core 
variables. 
Negative affect and excess attention to 
negativistic perceptions and thoughts. 
Decreased mu opioids and 
oxytocin 
Separation distress, other 
stressors, including physical 
illness and pain. 
Disinhibition/release of stress cascades; decreased 
5-HT and DA; overdriven NE. Promotion of pro-
inflammatory cytokine generation. 
Anhedonia and sadness, reduced 
positive affect and reduced sense of 
connection. Suicidality. 
Increased dynorphin in 
accumbens/VTA 
Stress cascades. Down regulation of VTA and mesolimbic DA 
system. 




Acute but probably not chronic 
stress, acute reduction of 
opioids. 
Promotion of stress cascades, decreased 
serotonergic and increased glutamatergic tone. 
Impairment of HPA axis negative feedback. 
Fatigue, malaise and appetitive losses. 






decreased mu opioids. 
Lowered dopaminergic and increased 
noradrenergic drive. Less functional segregation 
among brain systems. 
Poor affective regulation. Impulsivity. 
Obsessive thought, suicidality. 
Diminished 
catecholaminergic  
(DA and NE) tone 
Constitutional vulnerability, 
stress and poor reward 
availability. 
Reduced “signal-to-noise” processing in all 
sensory-perceptual and motor/executive systems. 
Fatigue, diminished psychic “energy”: 
appetitive sluggishness, dysphoria. 
Impaired coordination of cognitive and 
emotional information processing. 





The separation-distress model of depression.  Examining the role of 
endogenous opioids in this multifactorial complex is a vital task.  Opioids remain integral 
to newer articulations of the separation-distress hypothesis of depression.  As is evident 
from Table 17, most of the neurochemical changes that exert depressive influences are 
driven by stress.  The links between stress and depression are clear and convincing, but 
although opioids are clearly implicated in regulating stress responses, their role with 
regard to depression is not well articulated.   
The literature on stress and depression has struggled to account for the variability 
of psychiatric responses to stress, with depression being just one possible outcome.  
Other difficulties in this literature include the question of why some individuals are more 
vulnerable to depression regardless of stressor severity, and of exactly how the various 
affective changes that characterize depression follow from stress (Slavich et al., 2010; 
Watt & Panksepp, 2009).  The separation-distress model of depression, which focuses on 
a very particular kind of stressor, social loss, embedded in a framework of core emotion 
systems, can make a significant contribution in this regard.   
The separation-distress model seeks to explain depression at both the 
neurobiological level, and at that of subjective feeling states, with both linked to the 
central concepts of social attachment and social loss.  The positive feeling states of 
comfort and security associated with social attachment are peptide mediated, involving 
increased levels of mu-opioids.  In contrast, separation-distress is characterized by 
reduced levels of mu-opioids, by increased stress chemistries, and elevated kappa-opioids 
(Panksepp & Watt, 2011).   
This model is based on the idea that for social brains, separation-distress 
constitutes a prototypic stress state.  The survival of infant mammals is dependent on 
intact primary attachment bonds.  The mammalian brain has clear links between 
attachment mechanisms and stress physiology.  Any threat to, or disturbance of, these 
social attachment bonds elicits immediate and marked distress.  Separation-distress 
powerfully activates the HPA axis, and, as reviewed above, early attachment experiences 
exert a permanent effect on stress neurophysiology.  The model thus proposes that failure 
of attachment, or social loss, activates chronic stress cascades that can lead to depression.  
It is thought that the trajectory to development of depression involves not only mu-opioid 
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mediated separation-distress/social pain, but also dysregulation of the kappa-opioid 
mediated shutdown mechanism for the original panic or protest phase.  Moreover, if 
critical attachment failures/social losses and the resultant stress cascades occur early in 
development, the model predicts that this will result in long-term vulnerability to 
depression via permanent changes in stress responsivity, including changes in opioid 
function.   
There is mounting evidence that social stressors are particularly depressogenic.  
The idea that social loss is a potent cause of depression has a long history, beginning with 
Freud‟s conceptualization of depression being related to mourning (Freud, 1917/1950).  
Compelling recent evidence indicates that personal loss is more depressogenic than other, 
equivalently severe, stressors.  A study contrasting targeted interpersonal rejection with 
equivalently severe stressors found that social rejection was three times more likely to 
lead to depression (Slavich, Thornton, Torres, Monroe & Gotlib, 2009).  These authors 
argue that the specific characteristics of social rejection are more important than simple 
stressor severity.  Similarly, investigators examining HPA axis development in human 
children state that it is particularly sensitive to social challenges (Flinn, 2006; Flinn et al., 
2009).  A longitudinal study (Slavich et al., 2010) demonstrated that participants who 
experienced early parental loss later developed depression following less severe 
interpersonal losses; this pattern was not seen in participants who had been exposed to 
other equivalently severe early stressors.  This indicates that disruption of early 
attachment bonds acts to sensitize individuals to loss and rejection, making them far more 
vulnerable to depression, as is predicted by the separation-distress model of depression.   
The current study has provided evidence of opioid system dysregulation 
subsequent to early social trauma, and it has also demonstrated reduced SEEKING in 
trauma-exposed participants.  As indicated previously, recent articulations of the 
separation-distress model propose that dysregulated kappa-opioid mediated 
downregulation of SEPARATION-DISTRESS mechanisms play a critical role in the 
development of anhedonia and depression.  The animal literature indicates that 
mesolimbic dopamine levels and SEEKING behavior are reduced in depression 
(Anisman & Matheson, 2005; Harro, Kanarik, Matrov & Panksepp, in press; Nestler & 
Carlezon, 2006; Pereira Do Carmo, Stevenson, Carlezon & Negus, 2009).  The 
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separation-distress model proposes that the stress of social loss recruits kappa-opioids, 
upregulating prodynorphin, especially in the nucleus accumbens (Berton & Nestler, 2006; 
Mu, Neumann, Panksepp, Schluter & Dong, 2011).  Kappa-opioids lead to changes in 
motivation and to dysphoria (Bals-Kubik, Ableitner, Herz & Shippenberg, 1993; 
Carlezon et al., 2006; Hasebe et al., 2004; Walsh, Strain, Abreu & Bigelow, 2001), 
reducing SEEKING by inhibiting dopamine release in the ventral tegmental area 
(Panksepp & Watt, 2011).  The results of the current study are in line with the arguments 
regarding the long-term impact of social trauma on the SEEKING system.     
It is important to provide a psychological-level account of the reciprocal 
relationship between the social bonding and SEEKING systems. It must be remembered 
that the separation-distress model of depression is an extension of Bowlby‟s original 
account of attachment.  In this account, attachment‟s chief function is to provide a safe 
base, and a sense of self-esteem or efficacy.  Crucially, when attachment is successful 
(„secure‟ in Bowlby and Ainsworth‟s terms), the infant is able to respond adaptively to 
novel environments, exploring confidently and with interest.  The secure base provided 
by this social attachment thus promotes adaptive SEEKING behavior.  Infants who are 
insecurely attached are far less willing to explore, apparently lacking the sense of security 
and confidence, or sense of agency, imparted by secure social attachment.  These well-
established behavior patterns yield insight into the reciprocal relationship between 
attachment/social bonding and SEEKING at the psychological level, and hence into the 
fact that SEEKING is impacted when social bonds are lost. 
In terms of associated feeling states, the model postulates that social comfort and 
social loss are characterized by inverse patterns of mu- and kappa-opioids (Panksepp & 
Watt, 2011; Zellner et al., in press).  Feelings of social comfort are created by high levels 
of mu-, and low levels of kappa-opioids; whereas feelings of social loss are characterized 
by low mu- and high kappa-opioids.  Social loss is thus argued to feel bad in a very 
particular way.  The shutdown of the separation-distress protest phase is also associated 
with quite specific feeling states.  Whereas activation of SEEKING is associated with 
dopamine mediated positive affect, including feelings of motivation, agency, engagement 
and positive expectancy states, shutdown of SEEKING is associated kappa-opioid 
mediated reductions in dopamine, and with feelings of hopelessness, loss of interest and 
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lack of motivation – essentially by the characteristics of anhedonia.  Moreover, the 
transition from protest to despair may thus involve a new feeling state; one that might 
comprise a combination of the pain of social loss, in addition to feelings of lassitude and 
despair. 
It must be admitted that the current study, in line with the clinical literature on 
buprenorphine, focused only the mu-opioid agonist effects of this opioid medication.  
This focus was due to the known and marked effects of full mu-opioid agonists on mood; 
the mu-opioid effects of buprenorphine thus seemed most relevant.  However, 
buprenorphine also impacts on kappa-opioids, acting as an antagonist at these receptors.  
This new idea in the separation-distress model, that inhibiting kappa-opioid effects may 
be as important as enhancing mu-opioid effects in treating the symptoms of depression, 
only increases the importance of investigating the actions and efficacy of buprenorphine. 
The results of the current study are consistent with these most recent formulations 
of the separation-distress hypothesis of depression, where both mu- and kappa-opioids 
are implicated, and both the SEEKING and SEPARATION-DISTRESS systems are 
involved.  This study demonstrated reduced SEEKING in trauma-exposed participants, as 
well as a marked effect for buprenorphine in this group in reducing response to negative 
social signals in the anterior insula – a region known to be implicated in both physical 
and social pain, and thus a candidate region for the SEPARATION-DISTRESS system in 
humans.   
There are very exciting prospects ahead, both in terms of research and in terms of 
implications for treatment.  The importance of investigating buprenorphine‟s efficacy has 
been stated; clearly there is hope that this medication can give relief to some individuals 
with refractory major depression.  In addition, one of the strengths of this model of 
depression is that its focus extends beyond neurobiology.  Incorporating an understanding 
of emotion enables the development of therapeutic interventions at multiple levels.  In 
addition to its implications regarding the need to raise mu-opioids and reduce kappa-
opioids, the model also suggests that promotion of prosocial activities that impact on 
these chemistries (e.g., CARE and PLAY) should be effective interventions.   
Perhaps a key understanding that emerges from this perspective is that the 
mammalian brain treats social threats similarly to the way in which it treats physical 
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threats/stressors.  The fact that social threats elicit such strong physiological stress 
responses, and that social challenges exert a disproportionate effect on HPA axis 
development, indicate that mammalian brains treat these threats as highly salient. This is 
indicative of the fact that, for mammals, social needs are as critical as physical needs; 
thus the need for evolution to wire in a system that signals both physical and social pain.  
In fact, in infant mammals, social needs take precedence, because if the bond with the 
primary caregiver is not intact, the infant‟s physical needs will not be met (Lieberman & 
Eisenberger, 2009).  The adaptive importance of mammalian social bonds, and the 
neurobiological response to threats to these bonds, both support the idea that early social 
loss serves as a prototypic stressor for mammalian young.  One critical point emphasized 
in this separation-distress model is that depression seems inherently linked to our 
capacity for social attachment – it is the price we pay for being such highly social 
creatures (Panksepp & Watt, 2011; Watt & Panksepp, 2009).    
 
Considerations for Future Studies 
 
The placebo effect.  A potential problem with using a placebo control condition 
in the investigation of mu-opioid effects came to light towards the end of the data 
collection period.  The design used in this study was chosen because placebo controlled 
designs are the gold standard in medical research.  Although knowledge of placebo 
effects is longstanding, these effects were thought to result from psychological 
expectancies.  Placebo was considered physiologically inert, and therefore the best 
contrast when examining the effects of active agents.  However, research around placebo 
effects is currently posing a major threat to this traditional gold-standard medical research 
design (Diederich & Goetz, 2008; Posternak & Zimmerman, 2007).  It has been shown 
that placebo exerts its effects through the opioid system – in other words, the placebo 
effect is an opioid effect.   
The relationship between placebo and opioid effects is obviously highly relevant 
to the line of research I am pursuing.  Early on, a landmark study demonstrated that 
placebo effects could be completely blocked by the mu-opioid antagonist, naloxone 
(Levine, Gordon & Fields, 1978).  Very recently, researchers have directly shown that 
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placebo activates mu-opioid transmission in regions associated with modulating both pain 
and emotion, and with reward processing, including the periaqueductal grey, nucleus 
accumbens, rostral anterior cingulate and insula (Scott et al., 2008; Wager, Scott & 
Zubieta, 2007; Zubieta & Stohler, 2009).   
Using a placebo control may thus not be ideal when attempting to examine mu-
opioid effects, as subtracting the placebo effect may actually remove part of the very 
effect I am seeking to examine.  It must be noted that most of the experimental work cited 
above examined placebo effects in relation to physical pain, where participants perhaps 
specifically expected pain to reduce.  In contrast, my work did not set up any clear 
expectancies.  It is thus not entirely clear what impact placebo effects would have in this 
context.  Nonetheless, the possibility that placebo may elicit mu-opioid activity and thus 
mimic at least part of buprenorphine‟s effect, is a problem I intend to avoid in future 
work.  I have designed and received funding for a follow-up study, where the effect of 
buprenorphine will be contrasted with that of a mu-opioid receptor blockade, created by 
the agent naltrexone.  This design should yield a clearer contrast.  Use of this mu-opioid 
blockade could also permit direct examination of buprenorphine‟s kappa-opioid effects, if 
buprenorphine is administered once the mu-opioid blockade is in place.  Given the 
importance of kappa-opioid effects in the newer articulations of the separation-distress 
hypothesis of depression, this is a very important line of investigation to pursue.   
 
Adapting the neuroimaging protocols.  For the fMRI component, this study 
used a standard echoplanar functional imaging protocol.  There are two main problems 
with this: First, the areas in which I am most interested are not best imaged by default 
scanner protocols – specialized protocols are required to reduce artifact from mouth and 
sinus areas, and properly image deep midbrain and medial forebrain structures in any 
detail.  I will use such adapted protocols in the follow-up study.  Second, there is a recent 
trend in imaging to use arterial spin labeling (ASL) rather than BOLD imaging to 
examine small regions in detail (E. Meintjes, personal communication, 11 March 2011).  
ASL does yield better specificity, so it would seem better suited to imaging the small, 
deep brain regions that are of key interest here.  However, BOLD imaging yields a far 
stronger signal than ASL.  Given this trade-off between specificity and power, I am 
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considering using both imaging methods in the neuroimaging investigation that forms 
part of the follow-up study. 
Another consideration related to the neuroimaging component is how best to 
approach region of interest analyses.  Given the theoretical base on which my research is 
grounded, there are very specific regions that are of interest, so whole brain analysis is of 
limited relevance to this work.  However, defining regions of interest is no simple matter.  
Using functionally defined regions of interest from whole brain analyses (as was done in 
the current study) can be problematic, especially if the contrasts in these ROI analyses are 
not independent of those in the whole brain analysis.  However, mask-based region of 
interest analysis may have limited success.  It involves creating an anatomical mask that 
includes a specific area (e.g. amygdala, or a section of the anterior cingulate cortex), and 
conducting the analysis only within that area.  Difficulties may occur because most often 
the size of an activation cluster is far smaller than that of the entire masked region, but as 
all the voxels in the mask are included in the analysis, this activation may not be detected.  
Some researchers use functional localizers in separate imaging sessions to define their 
regions of interest, but this approach is also open to criticism (Friston et al., 2006).  It is 
possible that using masks for very small deep brain regions of interest would be the best 
approach, in combination with either functional localizers or functional definition for 
larger cortical regions. 
In terms of functional tasks used in the scanner, it would be helpful to investigate 
activation in response to social rejection, and how this is mediated by opioid 
manipulation.  I have obtained a version of the cyberball task that has been used in a 
number of imaging studies (e.g., Eisenberger et al., 2003; Masten et al., 2009; Way et al., 
2009).  In this task, participants are initially included in, and are then excluded from a 
social computer game, thus allowing online tracking of the response to social rejection. 
 
Additional physiological and emotional measures.  It would be most helpful to 
include measures of cortisol and cytokine activity in the comparison groups, to illustrate 
more clearly the interplay between these factors and the opioid system.  Physiological 
measures such as skin-conductance and heart-rate during the social rejection scanner task 
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would also contribute to a fuller picture of the response to social stress in trauma-exposed 
versus control participants. 
Obtaining more differentiated measures of emotional response would help to 
refine our understanding of affective responses in these participants.  Positive and 
negative affect are broad constructs; measuring various emotions more specifically would 
yield a more nuanced picture. 
 
Adjusting the sample composition.  For the follow-up study I intend to have a 
minimum of 15 participants per comparison group.  I also intend to recruit only females.  
There are clear gender differences in both the incidence of depression, and in some 
opioid-mediated effects.  Critically, gender differences in the functioning of the mu-
opioid system have been reported; both in terms of baseline receptor binding potential, 
and in terms of response to stressors, including physical pain (Liberzon et al., 2002; 
Zubieta et al., 1999; Zubieta et al., 2002).  There are also indications that women respond 
more strongly to social pain, showing an enhanced inflammatory response that is 
associated with increased activation in the dorsal anterior cingulate and anterior insula 
(Eisenberger, Inagaki, Rameson, Mashal & Irwin, 2009).  Including both genders may 
thus introduce confounds into the data.  A better strategy is to include only one gender, or 
to recruit sufficient males and females to permit a comparison across the sexes.  
Investigating gender differences is going to be imperative in the long term, as any 
explanatory theory of depression must be able to account for the greater prevalence of the 
disorder in women. 
 
Examining genetic factors.  Another factor that might contribute to risk for 
depression is the polymorphism on the mu-opioid receptor gene.  Carriers of the G 
variant (A118G) have reduced mu-opioid receptor messenger RNA, and seem to 
experience more physical pain (Coulbault et al., 2006; Klepstad et al., 2004; Landau, 
Kern, Columb, Smiley & Blouin, 2008; Lotsch & Geisslinger, 2006; Sia et al., 2008; 
Zhang, Wang, Johnson, Papp & Sadee, 2005).  A recent study investigated if this 
polymorphism was also associated with increased sensitivity to social pain.  The authors 
found that the G variant was associated with dispositional sensitivity to rejection, and that 
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when experiencing social rejection, carriers showed greater reactivity in regions known to 
be implicated in both physical and social pain – the dorsal anterior cingulate and anterior 
insula (Way et al., 2009).   
 
In the long term, examining the impact of different kinds of social trauma at 
different ages in childhood, along with how these variables interact with genetic factors is 
going to be required.  Examining what factors may buffer these effects will also be 





This initial exploratory study has indicated that even healthy normal individuals 
who have been exposed to early social trauma show evidence of altered opioid function.  
Although these individuals did not differ from controls on baseline measures of negative 
emotion, they did differ on SEEKING, a crucial primary process appetitive, motivational 
emotion system, that is strongly implicated in the mechanism of depression in new 
articulations of the separation-distress model.  Moreover, in response to opioid 
manipulation these trauma-exposed participants consistently demonstrated a different 
pattern of reaction to that seen in controls who had no exposure to early social trauma.  
When given a once-off low dose of buprenorphine, trauma-exposed participants 
responded differently to controls in terms of subjective affect, social cognition, and 
neural activation.  These findings add to a growing body of evidence implicating the 
endogenous opioids in depression, via their role as mediators of emotional responses to 
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A.  Personal Details: 
 
Full Name: _______________________________________ 
Date of Birth:      _______________________________________ 
Gender:  _______________________________________ 
Occupation:         _______________________________________ 
Student number: _______________________________________ 
 
 
B.  Contact Details: 
 
Address:  _______________________________________ 
   _______________________________________ 
   _______________________________________ 
 
Tel. number (h) : _______________________________________ 
                   (w):   ______________________________________ 
      (c) :   ______________________________________ 
 
Email Address: _______________________________________ 
 
 
C.  Medical Details:               Please circle  
       
1. Are you right-handed?       Yes  /  No  
 
2. Do you take any kind of medication on a regular basis?  Yes  /  No 
    If yes, please specify what kind 
____________________________________________________________________ 
 
3. Are you allergic to any medication?     Yes  /  No 
    If yes, please specify what kind 
____________________________________________________________________ 
 
4.  Have you ever had a head injury?     Yes  /  No 
     If yes, describe most severe:________________________________________ 
 
    Were you knocked unconscious?     Yes  /  No 
    If yes; how long? __________________________________________________ 
 
    Any surgery/hospitalisation as a result of your head injury? Yes  /  No 




5. Do you have a metal object in your body (eg. aneurysm clip)? Yes  /  No 
    If yes, please specify:_____________________________________________ 
 
6. Do you wear a metal prosthesis (eg. artificial leg)?   Yes  /  No 
    If yes, please specify: _____________________________________________ 
 
7. Do you have a pace-maker?      Yes  /  No 
 
8.  Have you ever been diagnosed with asthma?    Yes  /  No 
 
9.  Have you ever been diagnosed with chronic bronchitis,  Yes  /  No 
     emphysema, or any other respiratory problems?                               
 
10.  Have you ever been diagnosed with a hepatic (liver)  Yes  /  No       
       problem/disorder?          
 
11.  If you are female, are you currently pregnant?   Yes  /  No 
 
 If you are female and answered no to question 10,  
      are you planning on becoming pregnant within  
      the next year?                                        Yes /  No 
  
12.  If you are female, are you currently a breastfeeding mother? Yes  /  No 
 
13. Have you ever been diagnosed with a renal problem/disorder?  Yes  /  No 
 
14. Have you ever had seizures or an epileptic fit?   Yes  /  No 
 
15. Has anyone in your immediate family (siblings, parents) ever Yes  /  No 
      been diagnosed with epilepsy? 
     If yes, please specify who: ________________________________________ 
 
16. Have you ever been diagnosed with a psychiatric illness? Yes /  No 
      If yes, please specify: ___________________________________________ 
 
17. Have you ever had any neurological condition?   Yes  /  No 
     If yes, please specify: ____________________________________________ 
 








Brief Telephonic Verbal Consent Form 
 
                                  
 
This study is entitled ‘Functional brain imaging in healthy participants with a 
history of early adversity’. It will look at the effects of the opioid, 
buprenorphine, on brain function. You will be administered a small dose of 
buprenorphine on 2 occasions. You will also perform neuropsychological tasks, 
undergo brain imaging, and have blood drawn for genetic testing.  
 
 
          Please circle  
 
1. At this stage, do you consent to participate in this study?  Yes / No 
 
2.  Do you acknowledge that all of the details (eg age & medical details) given 
to the researcher by you are correct?     Yes / No 
 
3.  Are you satisfied that any questions that you may have   Yes / No 
at this stage have been appropriately answered? 
   
 
Signature of research assistant:   
 
Date:                                                                                                             
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APPENDIX B:  
 
PARTICIPANT INFORMATION AND CONSENT DOCUMENTS FOR  
BEHAVIORAL AND SCANNER SESSIONS 
 
 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
FOR BEHAVIORAL SESSIONS 
 
 
TITLE OF THE RESEARCH PROJECT: Functional brain imaging in healthy subjects with  
a history of early adversity 
 
US PROTOCOL NUMBER: OP-0307 
 
UCT REFERENCE NUMBER: 018/2009 
 
PRINCIPAL INVESTIGATOR: Professor Dan J Stein 
 
ADDRESS: MRC Anxiety & Stress Research Unit, University of Stellenbosch 
Department of Psychiatry/ University of Cape Town Department of Psychiatry 
 
CONTACT NUMBER: +27 21 938-9228  
 
 
You are being invited to take part in a research project.  Please take some time to read 
the information presented here, which will explain the details of this project.  Please ask 
the study staff or doctor any questions about any part of this project that you do not fully 
understand.  It is very important that you are fully satisfied that you clearly understand 
what this research entails and how you could be involved.  Also, your participation is 
entirely voluntary and you are free to decline to participate.  If you say no, this will not 
affect you negatively in any way whatsoever.  You are also free to withdraw from the 
study at any point, even if you do agree to take part. 
 
This study has been approved by the Committee for Clinical Trials at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of 
the international Declaration of Helsinki, South African Guidelines for Good Clinical 
Practice and the Medical Research Council (MRC) Ethical Guidelines for Research. 
 
This trial is being run at the Department of Psychiatry, University of Cape Town. We aim 
to recruit a total of 40 participants over a period of 2 years 
 
What is this research study all about?  
The purpose of this study is to find out what effects Buprenorphrine has on individuals 
who have experienced a childhood traumatic event versus those who have not. This 
study will make comparisons between treatments.  Randomisation means that the 
participants are put into treatment groups by chance.  The groups are selected by a 
computer that has no information about the individual participants.  Participants in each 
group (Buprenorphrine or placebo) then have a different treatment and their responses 
are then compared.  
In a blinded study the treatment provided will be hidden or concealed so you will not 
know which treatment you will receive. This research study is called "double blind". In a 
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double blind research study neither you nor your study doctor will know in which 
treatment group you are (although if your doctor needs to find out he/she can do so). 
 
A placebo is a dummy treatment such as a pill or a capsule, which looks like the real 
thing but is not. Placebo medications do not contain active ingredients. 
 
In a crossover study you will first receive one treatment and then the other. If you agree 
to take part in this study you will be given either Buprenorphrine or placebo on one visit 
and the other (either Buprenorphrine or placebo) on the following visit.  
 
Procedures 
If you agree to take part in the study and if you meet all of the conditions required to 
enter the study, you will have the following tests and procedures: 
At the first clinic visit your study doctor will ask you some questions to confirm whether 
you have been exposed to a traumatic event in your childhood. 
If you are eligible and agree to participate in the study you will be asked to attend the 
clinic on up to 2 more occasions. You will receive study medication from your doctor 
which you will be given in the morning of your visit. You will then be asked to complete 
questionnaires and do some tasks as well as have a brain image scan done (if you 
agree to do so). 
 
At each visit your past and current medical conditions together with any medications 
that you are taking currently or have taken recently will be recorded. A record will also 
be taken of any side effects that you may be experiencing. 
 
You will be given a physical examination and your weight, blood pressure and heart rate 
will be measured at each visit. 
 
Blood samples (about 30 ml [6 tablespoons]) will be collected for routine laboratory 
testing, for a pregnancy test (if you are female) and for possible future genetic studies. 
You will be asked to have your blood drawn on the first day of attendance.  
Approximately 30ml of blood will be drawn from your arm.  We may need to contact you 
again to get another blood sample should we fail to get a DNA sample from your blood.  
The blood sample you give may be used to create a cell line.  This is done by changing 
some of your blood cells so that they can grow forever.  The cell line is living tissue and 
it can be used to make more of your DNA at any time in the future.  Candidate 
polymorphisms identified to be associated with anxiety or depression and possibly 
playing a role in explaining variance in the fMRI results will be investigated later on.  
This process will take place at the MRC Centre for Molecular and Cellular Biology and 
the Division of Medical Biochemistry, Faculty of Health Sciences, at the University of 
Stellenbosch.  The DNA will then be taken from the cell line and saved for scientific 
analyses which will be performed now, and possibly in the future.   
 
We may contact you later for further information, or request you to complete another 
interview at a later date, in order to obtain follow-up information that may be of use in 
our genetic analyses.  This may involve an assessment similar to the current 
assessment, including a series of interviews and/or another blood sample.  Your current 
participation is in no way binding to your future participation. 
 
Your cell line and DNA will be maintained permanently, unless you request to have it 
removed.  If at any time in the future you wish to have your DNA, cell lines or clinical 
data removed from the storage site, you may do so by contacting the researchers 
CHR Informed Consent (General), Version 1, dated 19 May 2006 Page 3 of 11 
conducting this study. 
 
What will your responsibilities be? 
Your doctor will be required to ask you about medications that you may be taking 
currently or that you may have taken recently.  
 
Your doctor will also advise you on which prescription or over-the-counter medications 
or any other remedies or foods that you will be required to either stop or restrict your 
consumption of during the entire length of the study. This will include a restriction on the 
amount of alcohol that can be consumed. 
 
At each visit you may be asked to complete questionnaires or tasks to check the status 
of your symptoms. These will measure your mood, emotional responses, trust, 
sociability and emotional resilience. 
 
Will you benefit from taking part in this research? 
If you agree to participate in the study, no direct benefit to you can be guaranteed, but 
you will be seen by the study doctor or staff at regular intervals. 
Your participation in this study will add to the medical knowledge about the use of this 
medicine. 
 
If you agree to participate in this study Buprenorphine may or may not be beneficial in 
treating or improving your symptoms. However, the information learned from this study 
may help to establish a new medication for the treatment of people who have been 
exposed to trauma in their childhoods. 
 
Are there in risks involved in your taking part in this research? 
All drugs and even placebos may cause side effects in some people. There may be 
risks, inconveniences or side effects that are not known at this time. 
 
The most commonly reported adverse reactions of  Buprenorphrine administration are 
constipation, headaches, insomnia, drowsiness, nausea and vomiting, fainting and 
dizziness, orthostatic hypotension, sweating. 
 
Special caution should be exercised when driving or using machinery since the study 
medication may cause drowsiness. 
 
You will receive both buprenorphrine and placebo, each at a separate visit. At the visit 
that you receive placebo (the medically inactive substance), your symptoms may not 
improve or may worsen.  Even if you receive active medication during the study, your 
symptoms may not improve or may worsen. As mentioned earlier this research study is 
called "double blind". In a double blind research study neither you nor your study doctor 
will know in which treatment group you are. It is possible that you may not report any 
side effects when receiving treatment. This does not mean that you have received 
placebo. Similarly, even if you do receive placebo you may experience some side 
effects which you and your doctor feel could be associated with the study drug. 
 
Because the effects of Buprenorphrine on the unborn foetus (child/baby) or nursing 
baby/infant are uncertain, you will not be allowed to enter this study if you are pregnant 
or breastfeeding or planning to become pregnant within 6 weeks of your screening visit. 
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If you choose to participate in this study, you must use one of the allowed contraceptive 
methods (a way to prevent you from becoming pregnant) for the specified period of time 
before and after you enter the study. Ask your doctor if you have any questions about 
these choices and which might be best for you. 
Acceptable contraceptive methods, when used consistently and in accordance with both 
the product label and the instructions of your doctor, are as follows: 
a Non-childbearing potential (i.e., physiologically incapable of becoming pregnant, 
including being post-menopausal. For purposes of this study, postmenopausal is 
defined as one year without menses); or 
b Child-bearing potential, you must agree to one of the following: 
 Male partner who is sterile prior to your entry into the study and is your sole 
sexual partner; 
 Oral contraceptives (either combined or progestogen only); 
 Double-barrier method of contraception consisting of spermicide with either 
condom or diaphragm;  
 IUD with a documented failure rate of less than 1% per year; or 
 
 
Even when you use one of the allowed contraceptive methods, there may be a small 
risk that you could become pregnant. Because of this, you will be tested during the 
study to see if you are pregnant. If one of these tests shows that you have become 
pregnant, your unborn baby may have been exposed to Buprenorphrine even if you 
stop taking the drug right away. So, if you think you are pregnant or may become 
pregnant, you must tell Dr_________________________ at the earliest opportunity. If 
you should become pregnant during the study you will be asked, required or requested 
to, stop taking the study drug immediately. You will also be followed to determine the 
outcome of the pregnancy. Generally, follow-up will be no longer than 6 to 8 weeks 
following the estimated delivery date. Any premature termination of the pregnancy must 
be reported to your study doctor. 
 
There may be other risks, inconveniences and side effects to the embryo, foetus 
(unborn child), or nursing infant that are unknown at this time. 
 
 
Who will have access to your medical records? 
Maintaining your confidentiality is important. Your personal information (for example 
your gender, age, the details of your medical conditions) and other information (the data 
collected by the investigators as part of the study) will be identified by a number (i.e., 
coded). Your name will not appear in any publications or reports produced from this 
study. The investigators will keep the information and the results collected about you in 
this study. This information about you will be kept in a secure place. By agreeing to take 
part in this study, you will be allowing certain persons to see the information about you 
(both personal, including your name, and other information) held by the study doctor. 
You have the right to withdraw your consent to participate in this study at any time. If 
you withdraw your consent to participate in this study no new information will be 
collected from you and added to existing data or to a database. Your information will be 
processed electronically (i.e., by a computer) or manually and analysed to determine 
the outcome of this study. Your information may/could be sent to regulatory authorities 
and to the Ethics Committees. You have the right to ask the study doctor about the data 
being collected on you for the study and about the purpose of this data. You have the 
right to ask the study doctor to allow you to see your personal information and to have 
any necessary corrections made to it. 
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What will happen in the unlikely event of some form of injury occurring as a direct 
result of your taking part in this research study? 
If you become ill or injured as a result of participation in this clinical study, you will be 
referred for appropriate medical treatment. The University of Stellenbosch’s insurance 
policy will cover the costs of such treatment. If you have any questions concerning the 
availability of compensation/medical care or if you think you have experienced a 
research-related illness or injury, contact details are below. 
 
Your right at law to claim compensation for injury where you can prove negligence is not 
affected.  For medicines that have already been approved by the Medical Authorities to 
treat this condition, normal legal rules on compensation will apply. 
If you have any questions about your rights as a research subject, you should contact 
the Committee for Pharmaceutical Trials of the University of Stellenbosch, Tel: (021) 
938 9075, Fax:  (021) 933-6330. 
 
If you have questions about this trial you should first discuss them with your study 
doctor or the Committee for Pharmaceutical Trials of the University of Stellenbosch.  
Dr S Seedat: Tel (24hr contact number): 082-784-8148 
Dr P Carey: Tel (24hr contact number): 083-700-0046 
Dr D Stein: Tel (24hr contact number): 083- 263-9679 
 
After you have consulted your doctor or the ethics committee and if they have not 
provided you with answers to your satisfaction, you should write to the South African 
Medicines Control Council (MCC) at: The Registrar, SA Medicines Control Council, 
Department of Health, Private Bag x 828, Pretoria, 0001, Fax: (012) 323 4474 
 
Will you be paid to take part in this study and are there any costs involved? 
 
No you will not be paid to take part in the study but your transport and meal costs 
(R100) will be covered for each study visit.  There will be no costs involved for you, if 
you do take part. 
 
Is there any thing else that you should know or do? 
 You can contact Dr ……………….………..….. at tel ……………………… if you 
have any further queries or encounter any problems. 
 You can contact the Committee for Human Research at 021-938 9207 if you 
have any concerns or complaints that have not been adequately addressed by 
your study doctor. 




Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a 
research study entitled (insert title of study). 
 
I declare that: 
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 I have read or had read to me this information and consent form and it is 
written in a language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been 
adequately answered. 
 I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
 I may choose to leave the study at any time and will not be penalised or 
prejudiced in any way. 
 I may be asked to leave the study before it has finished, if the study doctor or 
researcher feels it is in my best interests, or if I do not follow the study plan, 
as agreed to. 
 
 




 ..............................................................   ............................................................ 
Signature of participant Signature of witness 
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Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
 I explained the information in this document to ………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer 
them. 
 I am satisfied that he/she adequately understands all aspects of the 
research, as discussed above 
 I did/did not use an interpreter.  (If an interpreter is used then the interpreter 
must sign the declaration below. 
 
 




 ..............................................................   ............................................................ 
Signature of investigator Signature of witness 
 
 
Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
 I assisted the investigator (name) ………………………………………. to 
explain the information in this document to (name of participant) 
……………..…………………………….. using the language medium of 
Afrikaans. 
 We encouraged him/her to ask questions and took adequate time to answer 
them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of this 








 ..............................................................   ............................................................ 
Signature of interpreter Signature of witness 
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F-MRI PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
 
 
TITLE OF THE RESEARCH PROJECT: Functional brain imaging in healthy subjects 
with a history of early adversity.  
 
 
US PROTOCOL NUMBER: OP-0307 
 
UCT REFERENCE NUMBER: 018/2009 
 
PRINCIPAL INVESTIGATOR: Professor Dan J Stein 
 
ADDRESS: MRC Anxiety & Stress Research Unit, University of Stellenbosch Department of Psychiatry/ 
University of Cape Town Department of Psychiatry 
 




You are being invited to take part in a research project.  Please take some time to read 
the information presented here, which will explain the details of this project.  Please ask 
the study staff or doctor any questions about any part of this project that you do not fully 
understand.  It is very important that you are fully satisfied that you clearly understand 
what this research entails and how you could be involved.  Also, your participation is 
entirely voluntary and you are free to decline to participate.  If you say no, this will not 
affect you negatively in any way whatsoever.  You are also free to withdraw from the 
study at any point, even if you do agree to take part. 
 
This study has been approved by the Committee for Clinical Trials at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice 
and the Medical Research Council (MRC) Ethical Guidelines for Research. 
 
If you receive this invitation to participate, you will already have given your 
consent/assent to participate in the part of this study that is assessing the effect that 
Buprenorphrine has on individuals who have experienced a childhood traumatic event.  
 
STUDY PROCEDURES 
At each visit, besides getting the study medication from your doctor and being asked to 
complete the questionnaires and tasks, if you are agreeable you will have a type of 
brain scan, called an fMRI (functional magnetic resonance imaging) scan. As the scan 
is done in a relatively confined space, occasionally people become anxious. This does 
not happen often, and if you feel anxious, we will spend time allowing you to get used to 
the surroundings. During the scan, you will be asked to perform some simple tasks of 
memory and attention, which will enable the investigators to determine your brain 
function.  The scan will require you to lie on your back on a table that will move into the 
scanning machine for the 30 minutes it will take for the scan. During this time you will be 
able to close your eyes and rest. You will also be able to talk to the study 
doctor/assistant at all times during the scan if you should experience any discomfort. 
The scan is a safe procedure if you have been screened correctly for the presence of 
any magnetic material on or inside you such as pace-makers, surgical clips and metal 
objects in the eyes. A formal screen for this will be done at the screening visit by a 
member of the study team. When the magnet in the machine is switched on, it will make 
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some loud banging noises, but you will be clearly warned when this will take place. At 
this time you will feel nothing and the noise is not harmful to you in any way. To 
minimise the possible discomfort associated with this, we will give you some soft 
earplugs to put in and will also put earphones on so that you can listen to music if you 
so choose.  
 
DISCOMFORT ASSOCIATED WITH THE STUDY 
There are only low or minimal risks associated with your participation in this study. If 
you feel tired at any point in any of the visits, you should please ask your study 
doctor/psychologist for a rest. If for some reason you are unable to complete a visit on a 
particular day we may reschedule to complete the assessments at another time.  
 
POTENTIAL BENEFITS 
There may be no direct benefits to you for participating in this study.  However, you will 
be making an important contribution to this research that may benefit others in the 
future.  We expect that the results of this study will help us understand the effects of 
apathy and depression on brain function as well as memory and concentration.   
 
COMPENSATION FOR STUDY PARTICIPATION 
While you will not be paid to take part in this study, all evaluations will be provided at no 
cost to you or your medical aid.  You will be compensated for travel and meal costs for 
each session (R100 per session).   
 
CONFIDENTIALITY 
Your participation is regarded as strictly confidential.  The results of the study will be 
published in the professional literature and made available to of the Committee for 
Human Research of Subcommittee C at the University of Stellenbosch, but your identity 
will not be revealed at any time to people outside of the study team.  
                                     
THE RIGHT TO ASK QUESTIONS/WITHDRAW FROM THE STUDY 
You have the right to ask questions at any time about any aspect of the study. If you 
have any queries, you can contact: 
Dr S Seedat: Tel (24hr contact number): 082-784-8148 
Dr P Carey: Tel (24hr contact number): 083-700-0046 
Dr D Stein: Tel (24hr contact number): 083- 263-9679 
 
Your participation in the study is entirely voluntary.  You have the right to withdraw at 
any time.  If you decide to withdraw from the study, it will not jeopardize you or any 
future treatment you may require in any way. 
 
You are entitled to a signed copy of this document. 
 
If you agree to take part, please complete the following section.   
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I )………………………………………………. have been invited to take part in the above 
research project entitled Functional brain imaging in healthy subjects with a history of 
early adversity.  
 
The study doctor/nurse has explained the details of the study to me and I understand 
what they have said to me. 
They have also explained that this study will involve up to 3 assessments which include 
interviews, filling questionnaires, a physical examination including a blood test, and 
brain scan.  
I also know that I am free to withdraw from the study at any time if I am unhappy. 
By writing my name below, I voluntary agree to take part in this research project.  I 





Name of Participant (printed) 
 
    
Signature of Participant  Dated 
 
  
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
I explained the information in this document to ………………………………….. 
I encouraged him/her to ask questions and took adequate time to answer them. 
I am satisfied that he/she adequately understand all aspects of the research, as 
discussed above 
I did/did not use an interpreter (if an interpreter is used, then the interpreter must sign 
the declaration below). 
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Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
I assisted the investigator (name) ………….…………………………. to explain the 
information in this document to  ……...………………………... using the language 
medium of Afrikaans. 
We encouraged him/her to ask questions and took adequate time to answer them. 
I conveyed a factually correct version of what was related to me. 
I am satisfied that the parent/legal guardian fully understands the content of this 
informed consent document and has had all his/her questions satisfactorily answered. 
 
 




   









Guidelines for Interpretation of CTQ-SF Scores 
 
Table C1 










Emotional Abuse 5-8 9-12 13-15 16 and above 
Physical Abuse 5-7 8-9 10-12 13 and above 
Sexual Abuse 5 6-7 8-12 13 and above 
Emotional Neglect 5-9 10-14 15-17 18 and above 
Physical Neglect 5-7 8-9 10-12 13 and above 
 
 
Guidelines for Interpretation of BDI Scores 
 
Table C2 
Total BDI Score Interpretation 
0 - 13 No or Minimal symptoms of depression  
14 - 19 Mild symptoms of depression 
20 - 28 Moderate symptoms of depression 
29 - 63 Severe symptoms of depression 
 
Appendix D 
Results for the fMRI subset 
 
In the text of the thesis I present the results for the full sample.  However, only a subset of 
these participants’ data was usable for the fMRI analysis.  In this appendix, I present the 
results of the same analyses as were conducted on the full sample, to demonstrate that the 





Beck Depression Inventory – 2
nd
 Ed. (BDI-II). The trauma and control groups did not 
differ significantly on depression scores (see Table D1).  Participants’ scores all fell within 
the None–Minimal range of depressive symptoms.   
Table D1 
BDI-II: Group means for the fMRI subset 
Trauma group Control group t p d 
(n = 9) (n = 10)    
6.00 (4.40) 4.40 (5.28) 0.72 .24 .33 
Note: Means, with standard deviations in brackets, are presented. 
Data were missing for two trauma group participants and one control group participant.    
 
PANAS – general ratings.   
The same pattern of results as seen in the full sample was evident for the fMRI subset, 
with no interaction between trauma status and affect, F(1,20) = 0.31, p = .59, partial eta
2
 = 
.02.  Both the trauma and control groups reported far more positive than negative general 






PANAS – general ratings: Group means for the fMRI Subset  
Trauma group 
(n = 11) 
Control group 
(n = 11) 
Positive affect Negative affect Positive affect Negative affect 
35.46 (4.63) 14.55 (4.23) 34.46 (4.32) 12.18 (2.68) 
Note: Means, with standard deviations in brackets are presented. 
 
 
Affective Neuroscience Personality Scales (ANPS).   
A significant group difference (in the same direction as that seen in the full sample) on the 
SEEKING subscale was also evident in the fMRI subset, t(20) = 1.99, p < .03, d = .85.  
Control participants scored significantly higher on this subscale than trauma participants.   
As was seen for the full sample, the prediction that the trauma group would score 
higher on the SADNESS subscale was not supported, t(20) = 0.22, p < .41, d = .09,  
respectively. 
 
Table D3  
ANPS subscales: Group means for fMRI subset 
ANPS Subscale Control group 
(n = 11) 
Trauma group 
(n = 11) 
SEEKING 22.46 (1.97) 20.46 (2.70) 
FEAR 16.09 (2.91) 16.73 (1.85) 
CARE 18.64 (4.74) 20.09 (3.65) 
ANGER 16.00 (2.61) 15.77 (4.78) 
PLAY 20.73 (2.33) 20.36 (4.23) 
SADNESS 16.66 (2.01) 16.91 (3.56) 






Impact of Opioid Manipulation on Subjective Experience of Affect 
 
PANAS – moment ratings.   
The same pattern of results as seen for the full sample was evident for the fMRI 
subset: both the trauma and control groups reported far more positive than negative affect, 
F(2.21, 44.23) = 77.53, p <.0001, partial eta
2
 = .16, and there was a significant interaction 
between trauma status and medication-PANAS ratings, F(2.21, 44.23) = 5.29, p <.003, 
partial eta
2
 = .21.  For a graphical representation of this interaction, see Figure 1.  The data 
patterns illustrated here are very similar to those shown for the full sample.  
 
Table D4 
PANAS current affect ratings: Group means for the fMRI subset on and off buprenorphine 
 Trauma group 
(n = 11) 
Control group 
(n = 11) 
Placebo - positive affect 29.10 (9.17) 28.91 (5.21) 
Placebo – negative affect 15.36 (5.35) 11.19 (2.96) 
Medication – positive affect 25.18 (6.29) 32.00 (4.98) 
Medication – negative affect 13.55 (4.63)  11.09 (1.05)  




Interaction of trauma status with medication – PANAS ratings of current affect 
 
Simple effects analysis of the interaction indicated the same patterns as those seen for 
the full sample:  There were no significant within-groups effects.  That is, within the trauma 
and control groups, no significant change in either positive or negative affect on medication 
versus placebo was observed.  The opioid manipulation was not sufficiently powerful to 
result in statistically significantly altered experience of emotion within the groups. 
In terms of positive affect, participants in both the trauma and control groups reported 
very similar scores on placebo (p < .96).  However, on the opioid medication, the control 
group reported significantly more positive affect than the trauma group (p < .011). 
In terms of negative affect, on placebo the trauma group reported significantly more 
negative affect than the control group (p < .035).  However the between group difference was 







Impact of Opioid Manipulation on Behavior 
 
Response bias task.  A 2 (group) x 8 (medication condition – emotion) mixed-design 
ANOVA indicated a significant interaction between trauma status and types of errors made 
for neutral faces on and off medication, for both the full sample and the fMRI subset,  F(2.93, 
85.02) = 3.61, p < .017, partial eta
2






Response Bias: Group means for the fMRI subset; % of total choices for neutral faces on and 
off buprenorphine 




Placebo Anger 23.2 (12.6) 26.0 (10.3) 
 Happy 8.7 (8.9) 17.8 (14.5) 
 Sad 56.6 (19.9) 46.6 (12.1) 
 Fear 11.5 (8.6) 9.3 (5.7) 
Medication Anger 19.7 (10.8)  27.4 (9.5) 
 Happy 9.1 (7.3) 22.0 (15.7) 
 Sad 60.6 (20.4) 40.2 (20.3) 
 Fear 10.6 (9.4) 8.7 (6.1) 
Note: Means, with standard deviations in brackets, are presented.  
 
Simple effects analysis of the interaction indicated the following: for the full sample, 
on placebo, the trauma group was significantly more likely than the control group to judge 
neutral faces as sad (p < .049).  Although this trend was present in the fMRI subset, this 
contrast was not significant. 
 
On medication two group differences were found for both the full sample and the 
fMRI subset: firstly, the control group was significantly more inclined to judge neutral 
expressions as showing happiness than was the trauma group (p < .022); and secondly, the 
trauma group was significantly more inclined to judge neutral expressions as showing 
sadness than was the control group (p < .029). 
 
 
